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Abstract 
Cancer is an important cause of morbidity and mortality among the recipients of solid organ 
transplantation. Cancer transmitted from the donors often has a poor outcome and the fear 
of such transmission results in organs from certain donors not being accepted. A study of 
the transplant recipients in the UK over a period of 10 years identified 15 cases of 
transmitted cancers. The rate of cancer transmission was 0.05%. The risk of cancer 
transmission was 9 times higher from donors older than 45 years. Cancer transmission 
occurred from donors without a history of cancer. A comparison of the organ donor data 
with the guidelines classifying the donor’s risk of cancer transmission showed that a 
carefully selected cohort of donors, who are classed as a high risk of cancer transmission by 
the guidelines, could safely donate their organs resulting in valuable additional survival for 
the recipients, with low risk of cancer transmission. These results provide evidence, based 
on which the donor classification guidelines can be modified resulting in increased 
availability of safe organs for transplantation. The risk of recurrence after transplantation of 
cancers treated before transplantation was low in carefully selected recipients undergoing 
transplantation after a waiting period of 2 years following the diagnosis of cancer. No 
association was found between the donor-recipient CMV status and the risk of post 
transplant cancer. No chronological changes were noted in the incidence of PTLD or in the 
survival rates after the diagnosis of PTLD. This research estimated the risk of cancer 
transmission to the organ transplant recipients enabling improved risk assessment in 
transplantation. This research also explored the ways of increasing the number of safe 
organs for transplantation whilst reducing inappropriate wastage of donor organs. 
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This is to certify that I have, as first author, already published some of the text and the data 
presented in Chapters 3, 4, 6, and 8 of this thesis. These publications have been used to 
facilitate the development of evidence-based national guidelines for improving the selection 
of organ donors. Such content is referenced with their respective publications as follows: 
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organ donors-unavoidable but low risk. Transplantation, 94, 1200-7 
Chapter 4; pages 145 to 171 (paragraphs 4.1 to 4.5) published in: DESAI, R., COLLETT, D., 
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Surg, 101, 768-74 
Chapter 6; pages 192 to 217 (paragraphs 6.1 to 6.5) published in: DESAI, R., COLLETT, D., 
WATSON, C. J., JOHNSON, P. J., MOSS, P. & NEUBERGER, J. 2015. Impact of Cytomegalovirus 
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publications mentioned above 
 
 
 
3 
 
 
Dedication 
I wish to dedicate this thesis to my family, particularly to my wife Seema and children Rahul 
and Tanya, for their support, patience and encouragement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
Acknowledgements  
There are many people and organisations to thank, without whose help this work would not 
have been possible. I would like to thank: 
Professor James Neuberger for offering me the privilege of working with him and learn from 
him, the support, guidance, supervision and encouragement provided throughout the 
period of this research 
Professor Philip Johnson for his supervision and guidance in completing this work and Mrs 
Johnson for the secretarial support 
Professor Dave Collett for helping me in learning the statistical methods and enabling me to 
perform independently, all the statistical analyses needed to complete this research 
The team of statisticians, clinical governance team, information governance team, the duty 
office and the secretaries at Organ Donation and Transplantation, NHS Blood and 
Transplant, Bristol 
The NHS Blood and Transplant for funding this study 
Professor Chris Watson for the support and advice offered during the data collection and 
analysis 
Professor Paul Moss for his advice in writing chapter 6 
Dr Ian Rowe for his advice in writing chapter 1 
5 
 
 
The transplant doctors, specialist nurses and data management teams in all the transplant 
centres in the UK for helping me with the database search to identify cases of donor-
transmitted cancer 
The team of specialist nurses in organ donation at NHS Blood and Transplant, Birmingham 
for their help with the potential donors project 
Dr Tim Evans, Cancer Registration Information manager at Public Health England, 
Birmingham and Dr David Greenberg, Senior Analyst at the Eastern Cancer Registration and 
Information centre, Cambridge for their help in providing the data from the Cancer 
registries 
The IT departments at NHSBT Birmingham and Bristol for their support in IT related issues  
All the patients included in the study and their families for exhibiting their generosity 
particularly in periods of ill health and anguish, by consenting for their data to be used in 
research 
 
 
  
  
 
 
 
6 
 
 
Abbreviations 
ARDS  Adult respiratory distress syndrome 
AMR  Antibody mediated rejection 
AFP  Alpha-fetoprotein 
APC  Antigen presenting cell 
ALG  Anti-lymphocyte globulin 
ATG  Anti-thymocyte globulin 
ANZDATA Australia and New Zealand Dialysis and Transplant Registry 
BC  Before Christ 
BMI  Body mass index 
CNI  Calcineurin inhibitors 
CIS  Carcinoma-in-situ 
CNS  Central nervous system 
CNT  Centro Nazionali di Trapianti 
CCL2  Chemokine (c-c motif) ligand 2 
CCL5  Chemokine ligand 5 
CoE  Council of Europe 
CI  Confidence interval 
7 
 
 
CRP  C-reactive protein 
CT  Computerised tomography 
CXCL10 c-x-c motif chemokine 
CMV  Cytomegalovirus 
D  Donor 
DNA  De-oxy ribonucleic acid 
DCP  Des-gamma-carboxy prothrombin 
DBD  Donation after brain death 
DCD  Donation after circulatory death 
DDC  Donor derived cancer 
DOC  Donor origin cancer 
DTC  Donor transmitted cancer 
EBV  Epstein-Barr virus 
GIST  Gastrointestinal stromal tumour 
 HR  Hazard ratio 
HFSS  Heart failure survival score 
HBV  Hepatitis B virus 
HCV  Hepatitis C virus 
8 
 
 
HL  Hodgkin’s lymphoma 
HHV  Human herpes virus 
HIV  Human immunodeficiency virus 
HLA  Human leukocyte antigen 
HPV  Human papilloma virus 
HTLV  Human T-lymphotropic virus 
IFN  Interferon 
IL  Interleukin 
iNOS  Inducible nitric oxide synthetase 
IPITTR  Israel Penn International Transplant Tumour Registry 
Kg  Kilogram 
LAS  Lung allocation score 
MRI  Magnetic resonance imaging 
MHC  Major histocompatibility complex 
mTOR  Mammalian target of Rapamycin 
mTORC Mammalian target of Rapamycin complex 
m  Metre 
6MP  6-mercaptopurine 
9 
 
 
MELD  Model for end-stage liver disease 
MMF  Mycophenolate mofetil 
NCDR  National Cancer Data Repository 
NHS  National Health Service 
NHSBT  National Health Service Blood and Transplant 
NOMDS National Organ Matching and Distribution Service 
NTTRL  National Tissue Typing and Reference Laboratory 
NK  Natural killer 
NHL  Non-Hodgkin’s lymphoma 
NMSC  Non-melanoma skin cancer 
NS  Not specified  
NFAT  Nuclear factor of activated T-cells 
OR  Odds ratio 
OPTN  Organ Procurement and Transplantation Network 
ONT  Organizacion Nacional de Trasplantes 
PET  Positron emission tomography 
PTLD  Post-transplant lymphoproliferative disorder 
PCA  Prostate cancer antigen 
10 
 
 
PSA  Prostate specific antigen 
R  Recipient 
SHFM  Seattle heart failure model 
SN-OD  Specialist nurses in organ donation 
SIR  Standardised incidence ratio 
SAS  Statistical analysis software 
TCR  T cell receptor 
TTS  The Transplantation Society 
6TG  6-thioguanine 
TGF  Transforming growth factor 
TNF  Tumour necrosis factor 
UV  Ultraviolet 
UK  United Kingdom 
UKELD  United Kingdom end-stage liver disease 
UNOS  United Network for Organ Sharing 
USFDA  United States Food and Drug Administration 
USA  United States of America 
WHO  World Health Organization 
11 
 
 
Contents 
Abstract……………………………………………………………………………………………………………………..…………1 
Disclaimer…………………………………………………………………………………………………………………………….2
Dedication…………………………………………………………………………………………………………………………….3
Acknowledgements………………………………………………………………………………………………………………4
Abbreviations……………………………………………………………………………………………………………………….6
List of Tables……………………………………………………………………………………………………………………….20 
List of Figures……………………………………………………………………………………………………………………..23 
1. Introduction…………………………………………………………………………………………………………………26 
1.1 Background to this research……………………………………………………………………………….27 
1.2 History of transplantation…………………………………………………………………………………..28 
1.2.1 Early history…………………………………………………………………………………………………28 
1.2.2 Xenotransplantation…………………………………………………………………...................29 
1.2.3 Early human kidney allotransplantation………………………………………………………30 
1.2.4 First successful kidney allotransplantation………………………………………………….31 
1.2.5 Early human liver allotransplantation………………………………………………………….33 
1.2.6 Early human heart and lung allotransplantation………………………………………….33 
1.3 National transplant programme in the UK………………………………………………………….35 
1.4 Immunology of transplant rejection……………………………………................................35 
1.4.1 Historical background………………………………………………………………………………….35 
1.4.2 Immunological basis of allograft rejection…………………………………………………..36 
1.4.3 Stages of allograft rejection…………………………………………………………………………37 
12 
 
 
1.4.3.1 Sensitisation stage…………………………………………………………………………..37 
1.4.3.2 Effector stage…………………………………………………………………………………..40 
1.5 Clinical types of rejection……………………………………………………………………………………43 
1.5.1 Hyperacute rejection…………………………………………………………………………………..43 
1.5.2 Acute rejection……………………………………………………………………………………………48 
1.5.2.1 Acute antibody mediated rejection…………………………………………………48 
1.5.2.2 Acute cellular rejection……………………………………………………………………49 
1.5.3 Chronic rejection………………………………………………………………………………….........52 
1.6 Immunosuppressive agents………………………………………………………………………………..52 
1.6.1 Biological agents………………………………………………………………………………………….53 
1.6.1.1 Polyclonal agents…………………………………………………………………………….53 
1.6.1.2 Monoclonal agents………………………………………………………………………….55 
1.6.2 Xenobiotics………………………………………………………………………………………………….58 
1.6.2.1 Corticosteroids………………………………………………………………………………..59 
1.6.2.2 Antimetabolites………………………………………………………………………………60 
1.6.2.3 Calcineurin inhibitors……………………………………………………………………..62 
1.6.2.4 mTOR inhibitors……………………………………………………………………………..65 
1.7 Effects of immunosuppressive agents on post-transplant cancer………………………65 
1.7.1 Biological agents…………………………………………………………………………………………66 
1.7.2 Corticosteroids…………………………………………………………………………………………..67 
1.7.3 Antimetabolites…………………………………………………………………………………………68 
1.7.4 Calcineurin inhibitors…………………………………………………………………………………69 
1.7.5 mTOR inhibitors…………………………………………………………………………………………70 
13 
 
 
1.8 Current status of organ transplantation……………………………………………………………..72 
1.8.1 Organ donors: selection and assessment…………………………………………………….73 
1.8.2 Changing profile of the organ donor…………………………………………………………….76 
1.8.3 Organ recipients and the waiting list……………………………………………………………76 
1.9 Benefits of organ transplantation……………………………………………………………………….78 
1.10 Risks and complications of organ transplantation………………………………………………84 
1.11 Cancer after transplantation………………………………………………………………………………87 
1.11.1 Cancer transmission by organ transplantation……………………………………………88 
1.12 Assessment of the risk of cancer transmission from organ donors……………………105 
1.13 Guidelines for estimation of the cancer transmission risk…………………………………106 
1.14 Role of CMV in post-transplant cancer……………………………………………………………..111 
1.15 Post-transplant lymphoproliferative disorders………………………………………………….111 
1.16 Importance of this thesis………………………………………………………………………………….112 
2. Aims of the thesis………………………………………………………………………………………………………114 
3. Donor transmitted cancers in transplant recipients…………………………………………………..117 
Disclaimer………………………………………………………………………………………………………………….118 
3.1 Introduction……………………………………………………………………………………………………..119 
3.2 Aims…………………………………………………………………………………………………………………120 
3.3 Methods…………………………………………………………………………………………………………..120 
3.3.1 Classification of DOC…..……………………………………………………………………………..121 
3.3.2 Statistical analysis………………………………………………………………………………………123 
3.3.2.1 Incidence of DTC in different recipient groups……………………………….123 
3.3.2.2 Risk of cancer transmission from donors……………………………………….124 
3.3.2.3 Recipient survival following DTC……………………………………………………124 
14 
 
 
3.4 Results……………………………………………………………………………………………………………..125 
3.4.1 Recipient groups………………………………………………………………………………………..125 
3.4.2 Donor origin cancers………………………………………………………………………………….125 
3.4.3 Donor transmitted cancers………………………………………………………………………..128 
3.4.4 Donor factors associated with cancer transmission……………………………………133 
3.4.5 Time of diagnosis of DTC……………………………………………………………………………135 
3.4.6 Effect of DTC on recipient outcome……………………………………………………………135 
3.5 Discussion…………………………………………………………………………………………………………138 
3.5.1 Clinical implications……………………………………………………………………………………138 
3.5.2 Strengths and limitations of the study……………………………………………………….139 
3.5.3 Reducing the risk of cancer transmission……………………………………………………140 
3.5.4 Management of recipients with DTC………………………………………………………….143 
3.5.4.1 Before transplantation…………………………………………………………………..143 
3.5.4.2 After transplantation……………………………………………………………………..143 
3.5.5 Management of recipients of other organs………………………………………………..145 
4. Donors with a history of cancer…………………………………………………………………………………147 
Disclaimer………………………………………………………………………………………………………………….148 
4.1 Introduction……………………………………………………………………………………………………..149 
4.2 Aims…………………………………………………………………………………………………………………150 
4.3 Methods…………………………………………………………………………………………………………..150 
4.3.1 Actual donors and their recipients…………………………………………………………….151 
4.3.2 Identifying cancer diagnosed at organ retrieval…………………………………………151 
4.3.3 Potential donors………………………………………………………………………………………..152 
4.3.4 Statistical analysis……………………………………………………………………………………..153 
15 
 
 
4.4 Results………………………………………………………………………………………………………………153 
4.4.1 Cancers diagnosed at organ retrieval…………………………………………………………153 
4.4.2 Donors with a history of cancer…………………………………………………………………157 
4.4.3 Actual donors with unacceptable risk of cancer transmission……………………159 
4.4.4 Factors associated with non-transmission of donor cancer………………………..163 
4.4.5 Possible/potential donors excluded based on their history of cancer………..165 
4.5 Discussion…………………………………………………………………………………………………………165 
4.5.1 Balancing cancer transmission risk against the risk of waiting-list 
mortality……………………………………………………………………………………………………165 
4.5.2 Strengths and limitations of the study……………………………………………………….166 
4.5.3 Existing evidence and the need to change the present guidelines……………..168 
4.5.4 Donors with cancer of the CNS…………………………………………………………………..168 
4.5.5 Donors with non-CNS cancers……………………………………………………………………169 
4.5.5.1 Donors with past melanoma………………………………………………………….169 
4.5.5.2 Donors with past breast cancer……………………………………………………..170 
4.5.5.3 Donors with past ovarian cancer……………………………………………………171 
4.5.5.4 Donors with past colon cancer……………………………………………………….171 
4.5.5.5 Donors with past sarcoma/lymphoma……………………………………………172 
4.5.6  Impact on the number of organs available for transplantation…………………174 
4.5.7 Role of informed consent…………………………………………………………………………..174 
5. Recurrence of cancer in organ transplant recipients………………………………………………….176 
5.1 Introduction……………………………………………………………………………………………………..177 
5.2 Aims…………………………………………………………………………………………………………………178 
5.3 Methods…………………………………………………………………………………………………………..178 
16 
 
 
5.3.1 Data…………………………………………………………………………………………………………..179 
5.3.2 Statistical analysis……………………………………………………………………………………..180 
5.4 Results………………………………………………………………………………………………………………180 
5.4.1 Study cohort………………………………………………………………………………………………180 
5.4.2 Recipients with recurrence of cancer after transplantation……………………….182 
5.4.3 Recipients without recurrence of cancer after transplantation………………….184 
5.4.4 Impact of immunosuppression on the risk of recurrence…………………………..186 
5.5 Discussion…………………………………………………………………………………………………………188 
5.5.1 Summary of findings and comparison with literature…………………………………188 
5.5.2 Impact of immunosuppression…………………………………………………………………..193 
5.5.2.1 Calcineurin inhibitors…………………………………………………………………….193 
5.5.2.2 mTOR inhibitors…………………………………………………………………………….193 
6. Cytomegalovirus and cancer risk after transplantation………………………………………………195 
Disclaimer……………………………………………………………………………………………..…………………..196 
6.1 Introduction……………………………………………………………………………………………………..197 
6.2 Aims…………………………………………………………………………………………………………………198 
6.3 Methods…………………………………………………………………………………………………………..198 
6.3.1 Study cohort………………………………………………………………………………………………198 
6.3.2 Data…………………………………………………………………………………………………………..199 
6.3.3 Statistical analysis….………………………………………………………………………………….199 
6.4 Results………………………………………………………………………………………………………………201 
6.4.1 Risk of cancer among recipients in different CMV groups………………………….203 
6.4.2 Risk of individual types of cancers……………………………………………………………..205 
6.4.3 CMV and post-transplant survival……………………………………………………………..211 
17 
 
 
6.4.4 Causes of death among transplant recipients……………………………………………216 
6.5 Discussion…………………………………………………………………………………………………………218 
6.5.1 Strengths and limitations of the study……………………………………………………….218 
6.5.2 Impact of CMV on the risk of post-transplant cancer…………………………………219 
6.5.3 Impact of CMV on post-transplant patient survival……………………………………220 
6.5.4 Reasons for increased mortality among CMV exposed………………………………221 
7. Post-transplant lymphoproliferative disorders…………………………………………………………..224 
7.1 Introduction……………………………………………………………………………………………………..225 
7.1.1 Risk factors and pathogenesis of PTLD……………………………………………………….225 
7.1.2 Incidence of PTLD………………………………………………………………………………………227 
7.1.3 Classification of PTLD…………………………………………………………………………………228 
7.1.4 Clinical features and diagnosis of PTLD………………………………………………………229 
7.1.5 Management and prognosis of PTLD…………………………………………………………229 
7.2 Aims…………………………………………………………………………………………………………………230 
7.3 Methods…………………………………………………………………………………………………………..231 
7.3.1 Study cohort………………………………………………………………………………………………231 
7.3.2 Data…………………………………………………………………………………………………………..231 
7.3.3 Statistical analysis…………………………………………………………………………………….232 
7.4 Results………………………………………………………………………………………………………………233 
7.4.1 Recipient characteristics……………………………………………………………………………233 
7.4.2 Incidence and SIR of HL and NHL……………………………………………………………….236 
7.4.3 SIR of HL and NHL over 3 decades………………………………………………………………239 
7.4.4 Recipient survival after PTLD……………………………………………………………………..245 
7.4.5 Immunosuppression and post-transplant NHL…………………………………………..251 
18 
 
 
7.4.5.1 Impact of induction agent on SIR of NHL………………………………………..251 
7.4.5.2 Impact of ciclosporin/tacrolimus on the SIR of NHL……………………….253 
7.4.5.3 Impact of azathioprine/MMF on the SIR of NHL…………………………….255 
7.4.6 HLA and PTLD…………………………………………………………………………………………….257 
7.5 Discussion…………………………………………………………………………………………………………260 
7.5.1 Brief summary of findings………………………………………………………………………….260 
7.5.2 Strengths and limitations of the study……………………………………………………….260 
7.5.3 SIR of PTLD…………………………………………………………………………………………………261 
7.5.4 PTLD and recipient survival………………………………………………………………………..262 
7.5.5 PTLD and immunosuppression…………………………………………………………………..263 
7.5.6 PTLD and HLA…………………………………………………………………………………………….263 
8. Summary and Conclusions…………………………………………………………………………………………266 
8.1 Summary of research findings…………………………………………………………………………..267 
8.1.1 Setting the scene……………………………………………………………………………………….267 
8.1.2 Donor-transmitted cancer in the transplant recipient……………………………….269 
8.1.3 Donors with a history of cancer…………………………………………………………………272 
8.1.4 Recurrent cancer after transplantation………………………………………………………274 
8.1.5 CMV and the risk of post-transplant cancer……………………………………………….275 
8.1.6 Post-transplant lymphoproliferative disorders…………………………………………..276 
8.2 Strengths of this research…………………………………………………………………………………277 
8.2.1 New evidence with impact on clinical practice………………………….……………….278 
8.2.2 Quality of data: the UK transplant registry…………………………………………………280 
8.2.3 Quality of data: the cancer registries…………………………………………………………281 
8.3 Limitations of this research………………………………………………………………………………282 
19 
 
 
8.4 Conclusions………………………………………………………………………………………………………286 
9. Future work…………………………….…………………………………………………………………………………288 
9.1 Improvements in data………………………………………………………………………………………….289 
9.2 Improvements in donor selection and assessment………………………………………………291 
9.2.1 Cross-sectional imaging……………………………………………………………………………..292 
9.2.2 Histopathology: biopsy and autopsy………………………………………………………….293 
9.2.3 Tumour markers………………………………………………………………………………………..294 
9.3 Improvements in the recipient management……………………………………………………….295 
9.3.1 Lifestyle changes……………………………………………………………………………………….295 
9.3.2 Vaccination against oncogenic viruses……………………………………………………….296 
9.3.3 Immunosuppressive agents with anti-neoplastic properties………………………297 
9.3.4 Cancer screening after transplantation……………………………………………………..298 
9.3.5 Surveillance for cancer treated prior to transplantation……………………………299 
9.3.6 Role of CMV and EBV in post-transplant cancer………………………………………..299 
10. References…………………………………………………………………………………………………………………301 
Appendix 1. List of publications and presentation arising from this thesis……………………….325 
  Publications………………………………………………………………………………………………326 
  Oral presentations at learned societies……………………………………………………..327 
  Poster presentations at learned societies………………………………………………….329 
Appendix 2. Award and Distinctions…………………………………………………………………………………330 
Appendix 3. Published manuscripts………………………………………………………………………………….332 
20 
 
 
List of Tables 
Table 1.1 Kidney transplantation: patient survival after transplantation in the UK and 
USA…………………………………………………………………………….………………………………………………………80 
Table 1.2 Kidney transplantation: graft survival after transplantation in the UK and USA…..81 
Table 1.3 Liver transplantation: patient survival after transplantation in the UK and USA….82 
Table 1.4 Thoracic transplantation from deceased donors: patient survival after 
transplantation in the UK and USA……………………………………………………………………………………..83 
Table 1.5 Risks of organ transplantation…………………………………………………………………………….85 
Table 1.6 Cancers transmitted by organ transplantation…………………………………………………...90 
Table 1.7 Council of Europe guidelines for stratification of risk of cancer transmission…….109 
Table 3.1 Transplant activity in the UK and cases of DOC between 2001 and 2010…………..127 
Table 3.2 Cases of transmitted cancer from organ donors in the UK…………………………………129 
Table 3.3 Donor characteristics and the association with cancer transmission: results of 
univariate analysis…………………………………………………………………………………………………………….134 
Table 4.1 Donor cancers identified at organ retrieval and recipient outcome…………………..155 
Table 4.2 Recipient survival and risk-adjusted hazard of death in single-organ recipients from 
donors with unacceptable risk and standard/non-standard risk of cancer transmission…..160 
Table 4.3 Post-transplant cancers in the recipients from donors with unacceptable risk 
cancers……………………………………………………………………………………………………………………………..162 
21 
 
 
Table 4.4 Donors with unacceptable risk cancer (excluding CNS cancers): features associated 
with non-transmission of cancer………………………………………………………………………………………164 
Table 4.5 Suggested changes to present guidelines: donor cancers proposed to have a low 
risk……………………………………………………………………………………………………………………………………173 
Table 5.1 Recipients with and without a pre-transplant cancer: comparison of age, gender 
and survival of recipients of different organs……………………………………………………………………181 
Table 5.2 Recipients with recurrence of cancer after transplantation……………………………….183 
Table 5.3 Recipients without cancer recurrence (numbers is brackets indicate the number of 
recipients with cancer)……………………………………………………………………………………………………..185 
Table 5.4 Impact of individual immunosuppressive agents on the risk of recurrence of cancer 
after transplantation…………………………………………………………………………………………………………187 
Table 5.5 Published cases of transplant recipients with a history of cancer………………………190 
Table 6.1 Characteristics of recipients in different CMV groups………………………………………..202 
Table 6.2 Frequency and unadjusted incidence of different types of cancers in the recipient 
groups based on CMV status……………………………………………………………………………………………206 
Table 6.3 1-year and 10-year patient survival and risk-adjusted hazard of death……………..214 
Table 7.1. Recipient characteristics in different organ recipients over 3 decades……………..235 
Table 7.2 SIRs for NHL and HL among recipients of different organs…………………………………237 
Table 7.3. SIRs for NHL and HL among children and adult recipients…………………………………238 
22 
 
 
Table 7.4 SIR for HL and NHL among heart recipients and lung recipients………………………..244 
Table 7.5 Recipient survival and risk-adjusted hazard of death among organ transplant 
recipients with PTLD over three decades…………………………………………………………………………250 
Table 7.6 SIR for NHL among kidney recipients based on their induction agent……………….252 
Table 7.7 SIR for NHL among kidney recipients on ciclosporin or tacrolimus……………………254 
Table 7.8 SIR for NHL among kidney recipients on azathioprine or MMF…………………………256 
Table 7.9 HLA antigens and their association with PTLD among kidney recipients……………258 
 
 
 
 
 
 
 
 
 
 
 
23 
 
 
List of Figures 
Figure 1.1 Alloantigen recognition by the host T cell: a. Direct and indirect allorecognition. A. 
Allogenic APC bound with allogenic MHC is recognised by host T cell. B. Host APC binds with 
and processes allogenic MHC and presents it to host T cell. b.  The binding of the MHC-
antigen complex with the T cell receptor. A. Self MHC binds to foreign peptide and both the 
MHC and the peptide participate in binding to T cell receptor. B and C. T cell receptor binds 
with the allogenic MHC – donor peptide complex where the donor peptide may (A) or may 
not (B) participate in binding with the T cell receptor. Reproduced from Abbas and Lichtman 
……………………………………………………………………………………………………………………………………………39 
Figure 1.2 Mechanism of cytolytic T cell mediated target cell apoptosis. T cell identifies the 
target cell by recognising the antigen on the cell membrane. Activated T cell undergoes 
degranulation to produce perforin, which produces cell membrane pores through which 
granzymes enter the target cell and initiate caspase mediated target cell apoptosis. 
Reproduced from Abbas and Lichtman…………………………………………………………………..………….42 
Figure 1.3 Pathogenesis of rejection: A. Hyperacute rejection, B. Acute rejection and C. 
Chronic rejection. Reproduced from Abbas and Lichtman .....…………………………………………….45 
Figure 1.4 Kidney allograft biopsy with hyperacute rejection. A. Lymphocytic infiltration in 
the endothelium (arrow) and fibrin deposition. B. Necrosis and thrombosis of an interlobular 
artery with tubular infarction. Reproduced from Trpkov….………………………………………………..47 
Figure 1.5A Acute interstitial rejection showing severe tubulitis and interstitial infiltration. 
Periodic acid Schiff, magnification X100. Reproduced from the Atlas of Renal Pathology…..50 
24 
 
 
Figure 1.5B Acute vascular rejection showing endothelial infiltration and microthrombus. 
Periodic acid Schiff, magnification X200. Reproduced from the Atlas of Renal Pathology…..51 
Figure 3.1: 5-year survival of kidney recipients with and without DTC………………………………137 
Figure 3.2. Increasing proportion of older organ donors in the UK……………………………………142 
Figure 4.1 Donors with a history of cancer: exploded slices show cancers with unacceptable 
risk……………………………………………………………………………………………………………………………………158 
Figure 6.1 Risk-adjusted hazard of cancer within 10 years of transplantation, among 
different CMV groups compared with the D-R- group………………………………………………………204 
Figure 6.2 Comparison of risk-adjusted hazard (with 95% CI) of developing different types of 
cancers within 10 years of transplantation in different CMV groups, compared against the D-
R- group……………………………………………………………………………………………………………………………208 
Figure 6.3 Comparison of 10-year recipient survival between four groups based on CMV 
status………………………………………………………………………………………………………………………………212 
Figure 6.4 Causes of death (in %) among 6213 recipients of all organs who died within 10 
years of transplantation, divided into D-R- recipients and all other recipients…………………217 
Figure 7.1A SIR for NHL among kidney recipients (p = 0.20)…………………………………………….240 
Figure 7.1B SIR for HL among kidney recipients (p = 0.08)………………………………………………241 
Figure 7.2A SIR for NHL among liver recipients (p = 0.61)………………………………………………242 
Figure 7.2B SIR for HL among liver recipients (p = 0.70)…………………………………………………243 
Figure 7.3 Kidney recipient survival after the diagnosis of PTLD (p=0.84)………………………246 
25 
 
 
Figure 7.4 Liver recipient survival after the diagnosis of PTLD (p=0.76)…………………………….247 
Figure 7.5 Heart recipient survival after the diagnosis of PTLD (p=0.58)…………………………..248 
Figure 7.6 Lung recipient survival after the diagnosis of PTLD (p=0.49)…………………………….249 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
 
CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
1.1 Background to this research 
One of the major medical advances of the twentieth century is the successful 
transplantation of solid organs. Within decades, organ transplantation progressed from 
animal experiments and early human experiments to an established front-line treatment. 
Developments took place in all aspects of donation and transplantation including 
assessment and selection of the donors and the recipients, surgical techniques, anaesthetic 
techniques, intensive care and long-term post-transplant care. At present, transplantation is 
the most effective treatment for selected patients with end-stage organ failure. Successful 
transplantation has been shown to improve the length and the quality of life (NHSBT, 
2014b). It can be an effective life saving intervention in some cases with acute organ failure 
and also has a positive impact on the health care economy (NHSBT, 2009).  
 
Cancer, along with infection and cardiovascular disease, is one of the three most common 
causes of long-term mortality among the recipients of organ transplantation (USRDS, 2012, 
Pruthi et al., 2001, Rabkin et al., 2001, Jung et al., 2011). The incidence of cancer is higher 
among the recipients of organ transplantation compared to matched non-transplant 
population (Collett et al., 2010, Villeneuve et al., 2007, Adami et al., 2003, Hoshida et al., 
1997, Kyllonen et al., 1994, Kasiske et al., 2004) and the outcomes of post-transplant cancer 
are poorer as the disease tends to be more aggressive than in an immunocompetent 
patient, often resulting in graft loss and death (Barrett et al., 1993, Veness et al., 1999, 
Martinez et al., 2003).  
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In this chapter, an overview of organ transplantation is presented, including early and 
recent history of human organ transplantation, immunological and clinical aspects of graft 
rejection, immunosuppressive agents and the outcomes after transplantation with emphasis 
on post-transplant cancer. 
 
1.2 History of organ transplantation 
1.2.1 Early history 
Successful organ transplantation has only been achieved in recent history but the idea of 
replacing a human body part in order to improve the function or the appearance has 
fascinated several ancient human societies in different parts of the world. The oldest 
references to transplantation are in the ancient Greek, Roman, Indian and Chinese 
mythology. There are several examples of transfer of a part of the body, often from an 
animal to a God or a human such as Ganesh, the God with the head of an elephant, 
Narasimha, the God with the face and claws of a lion, Ox-Head and Minotaur, both 
examples of men with the head of a bull, Horse-Face and Chiron both of whom were half-
horse and half-human. The New Testament describes several accounts of re-implantation of 
amputated body parts including ears, limbs and breasts.  
 
Archaeological evidence shows that the practice of bone grafting existed in the Bronze Age. 
The skulls of people treated with trephination to relieve the intracranial pressure were 
reconstructed using bone autografts (SabistonDCJr, 1981). The earliest scientific 
documentation of transplantation is in the Sushruta Samhita, a surgical text written by the 
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Indian surgeon Sushruta who lived in the 6th century before Christ (BC) in the city of 
Varanasi, in northern India. Sushruta is regarded as the father of modern surgery and 
several surgical sub-specialties including ophthalmology and neurosurgery. The Sushruta 
Samhita was written in Sanskrit language, translated to English in 1918 (Bhishagratna, 
1963). Sushruta transplanted skin, technically the largest organ in the body. Cutting off the 
nose or ear lobes was a common social or religious punishment of the time and Sushruta 
performed skin grafts from the buttocks or forehead (on a vascular pedicle) to the nose or 
the ears of victims of such punishment.  
 
In the 16th century, Gasparo Tagliocozzi, a professor of anatomy and surgery in Bologna 
described a procedure to reconstruct the nose using a skin autograft raised from the 
forearm. Tagliocozzi recognised that allografts suffered with more problems than 
autografts. He referred to the uniqueness of each individual as ‘the force and power of 
individuality’ and warned that anyone who would consider breaching this force would be 
‘plainly superstitious and badly grounded in physical science’ (DuquesnoyRJ, 2005). It was 
not for another two centuries that the experiments of Gregory Mendel, which planted the 
seeds leading to the development of Genetics as a specialty.   
 
1.2.2 Xenotransplantation 
Transplantation of internal organs from animals to humans was first attempted in the early 
20th century. Princeteau inserted slices of rabbit kidney into the failed kidney of a child in 
1902 (Reemtsma et al., 1964). The recipient initially experienced improvement in symptoms 
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and urine production but died on the 16th day after transplantation from pulmonary 
congestion. Between 1906 and 1966, many surgeons performed transplantation of kidneys 
from pigs, goats, monkeys, sheep, chimpanzees and baboons. All the recipients died within 
days or weeks of transplantation (Taniguchi and Cooper, 1997). Starzl noted that his 
patients who were transplanted with baboon kidneys had developed much more aggressive 
immunological rejection as compared to the recipients of kidneys from chimpanzees (Starzl 
et al., 1964a). This experience, although unsuccessful, resulted in recognition of genetic 
diversity between the species and its correlation to the degree of rejection of the allograft. 
Xenotransplantation of liver was first performed in 1966 and until 1993, livers from 
chimpanzees, baboons and pigs and continued to be transplanted into humans. The longest 
survival of a liver xenotransplantation recipient was 70 days (Taniguchi and Cooper, 1997). 
Heart transplantation from chimpanzees, sheep, pigs and baboons were performed with 
recipient survival ranging between 0 and 20 days (Taniguchi and Cooper, 1997). In 1902, 
Emerich Ullman, an Austrian surgeon, performed the first kidney homotransplantation 
between two animals (Druml, 2002). He transplanted a kidney from one dog into another, 
using the neck vessels for anastomosis. Ullman demonstrated the production of urine from 
the ureter stitched to the skin, to the audience at the meeting of the Society of Physicians in 
Vienna. This transplant lasted for 4 days.  
 
1.2.3 Early human kidney allotransplantation 
In 1902, French surgeon Alexis Carrell described the technique of vascular anastomosis and 
followed this with pioneering work in attaching severed limbs and transplanting kidneys and 
hearts in dogs and cats. For this work, Carrell was awarded Nobel Prize in 1912 (Cooper, 
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2012). Between 1933 and 1936, Russian surgeon Yurii Voronoy performed the first case-
series of human kidney allotransplantation in 6 patients with acute renal failure using 
deceased donors (Matevossian et al., 2009). The first of these recipients was a 26-year-old 
lady with renal failure secondary to mercury chloride poisoning who was transplanted with 
a kidney from a 60-year-old donor who died following a skull-base fracture.  This recipient 
died within 48 hours of transplantation. All the grafts in Voronoy’s case series failed because 
of blood group incompatibility and the lack of recognition of the effect of prolonged warm 
ischemia. Voronoy used anastomosis between donor renal vessels and recipient brachial or 
femoral vessels and an uretero-cutaneous fistula. Although this method was technically easy 
and allowed relatively easy access to the graft for biopsy or excision, this was only suitable 
for patients with acute renal failure who needed the graft for relatively short periods. The 
technique of placing the kidney graft in the retroperitoneal area with vascular anastomosis 
using external iliac vessels and ureteric anastomosis to bladder was developed in 1951 in 
France. This remains the method used today. Between 1936 and 1945, there were isolated 
attempts at kidney transplantation, all of which were unsuccessful.  
 
1.2.4 First successful kidney transplantation 
The kidney transplantation performed in 1945 at Peter Bent Brigham Hospital, Boston by 
Charles Hufnagel, Ernest Landsteiner and David Hume was the first successful life-saving 
kidney transplantation. A lady with acute renal failure was transplanted with a deceased 
donor kidney, which was placed on her forearm, covered with a plastic bag and 
anastomosed to the ante-cubital vessels. This graft functioned for 4 days by which time the 
recipient’s own kidneys had recovered and she was discharged from the hospital. In 1950 in 
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Chicago, Richard Lawler performed the first successful intra-abdominal kidney 
transplantation on a recipient with renal failure due to polycystic kidney disease. This kidney 
functioned for 54 days and was removed at 10 months. This was followed in 1951 by a 
series of nine kidney transplantations from deceased donors, performed by a French team 
of surgeons led by Rene Kuss. The extra-peritoneal approach known as the ‘Kuss procedure’ 
was used for the first time in these patients and continues to be used today.  
 
By this time, kidney transplantation from living donors had started. The donor kidneys were 
usually obtained from healthy relatives of the recipient. Survival beyond the immediate 
post-transplant period was not achieved until 1954 when David Hume (Hume, 1979) 
reported a series of nine patients with kidney transplantation. Five of these did not show 
measurable creatinine clearance. Of the remaining four, three functioned to a degree 
sufficient to keep the recipients alive for 37, 110 days and 6 months and the survival 
duration was not specified for one recipient. Two donors in this series were living donors. 
The failed grafts were examined and the immunological processes involved in rejection of 
the graft were recognised. However, the only available drug to counter the rejection at this 
stage was adrenocorticotropic hormone. Some recipients in Hume’s series received 
adrenocorticotropical hormone with or without cortisone, although the longest surviving 
recipient did not receive these agents. In the longest surviving recipient, the graft was 
placed in a plastic bag with an intention to avoid contact between the donor and recipient 
tissues which may initiate graft rejection. 
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1.2.5 Early human liver allotransplantation 
Initial attempts at human liver transplantation were made between 1963 and 1967 in 
Denver (Starzl et al., 1963, Starzl et al., 1964b), Boston (Moore et al., 1964) and Paris 
(Demirleau et al., 1964). Some lessons learnt by transplanting kidney were useful but there 
were unique challenges related to transplanting the liver. The venous return to the heart 
needed to be maintained during the operation and Starzl achieved this by a veno-venous 
bypass from inferior vena cava and portal vein into the superior vena cava. Other challenges 
of liver transplantation included an operative site much closer to vital cardiothoracic organs, 
a recipient who was generally much sicker with profound coagulopathy than a kidney 
recipient. All the recipients died following the initial attempts at liver transplantation with 
longest recorded recipient survival of 23 days. In 1967-68, Thomas Starzl performed first 
series of 7 successful liver transplantations, of whom, one recipient survived for more than 
11 months (Starzl et al., 1968). All the 7 recipients of liver transplantation were matched 
with their donors for ABO blood groups; human leukocyte antigen (HLA) mismatch was 
limited to no mismatch in one recipient and 1 or 2 mismatches of the major HLA groups in 
the remaining recipients. The immunosuppression regimen included anti-lymphocyte 
globulin, azathioprine and prednisolone. In 1968 in Cambridge, Roy Calne performed the 
first liver transplantation in the United Kingdom (UK) (Calne et al., 1968). Calne continued to 
work in the field of transplantation improving the surgical techniques and developing more 
effective and safer immunosuppression.  
 
1.2.6 Early human allotransplantation of heart and lungs 
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Alexis Carrel and Charles Guthrie developed surgical technique of heart transplantation in 
1905. They performed the first heterotopic canine heart transplantation (Cusimano et al., 
1984). Between 1960 and 1965, Norman Shumway in California (Lower and Shumway, 1960, 
Hurley et al., 1962, Dong et al., 1965) showed the benefits of the cardiopulmonary bypass 
and cooling of the graft prior to implantation in dogs. In 1967, Christiaan Barnard performed 
the first human heart transplantation in Cape Town (Barnard, 1968) from a donor with brain 
injury. This recipient survived the operation but developed a post-operative pneumonia and 
died after 18 days. In 1968, Donald Ross in London performed the first heart transplantation 
in the UK, with the recipient survival of 9 weeks. Following this, heart transplantations were 
performed in several centres worldwide but the initial enthusiasm diminished as a result of 
poor recipient outcome, resulting in fewer heart transplantations in fewer centres. The 
advent of ciclosporin in the decade beginning 1980 resulted in resurgence of interest in 
heart transplantation with more procedure being performed in more centres across the 
world. 
 
In 1963, James Hardy performed the first human lung transplantation at the University of 
Mississippi (Hardy et al., 1963).  In the following two decades, the results remained poor for 
lung recipients due to airway complications, infection and other side effects of 
immunosuppression.  In 1981, the cardiovascular team at the Stanford University School of 
Medicine performed the first successful heart-lung transplantation (Reitz et al., 1982). In 
1986, long-term survival following single lung transplantation was reported by the Toronto 
Lung Transplant Group (Toronto, 1986). Further technical modifications included en-bloc 
double lung transplantation in 1988 (Patterson et al., 1988) and sequential bilateral double 
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lung transplantation in 1990 (Pasque et al., 1990) and more recently, lobar transplantation 
from living donors. 
 
1.3 National transplant programme in the UK 
Soon after the first successful kidney transplantation in the UK in 1968, the National Tissue 
Typing and Reference Laboratory (NTTRL) was started in Bristol. In 1971, the kidney donor 
card was introduced, which in 1981, was modified to organ donor card to enable donation 
of multiple organs. In 1972, the National Organ Matching and Distribution Service (NOMDS) 
was started with a role of maintaining national waiting lists for patients in need of organ 
transplantation and the first computers were used in the transplant programme for this 
purpose. The NTTRL and NOMDS were merged in 1979 to form the UK Transplant Support 
Service. The UK Transplant was created in 2000 and merged with the National Blood Service 
in 2005 to form the National Health Service Blood and Transplant (NHSBT). The position of 
Transplant Co-ordinators was created in 1980 to oversee the process of transplantation 
from the time the donor and the recipient are identified to transplantation operation and 
continuing through to the long-term post-transplant follow-up. In 1994, the national organ 
donor register was started as a database of all the individuals in the UK who have signed up 
to be organ donors.  
 
1.4 Immunology of transplant rejection 
1.4.1 Historical background 
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In the 19th century, the experience of blood transfusion from animals and transplantation of 
skin from animals and humans resulted in the development of early insight into the immune 
mechanisms involved in graft rejection. The understanding of humoral immunity developed 
in the late 19th and early 20th century based on the work of scientists including Louis Pasteur 
(germ theory of disease, vaccines against anthrax and rabies), Edward Jenner (small pox 
vaccine), Paul Ehrlich (antibody and auto-immunity), Jules Bordet and Octave Gengou 
(complement activation), Karl Landsteiner (ABO blood groups), Charles Richet and Paul 
Portier (anaphylaxis) and Nicolas Arthus (Arthus reaction). The understanding of cell 
mediated immunity was limited in the early 20th century and the components of humoral 
immunity including blood group antigens and anaphylaxis were thought to be the cause of 
the rejection of skin allografts (DuquesnoyRJ, 2005). By the time Yuri Voronoy performed 
the first human kidney transplantation (donor blood group B, recipient blood group O), he 
was aware of the problems of ABO mismatch but he believed his recipient (being the 
universal blood donor) would transfuse the transplanted organ with the universal donor 
blood and so would not cause agglutination by blood group incompatibility. Medawar and 
Gibson first described the histological details of the cell mediated graft rejection after 
studying the victims of firebomb attacks in the Second World War who underwent skin 
grafting. They described the graft rejection process in human skin graft recipient (Gibson 
and Medawar, 1943) and subsequently confirmed these findings in animal studies 
(Medawar, 1944).  
1.4.2 Immunological basis of allograft rejection 
The most important proteins responsible for the identification of genetic diversity between 
individuals are histocompatibility antigens. These are coded by the genes located in more 
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than 40 loci, the most important of which is the Major Histocompatibility Complex (MHC), 
located on the short arm of chromosome 6. Humans inherit the MHC genes from their 
parents in two half-sets (haplotypes) and express them co-dominantly, expressing both the 
alleles. So each individual’s MHC is 50% identical to their parent and there is a 25% chance 
that it will be fully identical to the MHC of one of their siblings. In physiological conditions, 
the major role of MHC molecules is to present the antigens to T cells, as the T cells only 
recognise antigens which are presented as a complex with a MHC molecule.  
 
The MHC molecules are divided into two classes (Beck et al., 1999): 
Class I: This includes 3 major (A, B and C) and 3 minor (D, E and F) molecules (Marsh et al., 
2005). These are expressed on the cell surface of all the nucleated cells and play an 
important role in presenting intracellular antigens such as viruses and tumour antigens. 
Class II: This includes DP, DM, DO, DQ and DR molecules (Marsh et al., 2005). These are 
expressed on the antigen presenting cells (APCs) such as dendritic cells, macrophages and B 
cells, and usually present extracellular antigens. 
 
1.4.3 Stages of allograft rejection: 
The series of reactions resulting in allograft rejection are divided into two stages: 
sensitisation stage and effector stage. 
 
1.4.3.1 Sensitisation stage:  
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This stage involves the recognition of alloantigens and activation of host immune system. 
This starts as soon as the allograft is placed and blood circulation is established. T cells by 
themselves, are incapable of recognising alloantigens and reacting to them and only 
recognise them when they are presented by APCs (Banchereau and Steinman, 1998). APCs 
express class II MHC molecules on their surface and are specialised in alloantigen 
recognition and presentation. APCs internalise the alloantigen by phagocytosis or 
endocytosis and form a complex of MHC with the alloantigen. A part of this alloantigen, to 
which the T cell has a receptor, is exposed on the cell membrane of the APC. T cell receptor 
(TCR) binds with the antigen-MHC complex resulting in T cell activation. The donor APCs 
bind with the alloantigens and present them to CD4 (‘helper’) and CD8 (‘cytolytic’) T cells by 
the direct pathway. The host APCs also bind with alloantigens and present them to the host 
T cells resulting in their activation via the indirect pathway. Activation of T cells by direct and 
indirect pathways occurs within the allograft as well as in the host lymph nodes, spleen and 
other lymphatic organs.  The process of alloantigen recognition leading up to T cell 
activation is shown in Figure 1.1a and b (Abbas AK, 2004). 
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Figure 1.1 Alloantigen recognition by the host T cell. a. Direct and indirect allorecognition. A. 
Allogenic APC bound with allogenic MHC is recognised by host T cell. B. Host APC binds with 
and processes allogenic MHC and presents it to host T cell.  
b.  The binding of the MHC-antigen complex with the T cell receptor. A. Self MHC binds to 
foreign peptide and both the MHC and the peptide participate in binding to T cell receptor. 
B and C. T cell receptor binds with the allogenic MHC – donor peptide complex where the 
donor peptide may (A) or may not (B) participate in binding with the T cell receptor. 
Reproduced from Abbas and Lichtman (Abbas AK, 2004).  
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1.4.3.2 Effector stage:  
The presentation of alloantigens by direct and indirect pathways results in activation of non-
specific inflammatory response with up-regulated expression of adhesion molecules, 
chemokines and cytokines, including Interleukin-2 (IL2), Interferon gamma (IFN-), 
chemokine ligand 5 (CCL5), C-X-C motif chemokine 10 (CXCL10), chemokine (C-C motif) 
ligand 2 (CCL2), Interleukin-6 (IL6), tumour necrosis factor-alpha (TNF-α), inducible nitric 
oxide synthetase (iNOS) and growth factors. These result in further influx of T cells, 
polymorphonuclear leukocytes and recipient APCs into the allograft. These increase antigen 
presentation and result in activation of more cytotoxic T cells. B cells are also activated, 
resulting in production of donor specific antibodies. Activated cytotoxic T cells undergo 
degranulation to release perforin, granzymes and granulysin. Perforin binds to the plasma 
membrane of the target cell and forms a pore in the plasma membrane, which facilitates 
entry of other enzymes into the target cell.  Granzymes enter the target cell through the 
pore formed by perforin and result in activation of caspase and caspase-activated-DNAase. 
These set off cascades of cleavage of substrates, leading to apoptosis, the programmed cell 
death (Krupnick et al., 2002). These reactions are shown in Figure 1.2. 
  
Natural killer (NK) cells are a distinct type of cytotoxic T lymphocytes that possess the ability 
to mount an effector response without prior sensitisation. They can produce cytokines such 
as IFN- and can also effect direct cytotoxicity by perforin-granzyme pathway as well as by 
fas-Ligand pathway (Kitchens et al., 2006). Another unique characteristic of NK cells, 
described as the “missing self” hypothesis, is that they can identify foreign cells by the 
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absence of MHC molecules on their cell membrane. With these features, NK cells play an 
important role in facilitating the response of other cytotoxic T cells in allograft rejection. 
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Figure 1.2 Mechanism of cytolytic T cell mediated target cell apoptosis. T cell identifies the 
target cell by recognising the antigen on the cell membrane. Activated T cell undergoes 
degranulation to produce perforin, which produces cell membrane pores through which 
granzymes enter the target cell and initiate caspase mediated target cell apoptosis. 
Reproduced from Abbas and Lichtman (Abbas AK, 2004). 
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The role of co-stimulation: 
A second signalling mechanism is usually required for effective activation of T cells. This 
mechanism is called co-stimulation, without which a state of tolerance referred to as clonal 
anergy (LaSalle and Hafler, 1994) may result. The co-stimulation response is antigen non-
specific and is mediated by several proteins on the surface of APC, of which the most 
important are CD80 and CD86. The full activation of T cell occurs following binding of CD80, 
CD86 proteins with the CD28 receptor present on the T cell. 
 
1.5 Clinical types of rejection: 
1.5.1 Hyperacute rejection: 
Hyperacute rejection is mediated by pre-formed anti-donor antibodies and often develops 
within minutes to hours after the allograft has been placed. The pre-formed antibodies 
usually develop as a consequence of previous antigen exposure due to a previous 
transplantation, blood transfusion or pregnancy. Hyperacute rejection may be delayed by 
days or weeks in cases where the antigen exposure was in the remote past with very low or 
absent levels of pre-formed antibody at the time of transplantation (Rosenberg et al., 2004). 
In such cases, anamnestic reaction results in rapid formation of antibodies against the 
allograft causing delayed hyperacute rejection. Kidney allografts are most susceptible to 
hyperacute rejection and the risk is reduced significantly by cross-matching prior to 
transplantation (O'Rourke et al., 2000). In contrast, liver allografts are least susceptible to 
hyperacute rejection. Hyperacute rejection of liver is almost exclusively seen in ABO 
incompatible transplantations and often presents more gradually than kidney, with rise of 
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serum transaminase levels and impaired coagulation days after transplantation (Hubscher, 
2012). The reasons for relative resistance of liver allografts to antibody mediated rejection 
are not fully understood and have been attributed to dual blood supply, large surface area 
of and expression of high levels of Fc receptors by the hepatic sinusoidal endothelial cells 
resulting in absorption of antigen-antibody complexes before they can reach hepatocytes. 
 
The pathogenesis of antibody-mediated rejection involves formation of complexes between 
the anti-donor antibodies and the antigens on the allograft vascular endothelium. This 
results in activation of complement cascade with release of C3a and C5a which act as 
chemokines attracting inflammatory cells. The inflammation in the endothelium also results 
in activation of platelets and coagulation cascade resulting in thrombosis. Figure 1.3 shows 
the pathogenesis of hyperacute, acute and chronic rejection (Abbas AK, 2004). 
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Figure 1.3 Pathogenesis of rejection: A. Hyperacute rejection, B. Acute rejection and C. 
Chronic rejection. Reproduced from Abbas and Lichtman (Abbas AK, 2004). 
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Pathologically, the inflammation is centred on the vascular endothelium with inflammatory 
infiltration and fibrinoid changes in the early stages followed by thrombosis and necrosis in 
the later stages. Pathological changes in a kidney allograft biopsy from a recipient who had 
preformed anti-donor antibodies is shown in Figure 1.4 (Trpkov et al., 1996). Corresponding 
changes in the liver allografts include severe preservation-reperfusion injury, non-occlusive 
thrombosis and haemorrhagic necrosis. 
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Figure 1.4 Kidney allograft biopsy with hyperacute rejection. A. Lymphocytic infiltration in 
the endothelium (arrow) and fibrin deposition. B. Necrosis and thrombosis of an interlobular 
artery with tubular infarction. Reproduced from Trpkov (Trpkov et al., 1996). 
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1.5.2 Acute rejection: 
Acute rejection can develop within the first week after transplantation but usually develops 
in the first year and less commonly later. Acute rejection is more commonly caused by 
cellular immune response than by antibody-mediated response. 
 
1.5.2.1 Acute antibody mediated rejection (AMR): 
Acute AMR is defined based on the presence of four diagnostic features (Colvin and Smith, 
2005): clinical (evidence of graft dysfunction), histological (acute graft injury with infiltration 
of neutrophils, macrophages, fibrinoid necrosis and thrombosis), immunopathological 
(deposition of complement C4d or C3 in the blood vessels) and serological (anti-HLA or 
other donor specific antibodies). Acute AMR may be a result of pre-formed donor specific 
antibodies or antibodies that develop de novo after transplantation (Terasaki and Mizutani, 
2006). These combine with donor antigens resulting in activation of complement cascade, 
recruitment of macrophages and neutrophils resulting in endothelial injury. It is more 
common in kidney allografts affecting 5-7% recipients (Colvin and Smith, 2005) than in liver, 
heart and lung recipients (Musat et al., 2011, Takemoto et al., 2004).  
 
Pathological changes in acute AMR are similar to but tend to be less severe than those in 
hyperacute rejection, discussed in section 1.5.1 and shown in Figure 1.4. Liver allografts 
undergoing AMR typically present with cholestatic picture, both on biochemical tests and 
histological examination. Inflammation of bile ducts associated with bilirubinostasis are 
often seen on biopsy and these have been attributed to ischemia secondary to occlusive 
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thrombosis of biliary microvasculature by antigen-antibody complexes (Hubscher, 2012).  In 
the lung allografts, the features of acute AMR include inflammatory cell infiltrate and 
complement deposition in the alveolar capillaries (DeNicola et al., 2013). 
 
1.5.2.2 Acute cellular rejection:  
Acute cellular rejection is characterised by graft dysfunction developing within weeks of 
transplantation along with typical histological features. In the kidney allograft, the 
histological features include a combination of acute interstitial rejection (referred to as Type 
I acute cellular rejection) and acute vascular rejection (Type II acute cellular rejection). 
These develop from different pathogenetic pathways, as shown in Figure 1.3B, but often co-
exist. Acute interstitial rejection is characterised by infiltration of cytotoxic T cells, 
eosinophils, macrophages along with tubulitis and interstitial oedema. Acute vascular 
rejection is characterised by endothelial inflammation, thrombosis, interstitial haemorrhage 
and necrosis. These changes are shown in Figure 1.5 (AJKD, 2001). 
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Figure 1.5 A. Acute interstitial rejection showing severe tubulitis and interstitial infiltration. 
Periodic acid Schiff, magnification X100. Reproduced from the Atlas of Renal Pathology 
(AJKD, 2001). 
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Figure 1.5 B. Acute vascular rejection showing endothelial infiltration and microthrombus. 
Periodic acid Schiff, magnification X200. Reproduced from the Atlas of Renal Pathology 
(AJKD, 2001).
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1.5.3 Chronic rejection: 
Chronic rejection can be mediated by humoral immunity or cell mediated immunity. It 
results in gradual progressive graft dysfunction, months to years after transplantation.  
Fibrosis is a common feature but other pathological features vary depending on the organ 
transplanted: kidney allografts show glomerulopathy, liver allografts show loss of bile ducts, 
heart allografts develop coronary atherosclerosis and lung allografts develop bronchiolitis 
obliterans.  
 
There are several contributing factors for the development of chronic rejection including 
untreated or undertreated acute rejection, ischemia-reperfusion injury, post-transplant 
cytomegalovirus (CMV) infection, donor factors (age, hypertension) and recipient factors 
(hypertension, dyslipidaemia, diabetes). Once established, chronic rejection is usually 
irreversible and the only effective treatment for non-renal recipients is re-transplantation 
(Chapman et al., 2005). 
 
1.6 Immunosuppression: agents, mechanisms of action and side effects 
With the exception of transplantation between identical twins, every allograft develops 
some degree of rejection. Interventions such as matching the donor and the recipient for 
blood group and HLA type, lymphocytotoxic assay between the recipient’s serum and donor 
lymphocytes and panel reactive antibody screen help to reduce the risk of rejection. 
However, to achieve long-term functioning of the allograft, majority of allograft recipients 
need life-long pharmacological immunosuppression.  
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Post-transplant immunosuppressive agents can broadly be classified into two groups: 
biological agents and xenobiotics. Biological agents exert their immunosuppressive action by 
acting on the receptors present on the cell wall of specific immunologically active cells, 
whereas, xenobiotics act by interfering with the intracellular mechanisms. Main groups 
among xenobiotics are corticosteroids, anti-proliferative agents, calcineurin inhibitors and 
mammalian Target of Rapamycin (mTOR) inhibitors. The mechanisms of action, efficacy and 
side effects of these agents are discussed below. The effect of immunosuppressive agents 
on post-transplant cancer is separately discussed in Section 1.7. 
 
1.6.1 Biological agents: 
The risk of acute allograft rejection is at its highest in the early post-transplant period and 
biological agents are often used to reduce this risk. Factors influencing the decision to use 
these agents include the organ transplanted, estimated risk of rejection, recipient co-
morbidities and preference of the transplant team. Commonly used biological agents 
include polyclonal agents such as anti-lymphocyte globulin (ALG) and anti-thymocyte 
globulin (ATG), and monoclonal agents and monoclonal human or chimeric antibodies 
against CD25 (basiliximab, daclizumab), CD3 (OKT3), CD52 (alemtuzumab or Campath 1H), 
CD20 (rituximab) and adhesion molecules (enlomimab, odulimomab and efalizumab). 
 
1.6.1.1 Polyclonal agents 
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ALG and ATG are polyclonal antibodies developed by inoculating animals (horses, or more 
commonly rabbits) with T cell lines or thymocytes followed by extraction of antibodies from 
the animal serum (Putnam et al., 1976). These are the oldest biological agents, in use since 
1960s. In the recent years, rabbit ATG is preferred over the horse ATG or ALG due to a 
favourable side-effect profile. These exert non-specific immunosuppression by acting on a 
variety of cell wall receptors causing lysis, apoptosis and depletion of T cells, B cells, plasma 
cells and NK cells along with inhibition of adhesion and co-stimulation pathways. With a 
half-life as long as 30 days for rabbit ATG (Bunn et al., 1996), the immunosuppression 
exerted by these agents is lasting. In comparison to no biological therapy, reduced rates of 
acute rejection following the use of ATG have been shown in recipients of kidney and heart 
(Mourad et al., 2001, Charpentier et al., 2003, Zuckermann et al., 2000) but not liver 
transplantation (Boillot et al., 2009, Bogetti et al., 2005).  
 
Common side effects of ALG and ATG can be grouped into non-specific reactions to animal 
serum, increased risk of infection and cancer. Non-specific side effects can be mild such as 
fever, chills and rigors, or as severe as anaphylactic shock, particularly in those with previous 
exposure to these agents. Some patients experience leukopenia and thrombocytopenia, 
which are usually dose-dependent. Serum sickness like reaction can also develop, often 
after a delay of several days with symptoms of fever, maculopapular rash, arthralgia, 
proteinuria and lymphadenopathy. Local inflammatory reaction following intravenous 
administration can cause thrombophlebitis or venous thrombosis. Use of these agents is 
associated with an increased rate and severity of CMV infection (Mourad et al., 2001, Issa 
and Fishman, 2009) and herpes simplex infection. The association of ATG therapy with an 
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increased risk of bacterial and fungal infection has been demonstrated (Issa and Fishman, 
2009).  
 
1.6.1.2 Monoclonal agents 
These are monoclonal human or chimeric antibodies against CD25 (basiliximab, daclizumab), 
CD3 (OKT3), CD52 (alemtuzumab or Campath 1H), CD20 (rituximab) and adhesion molecules 
(enlomimab, odulimomab and efalizumab). In contrast to the polyclonal agents, monoclonal 
antibodies block T cell proliferation by acting on specific receptors resulting in narrow 
spectrum immunosuppression. Basiliximab and daclizumab are humanised monoclonal 
antibodies (90% human and 10% murine), which act on CD25 (also called IL2 receptor) 
resulting in blockage of T cell proliferation rather than T cell depletion. Although pulmonary 
oedema and adult respiratory distress syndrome (ARDS) are reported following daclizumab 
administration, both basiliximab and daclizumab have a favourable side-effect profile. 
Hypersensitivity reactions are less common due to their greater structural similarity with 
human proteins. Basiliximab has largely replaced daclizumab, leading to cessation of 
European licence of the latter in 2008 (Krischock and Marks, 2010). Efficacy of basiliximab in 
reducing the rates of acute rejection is proven by several studies of kidney recipients (Kahan 
et al., 1999, Nashan et al., 1997, Gralla and Wiseman, 2010, Webster et al., 2004) however 
none of these studies demonstrated an improvement in graft or patient survival. A meta-
analysis of twelve trials assessing the use of IL2 receptor antagonists (IL2RA) in liver 
recipients showed a significant reduction of rates of acute rejection over 1 year (23% in 
induction group vs. 28% in no induction group, p=0.04) but no significant difference in graft 
or patient survival, or rates of infection (Wang et al., 2010). Studies of heart recipients 
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comparing basiliximab against placebo (Mehra et al., 2005) or against ATG (Mattei et al., 
2007, Carrier et al., 2007, Carlsen et al., 2005) did not show any difference in the rates of 
acute rejection between these agents. Results are conflicting among lung recipients with 
improved survival following IL2RA/ATG induction as compared with no induction in some 
studies (Hachem et al., 2008) and no difference in rejection rates or in patient survival in 
some others (Mullen et al., 2007, Brock et al., 2001). 
 
In comparison to no induction or to ATG, the rates of infectious complications are not 
increased following IL2RA use in heart recipients (Mehra et al., 2005, Beniaminovitz et al., 
2000, Mattei et al., 2007, Carrier et al., 2007), kidney recipients (no difference in clinically 
significant CMV infection) (Lebranchu et al., 2002) and liver recipients (no difference in 
hepatitis C recurrence rates) (Pageaux et al., 2004, Llado et al., 2008, Otero et al., 2009, 
Klintmalm et al., 2007). 
 
OKT3, a CD3 murine antibody, was introduced during 1980s. Following recognition of non-
superiority when compared against ATG or IL2RA and the side-effects including cytokine 
release syndrome, ARDS, aseptic meningitis and immunogenicity precluding future use, its 
use declined resulting in withdrawal in the United States in 2009. Humanised anti-CD3 
antibodies might improve the side effect profile but at present no such agents are available 
for clinical use. 
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Alemtuzumab is a CD52 humanised antibody. Introduced in 1990s, it was initially used in 
kidney recipients and subsequently in lung recipients. As CD52 is present on a variety of cells 
including B cell, T cell, NK cells and macrophages, alemtuzumab results in profound lasting 
immunosuppression similar to the polyclonal agents. Side-effect profile of alemtuzumab is 
similar to that of the polyclonal agents, including the first-dose reaction with fever and rash, 
and rarely anaphylaxis and shock. Its use is limited following recognition of better efficacy 
and safety of IL2RA. 
 
Rituximab, a CD20 antibody was used as an anti-rejection agent following identification of 
increased number of CD20+ T cells in kidney recipients with steroid-resistant rejection 
(Becker et al., 2004) and the association of a higher degree of allograft loss with more dense 
infiltration of CD20+ T cells (Muorah et al., 2009). Rituximab is shown in small studies to 
improve the renal function in kidney recipients with steroid-refractory rejection (Becker et 
al., 2004). With proven superiority of IL2RA in both efficacy and safety, the use of rituximab 
is limited to a minority of kidney recipients (Hardinger et al., 2013). It also has a potential 
role in pre-transplant desensitisation of highly sensitised prospective kidney recipients (Vo 
et al., 2010). 
 
Belatacept is a relatively new agent. This works by blocking the co-stimulation pathways of T 
cell activation. In kidney recipients, its efficacy and safety are similar to calcineurin inhibitor 
(CNI) based immunosuppression regimen for maintenance immunosuppression (Larsen et 
al., 2010) and it has also enabled a CNI-free and steroid-free regimen (Ferguson et al., 2011). 
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In comparison to CNI, it has a favourable profile in terms side effects such as nephrotoxicity, 
hypertension and dyslipidaemia. Side effects of belatacept include an increased risk of 
infection (similar to CNI), anaemia, oedema and diarrhoea. An increased risk of post 
transplant lymphoproliferative disorders (PTLD), mainly involving the central nervous 
system (CNS) was seen in patients receiving belatacept and the increased risk was 
predominantly in Epstein-Barr virus (EBV) negative recipients (Garnock-Jones, 2012). At 
present belatacept is contraindicated in EBV negative recipients for this reason. 
 
Monoclonal antibodies against leucocyte adhesion molecules have been studied to assess 
their effect on delayed graft function and acute rejection. None of the published studies 
assessing enlimomab (Salmela et al., 1999), efalizumab (Kuypers and Vanrenterghem, 2004) 
and odulimomab (Hourmant et al., 1996) have shown a benefit. ASKP1240, a fully human 
monoclonal antibody against CD40 is being studied in phase II trials to assess the safety and 
efficacy when it is used as a replacement for a CNI agent (Hardinger and Brennan, 2013).   
 
1.6.2 Xenobiotics 
This group includes agents which are started at the time of or just before transplantation 
and are continued, in most patients, for as long as the graft continues to function. Factors 
influencing the choice of immunosuppression regimen include the organ transplanted, 
primary disease causing the organ failure, perceived risk of rejection, age and co-morbidities 
of the recipient. In the immediate post-transplantation period, the most commonly used 
immunosuppressive regimen includes a combination of three agents: an anti-metabolite 
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(azathioprine, mycophenolate mofetil), a CNI (ciclosporin, tacrolimus) and a corticosteroid. 
Other immunosuppressants used for long-term immunosuppression include the more 
recently discovered group of mTOR inhibitors.  Often the immunosuppression is more 
intense in the early post-transplantation period, in accordance with a higher risk of rejection 
in that period. Transplant recipients are monitored for life, with regular assessment of graft 
function, co-morbidities, side effects of treatment and all these factors guide the 
immunosuppressive regimen used in the longer term. 
 
1.6.2.1 Corticosteroids 
Prednisolone and its pro-drug, prednisone, along with methyl prednisolone and 
hydrocortisone are commonly used for prevention and treatment of acute allograft 
rejection. In the immediate post-transplant period, these are used in nearly all organ 
recipients but long-term use is avoided or at least minimised in order to reduce the side 
effects. Corticosteroids exert their immunosuppressive action by regulating gene 
expression. Glucocorticoid receptor is present in the cytosol of nearly all types of human 
cells. Corticosteroid molecule forms a complex with the glucocorticoid receptor and this 
complex binds to the nuclear de-oxy ribonucleic acid (DNA) resulting in regulation of 
expression of several genes with a role in immune function and inflammation (Bergmann et 
al., 2012). They also regulate the expression of several other types of genes including those 
controlling growth and metabolism, some of which mediate the side effects of 
corticosteroids. In addition, the side effects are also mediated by their action on the 
mineralocorticoid receptors.  
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Main side effects of corticosteroids include hyperglycaemia, dyslipidaemia, osteoporosis, 
avascular osteonecrosis, Cushing’s syndrome, fat redistribution, weight gain, skin fragility, 
acne, mood disturbances, psychosis, cataracts, fluid retention and hypertension. An 
increased risk of infection among transplant recipients is well known however the relative 
risk of individual immunosuppressive agents contributing to the increased risk of infection is 
not well established. Studies comparing corticosteroid-containing regimen and 
corticosteroid-free regimen have produced conflicting reports with some showing an 
increased risk of infection with steroid-containing regimen (Griffin et al., 1987, Nematalla et 
al., 2007, Seydoux et al., 1997, Pelletier et al., 2005, Tan et al., 2006) and others showing no 
difference (Ko et al., 2007, Ahsan et al., 1999, Li et al., 2009, Tanchanco et al., 2008). 
 
1.6.2.2 Anti-metabolites - azathioprine and mycophenolic acid 
Azathioprine was the first potent immunosuppressive agent used in transplantation. Roy 
Calne led the pioneering work in the development of azathioprine and other 
immunosuppressive agents, some of which continue to be used today. The era of 
pharmacological immunosuppression begun following recognition of benefits of 
azathioprine in animal transplantation (Calne, 1961) followed by human kidney 
transplantation (Murray et al., 1963). Azathioprine is a pro-drug. Its metabolites, 6-
mercaptopurine (6MP) and 6-thioguanine (6TG) inhibit purine synthesis resulting in 
impaired DNA production. Another metabolite of azathioprine, thioinosinic acid results in 
inhibition of purine synthesis specifically in T cells. During the decades of 1960 and 1970, 
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azathioprine along with prednisolone and equine ALG were the mainstay of management of 
allograft recipients. Side effects of corticosteroids were unavoidable as azathioprine alone 
was not potent enough to enable rejection-free long-term graft survival. Today, 
azathioprine is used in nearly all transplant recipients immediately after transplantation and 
also, in many cases, as a long-term immunosuppressant. Important side effects of 
azathioprine include bone marrow toxicity resulting in leukopenia, thrombocytopenia and 
anaemia, gastrointestinal symptoms, hypersensitivity and hepatotoxicity. Bone marrow 
toxicity is dose-dependent and is often more severe in patients with thiopurine methyl 
transferase deficiency. 
 
Mycophenolic acid was first extracted from cultures of penicillium in 1893 (Sollinger, 2004). 
The earliest therapeutic use was in 1970s, when it was used in the treatment of psoriasis 
(Spatz et al., 1978). The benefits of mycophenolic acid in transplantation were first 
described in 1991 (Allison et al., 1991)  Mycophenolic acid exerts its effect by blocking 
inositol monophosphate dehydrogenase, an essential enzyme for DNA synthesis in 
lymphocytes but not in other human cells. The anti-rejection efficacy, short and long-term 
safety were demonstrated in animal studies (Platz et al., 1991) and in human kidney 
recipients (Sollinger, 1995). Mycophenolate mofetil (MMF), a synthetic derivative of 
mycophenolic acid was developed to improve its oral bioavailability and tolerance. MMF is 
now commonly used for post-transplant immunosuppression, often in combination with 
either a CNI or a mTOR inhibitor. Although they are not sufficiently potent to be used as 
monotherapy, antimetabolite agents enable a reduced dosage and hence toxicity of CNI. 
Diarrhoea is a common side effect of MMF, often needing a dose reduction. Other side 
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effects include cytopenia related to bone marrow suppression, pancreatitis and increased 
risk of infections. An increased risk of CMV (Boucher et al., 2006, Jorge et al., 2008, 
Sarmiento et al., 2000), herpes simplex and varicella zoster (Smak Gregoor et al., 2003) 
infections have ben shown to be associated with the use of MMF.  
 
1.6.2.3 Calcineurin inhibitors – ciclosporin and tacrolimus 
Calne in 1978 (Calne et al., 1978b, Calne et al., 1978a, Calne et al., 1979) and Starzl in 1980 
(Starzl et al., 1980) demonstrated beneficial effects of ciclosporin in recipients of kidney 
transplantation. Calne also demonstrated that steroid-free immunosuppression was capable 
of maintaining allograft function. Tacrolimus was discovered in 1984 in Japan (Hooks, 1994). 
Over the next decade, the effects of tacrolimus were tested and confirmed, initially as 
rescue therapy in human studies involving failing allografts with on-going rejection (Klein, 
1999, Woodle et al., 1996) and subsequently as first-line immunosuppressant in recipients 
of kidney and liver transplantation (Vincenti et al., 2002, Haddad et al., 2006).  
 
Calcineurin is a phosphatase enzyme with a key role in T cell activation initiated by 
presentation of foreign antigens. Calcineurin dephosphorylates the transcription factor, 
nuclear factor of activated T cells (NFAT) resulting in transcription of various cytokines 
including IL2, IL3, IL4, IL5, IFN- and TNF-α. Ciclosporin and tacrolimus are activated 
following binding with intracellular proteins (ciclophilin and immunophilin FKBP12, 
respectively). They then prevent calcineurin-mediated entry of NFAT into the nucleus and 
further transcription, resulting in inhibition of expression of inflammatory cytokines. 
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Another mechanism, independent of calcineurin inhibition, has also been described. 
Ciclosporin and tacrolimus are able to block Jun N terminal kinase and p38 signalling 
pathways resulting in supressed activation of transcription factors (Matsuda and Koyasu, 
2000).  This dual mechanism of action increases the T cell specificity of immunosuppression 
induced by CNI. 
 
CNI are now the cornerstone of post-transplant immunosuppression (Kapturczak et al., 
2004). The benefits of CNI in reducing rejection rates and improving survival after 
transplantation are well recognised (Isoniemi et al., 1993, Kahan, 1987, Morris, 1981). 
Studies comparing kidney recipients receiving ciclosporin or tacrolimus have shown fewer 
episode of acute rejection among recipients receiving tacrolimus but the rates of graft 
survival are similar (Sonoda et al., 2003, Pirsch et al., 1997).  
 
The most common side effect of CNI is nephrotoxicity. Histological evidence of 
nephrotoxicity has been observed in 100% recipients after 10 years of CNI use (Nankivell et 
al., 2004). It is mediated by several mechanisms including vasoconstriction of afferent 
arteriole, toxic tubulopathy and thrombotic microangiopathy resulting in acute kidney 
injury, arteriolar hyalinosis and interstitial fibrosis (Krejci et al., 2010).  Dose reduction or 
withdrawal of CNI are more effective in reversing the nephrotoxicity, in the early post-
transplant period and less so when chronic renal dysfunction is established. Studies 
comparing ciclosporin against tacrolimus have shown no significant difference in the degree 
of nephrotoxicity (Fioretto et al., 2011, Solez et al., 1998) or graft survival (Kaplan et al., 
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2003). Post-transplant diabetes mellitus is often multi-factorial, influenced by pre-transplant 
glucose intolerance, body mass index, genetic factors and post-transplant medications. CNI 
reduce insulin secretion by a direct inhibitory effect on the β cells of the islets of Langerhans 
(van Hooff et al., 2004). Insulin resistance mediated by concomitant use of steroids also 
contributes to diabetogenesis. Epidemiological evidence indicates a stronger association of 
post-transplant diabetes with tacrolimus than ciclosporin (Heisel et al., 2004, Knoll and Bell, 
1999). CNI are also associated with hypertension, dyslipidaemia, alopecia, hirsutism, gum 
hyperplasia, gastrointestinal symptoms and neurotoxicity. The evidence assessing which CNI 
agent is more likely to produce these side effects is conflicting (Campos et al., 2002, 
Montagnino et al., 2002, Kim et al., 2004).  
 
Newer calcineurin inhibitors such as CN585 have shown promise in preclinical in vitro 
studies (Erdmann et al., 2010) with selective inhibition of calcineurin, which mediates 
immunosuppression without inhibiting ciclophilin, which is responsible for many side effects 
of CNI. Voclosporin is a novel CNI agent which is under investigation for use as a 
maintenance immunosuppressant in recipients of kidney transplantation. Studies comparing 
voclosporin against tacrolimus, with follow-up up to 6 months post-transplantation have 
shown non-inferior rates of rejection (Busque et al., 2011). The rates of post-transplant 
diabetes were lower in low dose voclosporin group but not in medium dose or high dose 
groups (Busque et al., 2011).  Further studies with larger cohorts including patients in all risk 
groups are underway. 
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1.6.2.4 mTOR inhibitors – sirolimus and everolimus 
Sirolimus was extracted in 1975 from a fungus, Streptomyces hygroscopicus from the soil of 
Easter Island (Sehgal et al., 1975). Originally called Rapamycin, its antifungal, antibacterial 
and antitumour actions were recognised before its immunosuppressive action. Everolimus is 
a derivative of sirolimus with improved oral bioavailability. mTOR inhibitors form a complex 
with FKBP12 (same binding protein used by tacrolimus) and this complex inhibits mTOR 
pathway. mTOR is a serine/threonine protein kinase with an important role in cell growth 
and differentiation. Its blockage results in arrested growth of several cell types and in 
particular, IL2 mediated proliferation of T cells. It is a potent immunosuppressant often 
being used in cases where CNI dose minimisation or withdrawal is beneficial.  
 
Side effects of mTOR inhibitors include glomerular toxicity causing proteinuria, glucose 
intolerance, delayed wound healing and pneumonitis. Anti-tumour activity of several other 
derivatives of sirolimus such as temsirolimus, deferolimus and ridaforolimus is well 
established. The effect of sirolimus of post-transplant cancer is discussed in section 1.7.5. 
 
1.7 Effects of immunosuppression on post-transplant cancer 
There is ample epidemiological evidence confirming the increased risk of cancer following 
transplantation (Collett et al., 2010, Villeneuve et al., 2007, Adami et al., 2003, Kasiske et al., 
2004, Kyllonen et al., 1994, Hoshida et al., 1997). Many factors, relating to both the donor 
and the recipient, contribute to this increased risk including genetic, environmental, 
infection-related and socio-economical factors, but a central role is played by the post-
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transplant immunosuppression. Immunosuppression increases the risk of cancer by several 
mechanisms including reduced immune surveillance and increased risk of infection with 
oncogenic viruses. The effects of immunosuppression not only increase the risk of cancer 
development but also result in an aggressive disease and poorer outcomes with frequent 
graft loss and death. Immunosuppressive regimen change continuously as a result of 
introduction of newer agents, discontinuation of older agents, side effects of a particular 
agent, comorbidities, personal preferences of the recipient and the medical team and 
availability of new evidence. As a result of these limitations, it is difficult to tease out the 
effect of individual agents on the risk of cancer after transplantation. However, there is 
good evidence demonstrating the association between more intensive immunosuppressive 
regimen and an increased risk of cancer (Dantal et al., 1998, Vivarelli et al., 2002, Swinnen et 
al., 1990).  
 
1.7.1 Biological agents 
Studies assessing the risk of cancer following the use of biological agents have mainly found 
an association with PTLD. An increased risk of PTLD in recipients receiving ATG (RR 1.6, 
compared with no induction) but not in those receiving basiliximab, alemtuzumab or 
daclizumab was reported by United Network for Organ Sharing / Organ Procurement and 
Transplantation Network (OPTN/UNOS) in a study of 59560 kidney recipients (Kirk et al., 
2007). This is in contrast to a relatively older and smaller study form the same database 
(Cherikh et al., 2003), which did not show an increase in the risk of PTLD in recipients 
receiving ATG. A study of Collaborative Transplant Database including 715,000 patient years 
(approximately 200,000 transplant recipients) from 271 centres in 42 countries also showed 
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an increased risk of PTLD in patients receiving ATG or OKT3 but not IL2RA (Opelz and Dohler, 
2004). In this study, the increased risk of PTLD with ATG or OKT3 was noted in the first year 
after transplantation only. The evidence for the association of monoclonal agents with PTLD 
is conflicting with no association in some studies (Kirk et al., 2007) and an increased risk in 
others (Cherikh et al., 2003, Bustami et al., 2004). Bustami reported the risk of PTLD with 
individual monoclonal agents for daclizumab (RR 1.92), basiliximab (RR 1.83) and OKT3 (RR 
1.71) compared with no induction. The risk of tumours other than PTLD was not increased 
with either polyclonal or monoclonal agents (Bustami et al., 2004). 
 
1.7.2 Corticosteroids 
The scarcity of definitive epidemiological data assessing the use of corticosteroids with the 
risk of post-transplant cancer is explained by the fact that corticosteroids are seldom used 
as monotherapy for post-transplant immunosuprression. In the non-transplant population, 
corticosteroid use is shown to be associated with an increased risk of non-melanoma skin 
cancer (NMSC) (Karagas et al., 2001) with a standardised incidence ratio (SIR) of 1.5 for basal 
cell cancer and 2.5 for squamous cell cancer, and non-Hodgkin’s lymphoma (NHL) with a SIR 
of 1.3 (Sorensen et al., 2004). Corticosteroids have been used in the treatment of various 
cancers for their pro-apoptotic and anti-proliferative action. However, corticosteroids also 
have anti-apoptotic and proliferative action on cancer cells (Rutz, 2002, Rutz and Herr, 
2004), which might explain the increased risk of cancer with these agents. 
 
1.7.3 Anti-metabolites 
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Mechanism of action of azathioprine includes incorporation of 6TG into DNA. Normal 
human DNA is relatively resistant to absorption of ultraviolet (UV) - A wavelengths but 6TG-
incorporated DNA absorbs UVA, resulting in production of reactive oxygen species. High 
levels of reactive oxygen species cause oxidation of DNA resulting in DNA damage and 
genomic instability, facilitating carcinogenesis and proliferation of cancer cells (O'Donovan 
et al., 2005). Azathioprine is also shown to influence selection of cell clones with deficiencies 
in DNA mismatch repair, which is associated with development of post-transplant leukaemia 
(Offman et al., 2004).  
 
In epidemiological studies, azathioprine is shown to be associated with an increased risk of 
cancer in both immunocompetent and immunosuppressed individuals.  A four-fold increase 
in the incidence of lymphoma was noted in patients on azathioprine for inflammatory bowel 
disease (Kandiel et al., 2005). A report from the Israel Penn International Transplant Tumor 
Registry (IPITTR) showed that 93% of the 3,131 transplant recipients developing NMSC were 
receiving azathioprine (Penn, 1996a). A study assessing the effect of low-dose and high-dose 
ciclosporin on the risk of post-transplant cancer, along with showing the association of 
higher dose ciclosporin with an increased risk, also showed that the recipients with higher 
mean doses of azathioprine had an increased risk of cancer (Dantal et al., 1998).  
 
The risk of cancer in transplant recipients on mycophenolate therapy is increased to a 
similar degree to those on azathioprine and this is shown by several studies demonstrating 
no significant difference between these two agents on the risk of post-transplant cancer 
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(Robson et al., 2005, Wang et al., 2004, Dharnidharka et al., 2002, Funch et al., 2005, 
Clayton et al., 2012). There are several limitations in interpreting the data assessing the 
impact of immunosuppression on the risk of cancer. These include incomplete data 
collection particularly over long term post-transplant follow up, the fact the recipients often 
receive multiple immunosuppressive agents, each with a different degree of impact on the 
risk of cancer and the inability of statistical analysis to separate out the impact of individual 
immunosuppressive agents. Correction for the impact of other confounders influencing the 
risk of cancer such as oncogenic infections, lifestyle and socioeconomic status of the 
recipient was also not undertaken in these studies. 
1.7.4 Calcineurin inhibitors 
CNI increase the risk of development and proliferation of cancer cells by multiple 
mechanisms.  Transforming growth factor (TGF)-β1 has been implicated in the development 
and spread of cancers (Barrack, 1997, Teicher, 2007). CNI increase the production of TGF-β1 
by malignant and non-malignant cells (Prashar et al., 1995, Ohsawa et al., 2006, Khanna et 
al., 1999). Both ciclosporin (Hojo et al., 1999) and tacrolimus (Maluccio et al., 2003, Khanna 
et al., 1999) have been shown to increase the number of cancer metastases in animal 
experiments. CNI also facilitate carcinogenesis by other mechanisms such as increased 
angiogenesis (Duncan et al., 2007) and inhibition of DNA repair (Herman-Edelstein et al., 
2012).   
Several epidemiological studies have shown an increased incidence of cancer in transplant 
recipients receiving CNI when compared with recipients on azathioprine (Hiesse et al., 1997, 
Marcen et al., 2003, McGeown et al., 2000, Shuttleworth et al., 1989, Kyllonen et al., 2000, 
Tremblay et al., 2002). Studies comparing the risk of post-transplant cancer between 
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recipients on ciclosporin and those on tacrolimus have shown variable results depending on 
the cancer type. In particular, several large retrospective registry-based studies have shown 
an increased risk of PTLD with tacrolimus immunosuppression. In a study of the United 
States Renal Data System including 25127 kidney recipients undergoing transplantation 
between 1996 and 2000, PTLD was diagnosed in 344 patients. In this cohort, among patients 
without ATG induction the risk of PTLD was higher by 57% among recipients on tacrolimus 
as compared to ciclosporin, however in recipients receiving ATG there was no significant 
difference in the risk of PTLD between the two agents (Caillard et al., 2005). Two other large 
studies have shown an increased risk of PTLD among transplant recipients on tacrolimus: a 
cohort of 41686 kidney recipients from the Scientific Registry of Transplant Recipients data 
(Bustami et al., 2004) and a report from the Collaborative Transplant Database studying 
more than 200,000 recipients (Opelz and Dohler, 2004). However, a meta-analysis of 16 
randomised control trials including 3813 liver recipients did not show a significant difference 
in the risk of PTLD between ciclosporin and tacrolimus (Haddad et al., 2006). With regards to 
the risk of cancers other than PTLD, several studies have shown no significant difference 
between ciclosporin and tacrolimus, including a meta-analysis of 30 randomised control 
trials with a total of 4102 kidney recipients (Webster et al., 2005) and 3 randomised control 
trials including 413 lung recipients (Penninga et al., 2013). The difference between the two 
CNI agents with regards to the risks of PTLD and non-PTLD cancers may be explained by the 
fact that the pathogenesis of PTLD is significantly influenced by the intensity of 
immunosuppression. The relatively more potent immunosuppression provided by 
tacrolimus may be one of the reasons which increased the risk of PTLD in the tacrolimus 
group. 
1.7.5 mTOR inhibitors 
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mTOR is a serine-threonine kinase which plays an important role in the regulation of cell 
growth and proliferation.  mTOR is made up of two sets of proteins, mTOR complex 
(mTORC) 1 and mTORC2. These two complexes regulate two related aspects of cell growth. 
In presence of nutrients and other factors favourable for cell growth, mTORC1 regulates the 
anabolic activity and the rate of protein synthesis by controlling the synthesis of ribosomes, 
transcription of genes, promoting metabolism and biosynthesis of amino acids and fatty 
acids whereas, mTORC2 regulates spatial orientation of the cell growth by polarising the 
actin cytoskeleton in the direction where growth is needed. So, in summary mTORC1 
regulates the timing and mTORC2 regulates the direction of cell growth (Wullschleger et al., 
2006). mTOR inhibitors inhibit mTORC1 but not mTORC2. 
mTOR inhibitors, unlike other immunosuppressive agents used for prevention of allograft 
rejection, have anti-tumour properties. The anti-tumour effect is mediated by inhibition of 
different mechanisms including angiogenesis, cell cycle progression and UVB induced DNA 
damage. These properties have been demonstrated in both murine and human cancer cells 
(Guba et al., 2002, Luan et al., 2002, Boffa et al., 2004). Epidemiological evidence from 
several randomised controlled trials confirms a lower cancer risk among recipients on 
sirolimus immunosuppression in comparison to other immunosuppressive agents. The 
CONVERT trial (Alberu et al., 2011) included 830 kidney recipients randomly allocated to 
continue CNI immunosuprression or to switch to sirolimus. At two years following the 
switch, the risk of de novo cancer was significantly lower in patients on sirolimus therapy at 
2.1 cancers per 100 person-years as compared to 6.0 cancers in the CNI group. This 
difference was mainly due to lower incidence of NMSC in the sirolimus group. In another 
trial (Mathew et al., 2004) comparing the incidence of cancer following two-year treatment 
with ciclosporin in combination with sirolimus or with placebo, the incidence of skin cancer 
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was lower in patients receiving a combination of ciclosporin and sirolimus. This study also 
reported a lower incidence of cancer in patients on sirolimus monotherapy as compared 
against patients on a combination of ciclosporin and sirolimus. In another randomised 
controlled trial (Campistol et al., 2006) of 430 kidney recipients randomised at 3 months 
post-transplant to continue a combination of ciclosporin, steroids and sirolimus or to have 
ciclosporin withdrawn, the time to a cancer diagnosis was significantly longer in recipients 
on sirolimus and steroids as compared to recipients who were also on ciclosporin (1126 and 
491 days respectively). The risk of cancer (including both skin and non-skin) was 4.0% and 
9.6% respectively. There are several other reports showing an association between sirolimus 
and a lower incidence on NMSC (Campbell et al., 2012, Euvrard et al., 2012, Gu et al., 2012, 
Hoogendijk-van den Akker et al., 2013). 
 
These studies demonstrate a reduced risk of cancer, in particular NMSC, among patients on 
sirolimus immunosuppression as monotherapy or in combination with a CNI. With 
increasing long-term survival after transplantation and the increased risk of cancer in this 
group, it is likely that mTOR inhibitors use will increase in a selected sub-group of long-term 
transplant survivors. 
 
1.8 Current status of organ transplantation in the UK 
In the UK, NHSBT in collaboration with other organisations including the Department of 
Health, transplantation centres and other professional bodies, commissions, regulates and 
co-ordinates different aspects of organ donation and transplantation. Its remit encompasses 
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encouraging organ donation, optimising safety of organs, improving the safety, quality, 
effectiveness and clinical outcomes of transplant services. NHSBT also plays a central role in 
commissioning and conduct of research in the field of donation-transplantation within the 
UK as well as offering support, advice and collaboration to international health authorities.  
 
1.8.1 Organ donors: selection and assessment 
In 2009, the World Health Organization (WHO) in collaboration with the Transplantation 
Society (TTS) and the Organizacion Nacional de Trasplantes (ONT), issued a glossary of 
definitions relating to donation and transplantation (WHO, 2009); these definitions are used 
here. An actual organ donor is a deceased or living person from whom at least one solid 
organ or part of it is removed for the purpose of transplantation. A deceased donor can be a 
deceased donor after brain death (DBD) defined as a donor who was declared dead and 
diagnosed by means of neurological criteria, or a deceased donor after circulatory death 
(DCD) defined as a donor who was declared dead and diagnosed by means of 
cardiopulmonary criteria.  
Living donors can be: 
A. Related 
A1. Genetically related: 1st degree genetic relative such as a parent, sibling or 
offspring 
A2. Emotionally related: in-laws, adopted, friend or spouse (who is genetically 
unrelated) 
B. Unrelated: not genetically or emotionally related 
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A potential deceased donor is a deceased person without absolute contraindication to 
donation, with brain death or cardiac death diagnosis initiated or completed.  
 
The process of deceased donation starts when a potential donor is identified, such as a 
patient with a diagnosis of brain death or irreversible process necessitating withdrawal of 
active treatment. This usually happens in the setting of intensive care or emergency 
department. In the UK, the Specialist Nurses in Organs Donation (SN-OD) play a key role in 
facilitating organ donation. The death is explained to the family and careful exploration of 
the possibility of organ and tissue donation is undertaken, with consideration to the wishes 
of the potential donor (such as the organ donors’ card) and the family. After informed 
consent, suitability for donation is assessed. This process includes investigation into donor’s 
last illness, past medical history, social history, factors that can affect organ function such as 
trauma, prolonged hypoxia or hypotension. Donor blood group and the HLA type are 
determined. The potential donor is screened for transmissible infections and cancers. The 
screening for transmissible infection includes screening for human immunodeficiency virus 
(HIV) type 1 and 2, hepatitis B and C (HBV, HCV), human T cell lymphotropic virus (HTLV) 
type 1 and 2, CMV, EBV, toxoplasmosis, treponema pallidum, Creutzfeldt-Jakob disease, 
tuberculosis, rabies, malaria, West Nile virus, typhoid, Lyme disease, brucellosis and 
gonorrhoea. Screening for cancers and the guidelines for stratification of the risk of 
transmission of cancer are discussed in section 1.13.  
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Following confirmation of the suitability of the donor, the organ retrieval team is informed 
and a nationally co-ordinated process identifies the prospective recipients. The factors 
considered in this process include the priority status of the recipient on the waiting list, 
geographical location of the donor and the recipient, estimated cold ischemia time and the 
availability of the local transplantation team.  
 
In order to reduce the ischemia time for the donated organs and the inconvenience of a 
protracted delay to the family of the deceased, it is an important priority to complete the 
deceased donation in the shortest possible time. In comparison, the donation from a living 
donor provides the advantage of a planned non-urgent donation-transplantation process. A 
majority of the living donors in the UK donate kidneys. In 2013-14, of 2466 donors in the UK, 
1146 (46%) were living donors including 1114 kidney donors and 32 donors of a part of liver 
(NHSBT, 2014b). In addition to screening for transmissible diseases similar to the process in 
the deceased donor, the living donor assessment would in addition include tests to confirm 
the anatomical and physiological suitability of the organ for donation, physical fitness of the 
donor to undergo the donation operation and psychological assessment to assess the 
donor’s preparedness to donate and to confirm that the donation is free from coercion. The 
risks of donation are explained prior to informed consent of the living donor, including a 
small risk of wound infection, bleeding and thrombosis. The estimated risk of death from a 
kidney donation operation is approximately 1 in 3000. Living kidney donors do not 
experience a significant disadvantage in terms of future kidney dysfunction or life 
expectancy.  
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1.8.2 Changing profile of the organ donor 
The profile of the organ donors is changing in the UK. Between 2004-2005 and 2013-2014, 
the number of deceased organ donors in the UK increased by 63%, from 751 to 1320 
(NHSBT, 2014b). In the same period, the age and the rate of obesity (defined as body mass 
index [BMI] of ≥30 kg/m2 [kilogram per metre squared]) among deceased donors increased; 
the proportion of the deceased donors aged ≥ 50 years increased from 43% to 59% and the 
proportion of obese donors, from 16% to 24%. Possible reasons for these changes include 
increasing longevity and obesity rates in the UK population and also changing criteria for 
accepting donors. It is possible that influenced by the increasing waiting times for 
prospective recipients, donors who were previously not accepted due to age or co-
morbidities are being accepted for donation in the recent years.  
 
1.8.3 Organ recipients and the waiting list 
Organ transplantation is intended to improve the length and/or the quality of life in 
comparison to continuing without transplantation. The assessment of this benefit is 
complex and varies for recipients of different organs. When a patient with an organ failure is 
identified as a potential transplant recipient, assessment is performed to establish the 
feasibility of transplantation with regards to the recipient’s physiological function, 
psychological status, ability to engage with life-long post-transplant care and family support. 
Consideration is also given for conditions that would reduce the overall benefit of 
transplantation such as active or recent cancer, chronic infection like tuberculosis or 
systemic illness likely to increase the risk of peri-operative or long-term mortality. This 
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assessment is performed by a multi-disciplinary team involving physicians, surgeons, 
anaesthetists, transplant co-ordinators and in some cases other specialists such as addiction 
experts, psychiatrists, social services, nutritionists, radiologists and oncologists. There are 
several scoring systems designed to help in predicting the benefit of transplantation such as 
heart failure survival score (HFSS) (Aaronson et al., 1997) and Seattle heart failure model 
(SHFM) (Levy et al., 2006) for heart transplantation, lung allocation score (LAS) for lung 
transplantation (Egan et al., 2006), model for end-stage liver disease (MELD) (Wiesner et al., 
2003) and the United Kingdom end-stage liver disease (UKELD) (Barber et al., 2011) scoring 
systems for liver transplantation. These scores are useful in assessing the benefit of 
transplantation to the prospective recipient and also helpful in prioritising the urgency of 
the need for transplantation, however no scoring system can cover the complexities of all 
cases. 
 
Once a decision is made to proceed with transplantation, the prospective recipient is placed 
on a waiting list and will receive an offer of transplant when a suitable organ becomes 
available. As a result of the relative shortage of donor organs in comparison to the number 
of patients on the waiting lists, prospective recipients have to wait for the offer of an organ. 
In 2013-14 in the UK, the median waiting period for adult patients was 1114 days for kidney, 
441 days for heart, 265 days for lung and 145 days for liver transplantation (NHSBT, 2014b). 
Inevitably, during this waiting period, some patients develop complications and die or 
become unfit to receive a transplantation. The rates of removal from and death on the 
waiting list were 4% and 2% for kidney, 10% and 6% for heart, 5% and 10% for lung and 8% 
and 5% for liver transplant lists respectively (NHSBT, 2014b). 
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1.9 Benefits of transplantation: 
Depending on the indication for transplantation, the recipients can benefit from 
transplantation in different ways. There can be improvement in the quality of life, relief of 
specific symptoms or prolongation of life. Of these, the most widely used criterion to 
measure the success of transplantation is the survival of the recipient after transplantation. 
In this section, the recipient survival rates following transplantation in the UK are discussed 
and a comparison is made with the data from the OPTN/UNOS, which includes all recipients 
of organ transplantation in the United States of America (USA). In these analyses, the 
recipient survival refers to the duration from transplantation till death, censoring for the 
recipients who were alive at the end of the study period. Additionally, graft survival rates 
are shown for recipients of kidney transplantation where graft survival is defined as the 
duration from transplantation till the time of graft failure, censoring for recipients who died 
with a functioning graft and also for the recipients who had a functioning graft at the end of 
follow-up. The UK cohort includes first adult recipients of single organ transplantation and 
the USA cohort includes all single organ recipients of first or subsequent transplantation.  
 
The survival rates are shown for kidney recipients (Table 1.1), kidney grafts (Table 1.2), liver 
recipients (Table 1.3) and the recipients of heart or lung transplantation (Table 1.4). The 1-
year survival rates are similar in the two countries for all groups of recipients. However the 
5-year survival rates are higher for recipients in the UK than the recipients in the USA, 
particularly for kidney graft survival. A possible explanation for this could be that the UK 
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cohort was transplanted more recently (2006 to 2008) than the USA cohort (1997 to 2004). 
With time, the long-term survival rates have improved in both the countries and this is 
reflected in these results.     
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Table 1.1 Kidney transplantation: patient survival after transplantation in the UK and USA 
(percentage survival with 95% confidence interval [CI]) (NHSBT, 2014b, OPTN, 2013) 
 UK USA 
Donor type DBD DCD Living Deceased* Living 
Period 2006-2008 2006-2008 2004-2006 1997-2004 1997-2004 
Number of 
recipients 
2149 888 1317 24140 18306 
1-year 
survival 
96 
(96, 97) 
96 
(95, 97) 
99 
(98, 99) 
94.4 
(94.2, 94.7) 
97.9 
(97.7, 98.1) 
5-year 
survival 
89 
(88, 90) 
88 
(86, 90) 
96 
(95, 97) 
81.8 
(81.3, 82.3) 
90.1 
(89.6, 90.6) 
*including both DBD and DCD 
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Table 1.2 Kidney transplantation: graft survival after transplantation in the UK and USA 
(percentage survival with 95% CI) (NHSBT, 2014b, OPTN, 2013) 
 UK USA 
Donor type DBD DCD Living Deceased* Living 
Period 2006-2008 2006-2008 2004-2006 1997-2004 1997-2004 
Number of 
recipients 
2148 887 1317 23078 17901 
1-year 
survival 
93 
(92, 94) 
93 
(91, 94) 
96 
(95, 97) 
89.0 
(88.6, 89.4) 
95.1 
(94.8, 95.4) 
5-year 
survival 
85 
(84, 87) 
87 
(84, 89) 
92 
(90, 93) 
66.6 
(66.0, 67.1) 
79.8 
(79.2, 80.4) 
*including both DBD and DCD 
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Table 1.3 Liver transplantation: patient survival after transplantation in the UK and USA 
(percentage survival with 95% CI) (NHSBT, 2014b, OPTN, 2013) 
 UK USA 
Donor type DBD DCD Living Deceased* Living 
Period 2006-2008 2006-2008 - 1997-2004 1997-2004 
Number of 
recipients 
1099 149 - 13080 823 
1-year 
survival 
91 
(89, 93) 
91 
(85, 94) 
- 86.3 
(85.7, 86.8) 
90.1 
(88.1, 92.1) 
5-year 
survival 
80 
(78, 83) 
- - 72.0 
(71.3, 72.7) 
77.7 
(74.6, 80.8) 
*including both DBD and DCD 
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Table 1.4 Thoracic transplantation from deceased donors: patient survival after 
transplantation in the UK and USA (percentage survival with 95%CI) (NHSBT, 2014b, OPTN, 
2013) 
 UK USA 
Period 2006-2008 1997-2004 
Organ Heart Lung Heart Lung 
DBD DCD* 
Number of 
recipients 
311 334 84 13080 2668 
1-year 
survival 
84 
(80, 88) 
81 
(76, 85) 
81 
(70, 88) 
86.3 
(85.7, 86.8) 
83.3 
(82.0, 84.6) 
5-year 
survival 
78 
(73, 82) 
55 
(50, 61) 
- 72.0 
(71.3, 72.7) 
47.3 
(45.6, 49.0) 
* period is 2009 to 2012 
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1.10 Risks and complications of organ transplantation 
As with all medical interventions, organ transplantation has its risks and complications. 
Table 1.5 shows the complications of organ transplantation divided in three groups 
depending on when they develop after transplantation. The recipients who develop 
complications after transplantation are more likely to experience increased risk of graft 
failure and death.  
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Table 1.5 Risks of organ transplantation 
In the early post-transplant period 
1. Risks of major surgery 
- bleeding 
- wound infection 
2. Risks of intensive care 
- prolonged organ support such as mechanical ventilation or haemofiltration 
- pneumonia 
- venous thrombosis 
- sepsis related to vascular access 
- cardiovascular or cerebrovascular event 
3. Risks relating to transplanted organ 
- non-function or delayed function of the graft, need for re-transplantation 
- acute rejection 
- vascular complications like bleeding or thrombosis 
- anastomotic dehiscence or stricture – ureteric problems in kidney transplants, 
biliary problems in liver transplants, airway problems in lung transplants 
Weeks to months after transplantation 
1. Risks relating to immunosuppression 
- acute rejection 
- infections such as CMV, EBV 
- Side effects of drugs such as nephrotoxicity (CNI), cytopenia (azathioprine), 
hyperglycaemia (steroids, CNI), diarrhoea (MMF) 
2. Diseases transmitted from donor 
- infections such as HIV, CMV, HBV, HCV 
- transmitted cancers 
3. De novo cancers such as post-transplant lymphoproloiferative disorder, skin cancers  
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Months to years after transplantation 
1. Risks relating to immunosuppression 
- side effects of drugs – diabetes, nephrotoxicity, dyslipidaemia, coronary and 
cerebrovascular disease 
- de novo malignancy: cancer of the skin, lip, anus, Kaposi’s sarcoma, 
lymphoproliferative disorders, gastrointestinal tract, lung and bronchus, thyroid, 
bladder, cervix, oral cavity, kidney and liver 
- recurrence of cancer treated prior to transplantation 
2. Graft dysfunction 
- chronic rejection 
- recurrence of primary disease 
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1.11 Cancer after transplantation 
Cancer is a common cause of late morbidity and mortality among recipients of organ 
transplantation. Cancer in the transplant recipient can be one of the following three types 
(Myron Kauffman et al., 2002): 
I. Donor origin cancer (DOC):  
This can be donor-transmitted cancer or donor-derived cancer. 
Ia. Donor-transmitted cancer (DTC): this is the cancer transmitted to the recipient 
along with the transplanted organ. The presence of cancer may be known or 
unknown at the time of transplantation.   
 
Ib. Donor-derived cancer (DDC): this type of cancer develops in the donor cells 
subsequent to transplantation. The differentiation between donor-transmitted 
cancer and donor-derived cancer may be possible in cases where the donor is known 
to have cancer, or the presence of cancer in the allograft is identified at the time of 
or soon after transplantation. In cases where the recipient develops a cancer of 
donor origin later during post-transplant follow-up, definitive differentiation 
between donor-derived cancer and donor-transmitted cancer may be a challenge. 
 
II. De novo cancer:  
This type of cancer develops as a result of a combination of mechanisms including 
those related to long-term immunosuppression, reduced immune-surveillance and 
other factors such as infection with oncogenic viruses, environmental factors like 
exposure to sunlight. 
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III. Recurrent cancer:  
This is the recurrence after transplantation of a cancer treated prior to 
transplantation. The estimate of the risk of recurrence after transplantation of 
cancer treated before transplantation can be useful in assessing the overall benefit 
of transplantation for a patient who has previously been treated for cancer and also 
in utilising scarce donor organs to those recipients who are more likely to benefit. 
 
1.11.1 Cancer transmission by organ transplantation 
Transmission of cancer from organ donors to their recipients is an established complication 
of organ transplantation (Murray et al., 1965). It was recognised in the early years of human 
transplantation that organs from donors with cancer at the time of donation or in the past 
can transmit the cancer to their recipient (McIntosh et al., 1965, Martin et al., 1965, Matter 
et al., 1970, Barnes and Fox, 1976, Harvey and Fox, 1981). As a result of these reports from 
the initial years of transplantation, organs from the donors with an active or past cancer 
were avoided resulting in fewer reports of transmission of cancer in the subsequent period. 
More recent reports include transmission of cancers from donors who were not known to 
have cancer at the time of transplantation (Loh et al., 1997, De Soyza et al., 2001, Lipshutz 
et al., 2003, Snape et al., 2008, Lipshutz et al., 2009). In cases where cancer transmission 
occurred, it is important to know if the presence of cancer in the donor was known at the 
time of donation. The significance of the knowledge of cancer in the donor is that the 
transmission of cancer may be preventable in at least some of these cases. When cancer 
transmission occurs from a donor, it is also useful to know which organs resulted in cancer 
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transmission and which organs from the same donor did not, so that the risk stratification 
can be extended to the individual organs from the donor with a cancer. Table 1.6 shows a 
list of the cases in the published literature of cancer transmission by organ transplantation. 
Data regarding whether the presence of cancer was known in the donor and the outcome of 
all organ recipients from each donor are also included. 
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Table 1.6 Cancers transmitted by organ transplantation 
Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Breast (Buell et al., 
2004, Penn, 
1997) 
NS (not 
specified) 
Cancer treated within 
10 years of donation 
Kidney Died of sepsis 2 weeks after 
transplant, cancer noted post 
mortem in the allograft 
Kidney  NS 
(Myron Kauffman 
et al., 2002) 
Living donor No Kidney Bone and brain metastases, 
improved with chemotherapy, 
cessation of immunosuppression 
without graft nephrectomy  
Kidney None 
Choriocarci
noma 
 
 
 
 
 
 
(Detry et al., 
1993) 
Cerebral 
haemorrhage 
Autopsy showed 
haemorrhagic brain 
metastases and a 
cancerous nodule in 
the right kidney which 
was not accepted for 
transplant because of 
difficult anatomy 
Left 
kidney 
Cancer in the graft. Remission 
following transplant 
nephrectomy and 
chemotherapy  
Kidney, liver None 
Liver Cancer in the graft -not excised. 
Cancer spread and death 
despite chemotherapy 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Choriocarci
noma 
 
(Braun-Parvez et 
al., 2010) 
Cerebral 
haemorrhage 
in pregnancy 
Cancer diagnosed in 
the placenta 
Kidney-
pancreas 
Elevated human chorionic 
gonadotropin (HCG) levels 
improved with chemotherapy 
Kidneys, liver, 
heart 
None 
Liver Intestinal metastases, death 
Kidney Elevated HCG levels improved 
following graft excision 
Heart Metastatic cancer 
(Buell et al., 
2004, Buell et 
al., 2001, Penn, 
1997) 
Six donors, 
presumed 
brain 
tumour/ 
haemorrhage 
Diagnosed at autopsy Kidney, 
liver, 
heart-lung 
14 recipients: 1 had no  cancer, 
9 with disseminated cancer (6 
died of cancer and 3 in 
remission after treatment), 4 
with localised cancer 
Kidney, liver, 
heart-lung 
NS 
(Baquero et al., 
1988) 
Cerebral 
haemorrhage 
No Liver  Death due to cancer Two kidneys, 
liver 
None 
Kidney 1 Death due to cancer 
Kidney 2 Metastatic cancer, undetectable 
HCG following explantation 
Heart Well at 10 months 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Choriocarci
noma 
 
(Marsh et al., 
1987) 
Cerebral 
haemorrhage 
- presumed 
benign 
High HCG levels noted 
in the stored serum 
retrospectively, after 
the diagnosis of 
cancer in the recipient  
Liver Death due to cancer Liver and 
kidney  
Heart 
Kidney Prophylactic graft excision 
showed localised cancer, alive at 
5 months 
Kidney Metastatic disease and death 
despite graft excision 
Heart Prophylactic re-transplantation. 
Excised graft showed localised 
cancer, alive at 5 months  
(Gokel et al., 
1977) 
Cerebral 
haemorrhage 
Brain metastases on 
autopsy, 
choriocarcinoma 
excision 2 years prior 
 
 
 
 
Kidney Prophylactic graft excision 
showed localised cancer, died of 
unrelated cause 7 months later 
Kidney None 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Choriocarci
noma 
 
(Knoop et al., 
1994) 
 Cerebral 
haemorrhage 
6 months 
after child 
birth, 
presumed 
benign 
No Lung Nodule resected before 
implantation, which was later 
confirmed to be 
choriocarcinoma, died of graft 
rejection 
Kidney, liver, 
heart-lung 
None 
Liver Death due to metastatic cancer 
Kidney Metastatic disease-explantation, 
cancer-free survival of 4 years 
Colon (Zelinkova et al., 
2012) 
Cerebrovascu
lar event 
No Liver Death due to transmitted cancer Liver NS 
Kidney No transmission 
Kidney No transmission 
(Ison and 
Nalesnik, 2011) 
NS NS NS Two cases of confirmed 
transmission 
NS NS 
(Buell et al., 
2004) 
Brain death NS NS Two cases of confirmed 
transmission 
NS NS 
(Kim et al., 
2013) 
Cerebral 
haemorrhage 
No Liver Death due to transmitted cancer Liver None 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
CNS - 
Astrocytom
a 
(Kashyap et al., 
2009) 
Pilocytic 
astrocytoma 
Yes Liver Death due to transmitted cancer Liver NS 
(Penn, 1997, 
Buell et al., 
2003) 
Grade III 
astrocytoma 
Yes NS Death due to transmitted cancer Kidney NS 
CNS – 
Glioblasto
ma 
 
 
 
 
 
 
 
 
 
(Buell et al., 
2003) 
Glioblastoma Yes Kidney Graft excision, no recurrence  None 
Kidney Metastatic disease, death 
despite graft excision 
Liver Confirmed transmission, death 
5 others Death due to transmitted cancer 
(Jonas et al., 
1996) 
Glioblastoma Yes Liver Death due to transmitted cancer Liver Kidneys, heart 
(Val-Bernal et 
al., 1993) 
Glioblastoma Yes Kidney Localised tumour, no recurrence 
after graft excision 
  
(Ruiz et al., 
1993) 
NS Yes 2 kidneys Localised tumour, no recurrence 
after graft excision in both cases 
Kidneys None 
(Ison and 
Nalesnik, 2011) 
NS NS NS, 1 
recipient 
NS NS NS 
95 
 
 
Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
CNS - 
glioma 
(Morse et al., 
1990) 
Malignant 
glioma 
Yes Liver Death due to transmitted cancer Liver Heart, kidneys 
Kidney,heart No transmission to 3 recipients 
(Penn, 1997, 
Buell et al., 
2001, Buell et 
al., 2003) 
NS Yes 2 kidney 
recipients 
Confirmed cancer transmission Kidney Not specified 
CNS - 
Medullobla
stoma 
(Penn, 1997, 
Buell et al., 
2003) 
Medulloblast
oma 
Yes NS Metastatic disease in 3 
recipients 
Kidney NS 
(Lefrancois et 
al., 1987) 
NS Yes Kidney-
pancreas 
Death due to transmitted cancer 
despite graft excision 
Kidney, 
kidney-
pancreas, 
heart 
None 
Kidney Transmitted tumour, explant 
Heart Death due to transmitted cancer 
Hepatoma (Matter et al., 
1970) 
Metastatic 
hepatoma 
Yes Kidney Resolved following cessation of 
immunosuppression 
Kidney  None 
(Penn, 1997) NS Yes NS Metastatic disease Liver NS 
(Ison and 
Nalesnik, 2011) 
NS NS NS One case NS NS 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Kaposi’s 
sarcoma 
(Shaheen et al., 
1997) 
NS No Kidney Two cases of transmission from 
the same donor 
Kidney NS 
(Penn, 1997) 
(Penn, 1991) 
NS 
 
NS Liver Metastatic disease, death due 
to complication of treatment 
Kidney   
Kidney – 
renal cell 
carcinoma 
(Buell et al., 
2004) 
NS Excised ex-vivo before 
implantation, size 
2.1cm, Fuhrman I or II 
Kidney No recurrence in 14 such 
recipients 
Kidney NS 
(Barrou et al., 
2001) 
Cerebral 
haemorrhage 
1.7mm 
tubulopapillary 
tumour, Fuhrman 
grade I/II identified in 
right kidney which 
was not transplanted 
Left 
kidney 
Graft excision, re-transplanted 
and recurrence-free at 5 years 
Kidney, heart None 
Heart Death due to transmitted cancer 
Liver Death during transplant 
(Myron 
Kauffman et al., 
2002) 
NS No Kidney Transmitted renal cell cancer, 
treated with graft excision 
Kidney None 
(Ison and 
Nalesnik, 2011) 
NS No Kidney Seven cases of transmission Kidney Not specified 
NS Donors with cancer in 
one kidney 
Other 
kidney, liver 
75 recipients with no cancer 
transmission 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Kidney – 
renal cell 
carcinoma 
(Llamas et al., 
2009) 
NS No Kidney 1 Metastatic renal cell cancer, 
death despite explantation  
Kidney None 
Kidney 2 Localised cancer, recurrence-
free after graft excision 
Kidney - 
oncocytom
a 
(Myron 
Kauffman et al., 
2002) 
NS No Kidney Transmitted renal oncocytoma, 
treated with graft excision 
  
Kidney - 
nephroblas
toma 
(Knoop et al., 
1994) 
Cerebral 
haemorrhage
, presumed 
benign 
Tumour confirmed on 
right kidney which 
was not transplanted 
Lung Death due to metastatic disease Lung  Liver, left kidney 
(right kidney with 
cancer was 
discarded) 
Left 
kidney 
2 year cancer-free survival 
Liver Death due to graft failure 
Heart Lost to follow-up 
Lung  
 
 
(Barnes and Fox, 
1976) 
Brain 
metastases 
As described Left 
kidney 
Transmitted lung cancer, 
dissemination and death 
Kidney None 
Right 
kidney 
Prophylactic nephrectomy 
showed no cancer. No 
recurrence 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Lung (Buell et al., 
2004) 
Cerebral 
event 
Lung cancer 
secondaries 
Kidney Transmitted lung cancer NS NS 
(Penn, 1997) NS Lung cancer within 10 
years before donation 
Two 
kidney  
Transmitted lung cancer, death 
due to another cause 
Kidney NS 
(Ison and 
Nalesnik, 2011) 
NS NS NS Four cases of transmission, 
death due to cancer in three 
Not specified NS 
(Bodvarsson et 
al., 2001) 
Living donor Cancer in donor, 10 
months after 
donation 
Kidney Transmitted lung cancer, 
responded to graft excision and 
chemotherapy 
Kidney None 
(von Boehmer 
et al., 2012) 
NS No Lung Lung cancer with dissemination 
causing death 
Lung NS 
(Winter et al., 
2001) 
Living donor Cancer in donor, 8 
months after 
donation  
Kidney Metastatic cancer, responded to 
graft excision and 
chemotherapy 
Kidney None 
(Forbes et al., 
1981) 
Head injury 
 
Donor cancer 
diagnosed week after 
donation 
Right 
kidney 
Transmission of cancer, cause of 
recipient’s death not specified 
Kidney None 
 Left 
kidney 
Death due to metastatic cancer 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Lymphoma (Harbell et al., 
2008) 
Suspected 
meningitis 
Lymphoma in the 
donor’s brain was 
diagnosed subsequent 
to donation 
Kidney Remission of disseminated 
caner following graft excision 
Kidneys, 
pancreas and 
liver 
None 
Liver Disseminated lymphoma, death 
Pancreas Remission of disseminated 
caner following graft excision 
(Schutt et al., 
1993) 
Cerebral 
trauma 
No Kidney 1 Remission after graft excision Kidney Heart 
Kidney 2 No transmission 
Heart No transmission 
(Penn, 1997) NS NS Kidney Graft excision, remission Kidney NS 
(Ison and 
Nalesnik, 2011) 
NS NS NS Transmission to six recipients, 
fatal in four 
Not specified NS 
Melanoma 
 
 
 
(Birkeland and 
Storm, 2002) 
NS NS Kidney Transmitted cancer Kidney None 
(Elder et al., 
1997) 
Cerebral 
haemorrhage 
No Kidney Remission after graft excision  Kidney, liver Heart 
Liver Fatal transmitted cancer 
Heart No transmission 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
 
Melanoma 
 
 
 
 
 
 
 
(Milton et al., 
2006) 
Subdural 
haemorrhage 
No Lung Transmitted cancer, outcome 
NS 
Kidney, lung Kidney, heart 
Heart NS 
Kidney 1 Remission of transmitted cancer 
following graft excision 
Kidney 2 Prophylactic graft excision 
showed no transmission 
(Kim et al., 
2009) 
Cerebral 
haemorrhage 
No Kidney 1 Prophylactic graft excision, no 
cancer in the graft 
Kidney, liver Kidney 
Kidney 2 Fatal transmitted cancer 
Liver Fatal transmitted cancer 
(Morris-Stiff et 
al., 2004) 
Sub-
arachnoid 
haemorrhage 
No Kidney 1 Fatal transmitted cancer Kidney, liver Heart 
Kidney 2  Fatal transmitted cancer  
Liver Fatal transmitted cancer 
Heart No transmission for 5 years 
post-transplant 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Melanoma (Stephens et al., 
2000) 
Cerebral 
haemorrhage 
No Kidney 1 
and 2 
Disseminated transmitted 
cancer, fatal despite explant in 
both cases 
Heart, liver, 
kidney 
None 
Liver and 
heart 
recipients 
Disseminated transmitted 
cancer, fatal in both cases 
(Ison and 
Nalesnik, 2011) 
NS NS NS Two cases of transmission, one 
fatal 
Not specified NS 
(Penn, 1997) NS NS NS Twenty one cases, 13 deaths 
due to cancer, 5 remissions 
after graft excision 
Kidney NS 
(Jeremy et al., 
1972) 
NS Metastatic melanoma 
diagnosed on autopsy 
Kidney 1 Disseminated cancer, fatal 
despite graft excision 
Kidney Kidney 
Kidney 2 No transmission 
(Cankovic et al., 
2006) 
 No Kidney Fatal transmission of cancer Kidney, liver None 
Liver Fatal transmission of cancer 
(Wilson et al., 
1992) 
NS No Kidney Fatal transmission of cancer Kidney None 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Melanoma 
 
(MacKie et al., 
2003) 
Sub-
arachnoid 
haemorrhage 
No Kidney1 Fatal transmission of cancer Kidneys None 
Kidney2 Transmitted cancer, explant 
Neuroendo
crine 
carcinoma 
(Foltys et al., 
2009) 
Sub-
arachnoid 
haemorrhage 
No Liver Fatal transmission of cancer Liver Kidneys 
Kidney1 Fatal transmission of cancer 
Kidney2 Explanted for unrelated reason, 
no transmitted cancer 
(Begum et al., 
2011) 
 No Heart Post op death, cancer 
transmission status unknown 
Liver Kidneys 
(Baehner et al., 
2000) 
NS No Liver Transmitted cancer Liver, kidney None 
Two 
kidney  
Prophylactic explantation- 
transmitted cancer in both cases 
(Baehner et al., 
2000) 
NS No Kidney 1 Transmitted cancer, explant Kidney Liver 
Kidney 2 Lost for follow-up 
Liver No transmitted cancer  
(Ison and 
Nalesnik, 2011) 
NS NS NS NS NS NS 
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Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Ovary (Lipshutz et al., 
2009) 
Cerebral 
anoxia 
No Two 
kidney 
recipients 
Transmitted cancer, fatal 
despite graft excision in both 
cases 
Liver None 
(Ison and 
Nalesnik, 2011) 
NS NS NS NS NS NS 
Pancreas (Gerstenkorn 
and Thomusch, 
2003) 
NS Suspected during 
bench preparation of 
kidney 
Kidney Transmitted tumour, death due 
to unrelated cause 
Liver, kidney None 
Liver Re-transplanted (cancer in the 
explant); cancer-free at 1 year 
(Ison and 
Nalesnik, 2011) 
NS NS NS NS NS NS 
Pinealoblas
toma 
(Zhao et al., 
2012) 
Cerebral 
trauma 
Diagnosed on donor 
autopsy 
Multi-
visceral  
Fatal transmission of tumour Liver, 
pancreas, 
intestine 
None 
Prostate (Loh et al., 
1997) 
Sub-
arachnoid 
haemorrhage 
Diagnosed after heart 
retrieval, confirmed 
on autopsy 
Heart Alive on chemotherapy at 18 
months 
Heart None 
(Penn, 1997) NS Yes   NS NS 
104 
 
 
Type of 
transmitted 
cancer 
Reference Donor cause 
of death 
Cancer known in the 
donor 
Organ 
donated 
Recipient outcome Transplant organ and recipient 
cancer status 
With 
transmission 
Without 
transmission 
Sarcoma (Detry et al., 
2005) 
 No Kidney, 
liver 
Transmitted cancer Kidney, liver None 
(Penn, 1997) NS No Kidney Metastatic transmitted cancer Kidney  NS 
Thyroid (Penn, 1997) NS No Kidney Explant, remission Kidney NS 
Unspecified (Penn, 1997) Living donor Anaplastic cancer at 
nephrectomy site  
Kidney Metastatic disease and death Liver NS 
(Kakar et al., 
2002) 
NS NS Liver Cancer-free after re-transplant Liver None 
(Krapp et al., 
2005) 
Cerebral 
haemorrhage 
Yes Kidney Cancer-free at 8 months 
following graft excision 
Kidney None 
(Conlon and 
Smith, 1995) 
Cerebral 
haemorrhage 
No Kidney 1 Cancer-free following explant Kidney None 
Kidney 2 Fatal transmitted cancer 
Urothelium (Backes et al., 
2012) 
Cerebral 
haemorrhage 
No Liver Cancer-free after re-transplant Liver, kidney None 
Kidney Transmitted cancer 
(Ferreira et al., 
2010) 
Cerebral 
haemorrhage 
No Kidney1 Fatal transmitted cancer Liver, kidney Kidney 
Kidney2 No transmitted cancer 
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The cases summarised in the Table 1.6 showed transmission of twenty two different cancers 
by solid organ transplantation. It is difficult to draw clinically useful conclusions for the 
donor selection and recipient management based on this information due to the variations 
in donor assessment and recipient management.  
1.12 Assessment of the risk of cancer transmission from organ donors 
The evidence for the assessment of the risk of cancer transmission from organ donors 
comes from two types of sources – Registry reports and case reports. Data from both these 
sources have their own advantages and disadvantages. The reports from the transplant 
registries have the advantage of including a relatively large cohort of cases with a longer 
follow-up. Such data can be useful for calculating incidence rates and identifying trends in 
the outcome among different sub-groups. The variations in the detail of the data between 
cases, censoring of the data, underestimation of the risk due to variable reporting of cases 
and retrospective nature of the analysis are some of the limitations of the registry data. In 
comparison, case reports and case series often report greater detail of clinical events of a 
small number of cases.  However, trends cannot be identified from case reports and it can 
be misleading to extrapolate the findings and conclusions from a small cohort to all the 
patients.  
The major registries providing useful data about the risk of cancer transmission are IPITTR, 
OPTN/UNOS, ONT, Centro Nazionali di Trapianti (CNT, the Italian registry) and the Australia 
and New Zealand Dialysis and Transplant Registry (ANZDATA). 
Transmission of cancer is a relatively uncommon complication of transplantation. Studies 
from the transplant registries and the cancer registries have reported rates of cancer 
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transmission from donors between 0∙04% and 0∙2%. An analysis of the data from the 
OPTN/UNOS registry including 108,062 recipients from 34933 donors transplanted over 51 
months reported donor origin tumours in recipients of 14 donors (of 34933) at the rate of 
0.04% (Myron Kauffman et al., 2002). The Odense University Hospital in Denmark reported 
one case of transmitted cancer from a cohort of 626 donors (0.2%) (Birkeland and Storm, 
2002).  
 
1.13 Guidelines for the estimation of the risk of cancer transmission from organ donors 
The Council of Europe (CoE) has issued guidelines for the assessment of the risk of cancer 
transmission from organ donors (COE, 2010); these are summarised in Table 1.7. These 
guidelines classify the risk of cancer transmission into three groups based on the cancer 
type, stage and the cancer-free duration at the time of donation: standard risk, non-
standard risk and unacceptable risk. A standard risk donor is an acceptable donor for all the 
donated organs and for all the recipients, a non-standard donor is acceptable for life-saving 
transplantation justified by the severity of the recipient’s condition and the risk-benefit 
assessment. An unacceptable risk donor is a contraindication to organ transplantation other 
than in exceptional and life-saving situations.  
The evidence on which the CoE guidelines are based, comes from case series, registry 
reports and expert opinion. The data showing cancer transmission from donors with a 
history of cancer is given greater importance in risk stratification than the impact of 
exclusion of such donors on the morbidity and mortality of the patients on the waiting list 
for transplantation. A critical assessment of this evidence is included in sections 4.5. 
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All cancers present at the time of donation are classed as having an unacceptable risk of 
transmission with the exception of localised NMSC, low-grade (WHO grade I or II) tumours 
of the CNS and low-grade (Fuhrmann grade I or II) renal tumours identified during organ 
retrieval of 2.5cm to 4cm size.  
The assessment of the risk in a donor with a past history of cancer is more complex and 
depends on following factors: 
A. Cancer-free period 
For most cancers, a cancer-free period longer than 5 years is considered to be associated 
with non-standard risk of transmission. The CoE guidelines (COE, 2010) acknowledge that 
due to national variations within Europe, some countries would recommend a cancer-free 
period of at least 10 years for some cancers prior to accepting as non-standard risk donors.  
All donors with a history of melanoma (including carcinoma-in-situ), lymphoma, sarcoma, 
chronic leukaemia, choriocarcinoma, cancer of the breast, ovary or thyroid (other than 
capsulated papillary or minimally invasive follicular type) are considered to have an 
unacceptable risk of cancer transmission regardless of the cancer-free period at the time of 
donation.  
The evidence for classifying some cancers as having an unacceptable risk in spite of a long 
cancer-free period is based on reported cases of cancer transmission following 
transplantation of organs from donors with a past history of cancer (some of the cases in 
Table 1.6). Some of this evidence is also from the extrapolation of experience from reported 
cases of late recurrences of cancer in immunocompetent patients, i.e. recurrence rates of 
cancer in the general population. 
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The presence or absence of dormant cancer cells in the donated organ cannot be 
demonstrated conclusively despite a thorough assessment of the donor prior to accepting 
the organs for transplantation. Therefore, the risk of transmission of cancer from a donor 
cannot be estimated accurately. So this risk cannot be completely eliminated, and needs to 
be balanced against the risk to the prospective recipient of not accepting the organ and 
continuing without a transplant. 
B. Stage of cancer in the donor 
Stage at which a cancer is detected usually corresponds to the degree of malignant 
behaviour of the cancer. Early stage cancers have high rates of successful treatment and low 
long-term recurrence rates. Donors with regional or distant metastases of cancer pose a 
significant risk of transmission to the recipient, regardless of the duration between the 
diagnosis of cancer and organ donation. Therefore organs from such donors are usually not 
accepted for transplantation.  
C. Treatment of cancer in the donor 
When a donor presents with a history of cancer that has not been treated with curative 
procedure or when the follow-up information is not available, the risk of transmission of 
such cancer by organ transplantation cannot be assessed so organs from such donors are 
not accepted.  
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Table 1.7 Council of Europe guidelines for stratification of risk of cancer transmission  
DONORS WITH UNACCEPTABLE RISK OF TRANSMISSION 
Features applicable to cancer of any histological type at any time prior to donation 
- Presence of metastasis – lymphatic or distant 
- Absence of curative surgical treatment or missed follow-up (except low-grade prostate cancer under surveillance) 
- Palliative treatment of cancer 
Non-CNS cancer at any time prior to donation 
- Breast 
- Ovary 
- Choriocarcinoma 
- Malignant melanoma 
- Sarcoma 
- Chronic Leukaemia 
- Thyroid (except capsulated papillary or minimally invasive follicular type) 
Non-CNS cancer diagnosed during organ retrieval: All cancers, except 
- Renal cell cancer <2.5 to 4cm (pT1a), tumour free resection margin and Fuhrman grade I or II 
- Localised low grade (Gleason score≤6) prostate cancer 
- Small gastrointestinal stromal tumours (GIST) 
- Localised non-melanoma skin cancer 
Cancers of the CNS: 
- WHO grade IV cancers 
- WHO grade III cancers with following features: 
           Presence of ventriculo-peritoneal or ventriculo-atrial shunts 
           Craniotomy 
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           Systemic chemotherapy 
           Radiotherapy 
DONORS WITH NON-STANDARD RISK 
Carcinoma-in-situ (CIS) other than CIS of breast, lung, choriocarcinoma, melanoma or sarcoma 
WHO grade III cancers without the features mentioned in ‘unacceptable risk’ group 
Small localised GISTs 
DONORS WITH STANDARD RISK 
Donors without a history of cancer 
Localised non-melanoma skin cancers 
Localised low grade (Gleason score≤6) prostate cancer 
Stage pT1 bladder cancer 
Localised WHO grade I or II cancers of the CNS 
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1.14 Role of CMV in post-transplant cancer 
Viruses such as human papilloma virus (HPV), human herpes virus (HHV) 8, HIV, EBV, HBV 
and HCV have an established role in the development of cancer both in the 
immunocompetent population and in the immunosuppressed transplant recipients. But the 
role of CMV in post-transplant cancer is not well understood. The understanding of the role 
of CMV in the pathogenesis of post-transplant cancer is particularly important as up to 80% 
of the adult population is infected with CMV (CDC, 2010) and the dilemma of accepting an 
organ from a CMV positive donor into a CMV negative recipient, without full understanding 
of long-term implications, is not uncommon. In the non-transplant population, while CMV 
antigens have been identified in cells of certain tumours such as cancers of the colon, 
prostate, lymphoma and glioblastoma (Soderberg-Naucler, 2006), it is not known if the 
presence of CMV is an epiphenomenon or whether there is a causative association. The 
published data assessing the impact of CMV on post-transplant cancer are limited to studies 
with small cohort size which show conflicting opinions with some studies suggesting a 
reduced risk in CMV infected recipients (Couzi et al., 2010) and others showing an increased 
risk in CMV infected recipients (Courivaud et al., 2012). Considering the high prevalence of 
CMV, it will be useful to establish the impact of CMV on the risk of post-transplant cancer 
using a large cohort with results that are more unequivocal. Such data will have the 
potential to influence the clinical practice while accepting an organ for transplantation, 
depending on the CMV status of the donor and the recipient.  
 
1.15 Post transplant lymphoproliferative disease 
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PTLD is one of the most important complications of transplantation and therapeutic 
immunosuppression. Along with NMSC, PTLD is one of the two most common cancers after 
transplantation (Collett et al., 2010). The outcome of the patients with PTLD depends on 
factors such as the time of diagnosis after transplantation, immunosuppression before and 
after the diagnosis, the EBV status, the extent and the grade of PTLD and the organ 
transplanted. Data comparing the incidence of PTLD in different eras of transplantation, 
correlation with the immunosuppressive agents and HLA type of the donor and the recipient 
will be useful in understanding the evolution of this disease and to develop guidelines for 
diagnosis and management of PTLD in future recipients.  
 
1.16 The importance of this thesis 
Some donors are excluded from donating their organs as a result of the estimated risk of 
transmission of cancer. The risk of transmission of cancer determined at the time of 
accepting the donated organs needs to be balanced against the risk of not accepting these 
organs and the consequent increased waiting period for the patients on the waiting list. The 
factors associated with cancer transmission from organ donors are not identified and these 
factors would be useful in increasing the accuracy of this assessment, further reducing the 
risk of cancer transmission to the recipients of organ transplantation and also avoiding 
inappropriate refusal of an organ which may have a low risk of cancer transmission. Some 
patients with end stage organ failure, who have previously been treated for a cancer, are 
excluded from transplantation as a result of perceived risk of recurrence of cancer after 
transplantation. This risk also needs to be balanced against the risk of refusing 
transplantation to such patients. As the survival rates are increasing for the recipients of all 
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organs, the risk of cancer is likely to increase due to a combination of advanced age of the 
recipient and longer duration of exposure to immunosuppression. The incidence of PTLD in 
different sub-groups of recipients and its relation to HLA status will be useful in improving 
the understanding of the disease and is likely to influence the outcome for patients with 
PTLD. The assessment of the impact of CMV on the risk of post-transplant cancer in a large 
cohort will be useful in producing reliable results and help in resolving the conflict of 
opinion produced by the existing data, regarding the association of CMV with post-
transplant cancer. These factors highlight the importance of the research detailed in this 
thesis.  
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CHAPTER 2 
AIMS OF THE THESIS 
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This thesis aims to investigate the risk of cancer transmission from organ donors and 
explores the scope for increasing the number of safe organ donors. The recipients with 
donor-transmitted cancer are studied in order to explore measures which can mitigate the 
risk. The recipients with recurrence after transplantation of a cancer treated before 
transplantation are studied to assess the risk factors associated with cancer recurrence. The 
impact of CMV status of the donor and the recipient on the risk of post-transplant cancer 
are examined. The incidence of PTLD in chronology and its association with the HLA type are 
explored. 
 
The aims of this thesis are: 
 
1. To investigate the recipients of solid organ transplantation in the UK for donor-
transmitted cancers and identify risk factors associated with cancer transmission, 
assess the outcome of the recipients with donor transmitted cancers, explore the 
measures to reduce the risk of cancer transmission 
 
2. To examine the actual and potential solid organ donors in the UK with a history of 
cancer to determine the risk of transmission of cancer from such donors and to 
provide guidelines for the assessment of risk of cancer transmission from organ 
donors with past history of cancer 
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3. To study the recipients of organ transplantation with a history of cancer treated 
prior to transplantation, assess the risk of recurrence of cancer following 
transplantation  
 
4. To assess CMV status among organ donors and recipients and its association with 
the risk of post-transplantation cancer  
 
5. To study the recipients of organ transplantation with PTLD, examine the changes in 
the incidence of PTLD with time and its relation to the HLA  
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CHAPTER 3 
DONOR TRANSMITTED CANCERS IN TRANSPLANT RECIPIENTS 
(Data and text from this chapter have been published 
 (Desai et al., 2012)) 
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3.1 Introduction  
A majority of the published cases of DTC are from case reports or small series as shown in 
Table 1.6. Whilst these are useful, the findings and outcomes reported in small number of 
cases cannot be generalised to all the recipients with DTC. The most recent and the largest 
transplant registry report from OPTN/UNOS published in 2002, estimated that the risk of 
cancer transmission was 0.01% (15 of 108062 recipients) (Myron Kauffman et al., 2002). In 
this study 0.03% of the donors resulted in cancer transmission (9 of 34993 donors). Since 
this report, the average age of the donor, obesity rates among the donors and the 
proportion of DCD donors have all increased (NHSBT, 2014b) and some of these factors are 
likely to influence the risk of cancer among the donors. Therefore, an assessment of the risk 
of cancer transmission in a recent cohort of donors and recipients would be useful to 
understand the impact of the changing donor profile on the risk of cancer transmission.  
 
In this chapter, I present the results of the first comprehensive national survey of transplant 
recipients in the UK to establish the extent of DTC, DDC, donor characteristics associated 
with cancer transmission, circumstances of cancer transmission, recipient management and 
outcome. These data will enable an assessment of the risk of cancer transmission to the 
transplant recipient in the UK. This information will form an important part of the risk 
assessment whilst assessing the donors and accepting the organs for transplantation. It will 
also form an important part of the information provided to the prospective recipient whilst 
obtaining the informed consent for transplantation. 
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3.2 Aims  
The aims of this chapter are: 
1. To assess the risk of cancer transmission from organ donors to their recipients 
2. To investigate the donor factors associated with the risk of cancer transmission 
3. To study the time of diagnosis of the transmitted cancer and its impact on the 
management and outcome of the recipients with transmitted cancer  
4. To study the impact of the transmitted cancer on the recipient survival 
 
3.3 Methods 
The data recorded by the UK Transplant Registry were used to identify all the recipients of 
solid organ transplantation in the UK. Among these, the cases of DOC could not be identified 
from the UK Transplant Registry, as the Registry did not routinely record these cases. 
Individual transplant centres in the UK had recorded these cases on local databases. For the 
duration between 1st January 2001 and 31st December 2010, complete electronic records of 
all transplant recipients were available within individual transplant centres, which could be 
investigated to identify cases of DOC. Therefore, this duration was used for this study. 
Recipients who had developed DOC were identified by a combination of methods including 
a database search at the transplant centres, consultation with transplant doctors and 
coordinators and by searching through clinical governance reports held by NHSBT. To 
achieve this, I contacted each transplant centre in the UK and visited several of them. I 
presented the scheme of my research at the departmental meetings and multidisciplinary 
meetings at the transplant centres and sought their engagement with my project. I worked 
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with local data managers, transplant co-ordinators, doctors and secretaries to identify the 
cases of DOC. DOC in the recipients had been confirmed to be of donor origin using 
histology, molecular genetic techniques or HLA analysis in all cases except one case of donor 
derived lymphoma (where the donor origin of cancer was suspected). 
 
3.3.1 Classification of DOC as DDC and DTC  
The classification of DOC into DDC and DTC is useful but it can often be a challenge to 
distinguish the two. DTC can be diagnosed with high degree of confidence when the cancer 
is identified at the time of or soon after transplantation or in those cases where the donor is 
known to have the same type of cancer. I used the following criteria for inclusion as DTC: 
- Cancers identified in the graft at the time of or within six weeks of transplantation 
- Metastatic cancer deposit (of donor origin) identified in the allograft without 
evidence of primary cancer in the recipient (for example, colon cancer deposits in 
the liver graft with normal colonoscopy and normal colonic computerised 
tomography [CT] scan) 
 
Other DOC were classified as DDC.  
 
All organ donors for the duration of the study were identified using the data held by the UK 
Transplant Registry. By matching the data of the recipients who had developed DTC with the 
donor dataset, the donors whose organs had resulted in cancer transmission were 
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identified. The donor characteristics available for analysis included age, gender, donor type, 
smoking history and BMI. These characteristics of the donors resulting in DTC were 
compared with the donors whose organs did not transmit cancer. Donors with incomplete 
record of their characteristics (n=20) were excluded. In donors aged over 18 years, obesity 
was defined using the WHO definition (BMI≥30kg/m2) (WHO, 2011a). For donors aged 
between 5 years and 18 years WHO growth charts were used and BMI higher than the 95th 
percentile for age and gender was considered as obesity (WHO, 2011b).  
There are eleven cancer registries in the UK including eight regional cancer registries in 
England and a national cancer registry each in Scotland, Wales and Northern Ireland. These 
record all new cases of cancer diagnosed based on clinical data, imaging and histology, 
including biopsies and post-mortem examination. As a routine and mandatory practice, the 
information about all new cases of cancer is passed on from the primary care and the 
hospitals to the cancer registries. The eight cancer registries in England have pooled their 
data to form the National Cancer Data Repository (NCDR), which contains data relating to 
the cases of cancer registered by any one of the English registries. When a donation resulted 
in cancer transmission to one solid organ recipient, all other recipients of organs from this 
donor were identified using the UK Transplant Registry and their details (NHS number, 
name, address, gender, date of birth and date of death) were matched with the NCDR to 
establish if these donors and recipients were recorded to have cancer. Cancer data after 
2008 and data for residents of Wales, Northern Ireland and Scotland were not available in 
the NCDR. For these cases, data were obtained from the UK Transplant Registry and the 
transplant centres.  
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For assessment of the incidence, the recipients who received a kidney with or without 
another solid organ were included in the kidney recipient group. Recipients of a liver with or 
without another solid organ (except kidney) were included in the liver recipient group. 
Combined heart-lung transplant recipients were included with the lung recipient group. 
Recipients of pancreas with or without intestine were included in the pancreas recipients 
group. Recipients registered with non-NHS transplant centres (n=60) and recipients of 
intestinal transplant only (n=29) were excluded. 
 
3.3.2 Statistical analysis 
All calculations were performed using statistical analysis software SAS, version 9.3 (SAS 
Institute, Cary).  
 
3.3.2.1 Incidence of transmitted cancer in different recipient groups 
As described in section 3.3.1, the recipients were divided into 5 groups, based on the organ 
transplanted. Each of these categories was further divided into recipients with and without 
cancer transmission. As this is a comparison of categorical data that are classified in two 
different ways and there were small numbers in the categories, Fisher’s exact test was used 
to assess the differences in the incidence rates of transmitted cancer between the recipient 
groups. Unpaired t-test without assuming equal variances was used to compare donor age 
and BMI between donors resulting and not resulting in cancer transmission.  
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3.3.2.2 Risk of cancer transmission from donors 
The data included independent variables such as donor age, gender, type and obesity 
status. The dependent variable was a categorical variable with a binary outcome – cancer 
transmission occurred or did not occur. The outcomes were known for all the donors and 
there was no censoring of the data.  Use of a linear regression model would be unsuitable 
for this analysis as the dependent variable is binary rather than normally distributed (Tripepi 
et al., 2008). For these reasons, logistic regression was used to assess the association 
between donor characteristics and the risk of cancer transmission.  
 
3.3.2.3 Survival of recipients with and without DTC 
Post-transplant recipient survival was compared between the recipients with and without 
DTC. As described above in section 3.3.2.2, linear regression analysis was unsuitable for this 
analysis as the outcome was binary (alive or dead) rather than normally distributed. At the 
end of the follow-up period some recipients were alive, resulting in right censoring of the 
data. Similarly, those recipients who had not been followed-up until the end of the study 
period and who were alive at their last known follow-up would result in right censoring. In 
presence of censored data, logistic regression analysis would be inappropriate, since no 
account could be taken of the data from these patients. Therefore, survival analysis was 
used for this analysis. Kaplan-Meier survival curves and log-rank test were used to compare 
unadjusted survival and Cox regression was used for assessment of risk-adjusted hazard of 
death. 
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3.4 Results 
3.4.1 Recipient groups 
In the UK, a total of 30765 recipients underwent solid organ transplantation between 1st 
January 2001 and 31st December 2010.  The kidney recipient group included recipients of 
kidney only (n=19784), kidney and pancreas (n=1112), kidney and liver (n=119), kidney and 
heart (n=12) and kidney with liver and pancreas (n=2). The liver recipient group included 
recipients of liver only (n=6612), liver and pancreas with or without intestine (n=28), liver 
and heart (n=2) and liver and lung (n=3). The lung recipient group included recipients of 
lungs only (n=1257) and heart-lung recipients (n=110). The heart recipient group included 
1433 recipients.  
 
3.4.2 Donor origin cancers 
DOC were identified in 18 recipients (18 of 30765, 0.06%, Table 3.1). Of these, three cases 
were likely DDC (0.01%). The three cases of DDC are discussed here:  
The first case was a transitional cell carcinoma occurring in the recipient of a kidney from a 
living donor, diagnosed 23 months after transplantation. This was likely to be a DDC because 
of the interval from transplantation; the donor remained free from cancer 50 months after 
donation.  
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The second case was of a renal cell cancer found incidentally in a kidney explanted for 
benign disease. This was likely a DDC as the tumour was small (not seen on cross sectional 
imaging) and was diagnosed 38 months after transplantation. 
 
The third case was a lymphoma of suspected donor origin presenting as a mass in the hilum 
of the transplanted liver 5 months after transplantation. The deceased donor had no 
evidence of lymphoma at the time of donation. 
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Table 3.1 Transplant activity in the UK and cases of DOC between 2001 and 2010 
 
*the median follow up period for transplantations performed between 2001 and 2010 is relatively low. This is explained by the higher number of 
transplantations in the recent years (who will be censored as they remain under follow up), increasing survival rates for the recipients 
transplanted in the recent years and improving collection of survival data with time. 
 
 
Organ 
recipient 
group 
Number of 
transplants 
Age in years 
Mean  
(95%CI) 
Sex 
Male 
(%) 
Follow up in 
years 
Median* 
(95%CI) 
Cases 
of DDC 
Follow up in 
years 
Median 
(range) 
 
Incidence 
of DDC 
(%) 
Cases 
of DTC 
Follow up in 
years 
Median 
(range) 
 
Incidence 
of DTC 
(%) 
p-value 
(for DTC 
incidence) 
Kidney 21029 43∙9 
(43∙7, 44∙1) 
61 3∙95 
(3∙93, 3∙98) 
2 2.40  
(1.90, 2.90) 
0∙01 12 2.90 
(0.02, 8.97) 
0∙06 0∙67 
Liver 6645 43∙6 
(43∙1, 44∙1) 
58 3.71 
(3∙52, 3∙79) 
1 0.66 0∙02 2 3.32 
(0.95, 5.69) 
0∙03 
Heart 1433 37∙6 
(36∙5, 38∙6) 
69 4∙24 
(4∙00, 4∙81) 
0  0 0  0 
Lung 1367 44∙5 
(43∙7, 45∙3) 
54 2∙41 
(2∙06, 2∙79) 
0  0 1 0.84 0∙07 
Pancreas 291 41∙8 
(40∙7, 42∙9) 
51 2∙18 
(1∙98, 2∙87) 
0  0 0  0 
Total 30765 43∙7 
(43∙5, 43∙9) 
60 3∙89 
(3∙87, 3∙92) 
3 1.90 
(0.66, 2.90) 
0∙01 15 2.89 
(0.02, 8.97) 
0∙05  
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3.4.3 Donor transmitted cancers  
Fifteen recipients had DTC (15 of 30765, 0.05%) from 13 donors. The details of individual 
cases of DTC are described in Table 3.2. In none of the cases was the presence of cancer 
known at the time of transplantation. These 13 donors had donated organs to 19 other 
recipients, none of whom had evidence of cancer. Cancer was transmitted from one donor 
to multiple recipients on two occasions: lung cancer and lymphoma. 
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Table 3.2 Cases of transmitted cancer from organ donors in the UK 
 
 
 
Donor 
age, 
gender 
Recipient age, 
gender 
Cancer extent: 
Localised to graft 
or disseminated 
Time of 
diagnosis 
(days) 
How the cancer 
was discovered 
 
Explant / 
excision 
Recipient 
outcome 
Death 
due to 
DTC 
Follow 
up 
(months) 
Case 
1 
Donor 1 
46 years 
male 
Kidney recipient 1 
12 years, M 
Transmitted renal 
cancer, localised 
9 Incidental (biopsy 
to assess graft 
dysfunction) 
Explant Alive  107 
Kidney recipient 2 
69 years, M 
Data not available   No Deceased No 19 
Liver recipient 
52 years, male 
No cancer   No Alive  102 
Heart recipient 
58 years, male 
No cancer   No Alive  108 
Case 
2 
Donor 2 
51 years 
male 
Kidney recipient 1 
58 years, male 
Transmitted renal 
cancer, localised 
7 Incidental (biopsy 
to assess graft 
dysfunction) 
Explant Deceased No 34 
Kidney recipient 2 
59 years, male 
No cancer   No Deceased No 86 
Case 
3 
Donor 3 
48 years 
male 
Kidney recipient 1 
64 years, male 
Transmitted renal 
cancer, localised 
0 Incidental  
(protocol biopsy) 
Explant Alive  82 
Kidney recipient 2 
61 years, male 
No cancer   No Alive  85 
Case 
4 
 
 
 
 
 
 
Donor 4 
62 years 
female 
Kidney recipient 1 
61years, female 
Transmitted renal 
cell carcinoma, 
localised 
7 Incidental (biopsy 
to assess graft 
dysfunction) 
Excision Alive  12 
Kidney recipient 2 
46 years, male 
No cancer   No Alive  15 
Liver recipient 
61 years, male 
No cancer   No Alive  9 
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Donor 
age, 
gender 
Recipient age, 
gender 
Cancer extent: 
Localised to graft 
or disseminated 
Time of 
diagnosis 
(days) 
How the cancer 
was discovered 
 
Explant / 
excision 
Recipient 
outcome 
Death 
due to 
DTC 
Follow 
up 
(months) 
Case 
5 
Donor 5 
54 years 
male 
Kidney recipient 1 
47 years, male 
Transmitted renal 
cancer, localised 
0 Incidental 
(protocol biopsy) 
No Alive  101 
Kidney recipient 2 
51 years, female 
No cancer   No Alive  96 
Liver recipient 
53 years, male 
No cancer   No Alive  12 
Case 
6 
Donor 6 
53 years 
male 
Kidney recipient 1 
64 years, female 
Transmitted renal 
cancer, localised 
0 Incidental 
(protocol biopsy) 
Excision Alive  35 
Kidney recipient 2 
55 years, male 
No cancer   No Alive  34 
Case 
7 
Donor 7 
45 years 
male 
Lung recipient 
30 years, male 
Transmitted non-
small cell lung 
cancer, 
disseminated 
192 Lymphadenopath
y 
No Deceased Yes 10 
Kidney recipient 1 
35 years, female 
No cancer   No Alive  43 
Kidney recipient 2 
52 years, female 
No cancer   No Alive  47 
Liver recipient 
69 years, male 
No cancer   No Alive  47 
Case 
8 
Donor 8 
57 years 
female 
Kidney recipient 1 
47 years, male 
Transmitted 
squamous lung 
cancer, localised 
0 Incidental 
(protocol biopsy) 
Explant Alive  37 
Kidney recipient 2 
52 years, female 
No cancer   Explant Alive  47 
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Donor 
age, 
gender 
Recipient age, 
gender 
Cancer extent: 
Localised to graft 
or disseminated 
Time of 
diagnosis 
(days) 
How the cancer 
was discovered 
 
Explant / 
excision 
Recipient 
outcome 
Death 
due to 
DTC 
Follow 
up 
(months) 
Cases 
9 and 
10 
Donor 9 
59 years 
male 
Kidney recipient 1 
64 years, male 
Transmitted small 
cell lung cancer, 
localised 
0 Incidental (on 
protocol biopsy) 
Explant Alive  26 
Kidney recipient 2 
41 years, female 
Transmitted small 
cell lung cancer, 
localised 
39 On explant 
(performed 
following 
diagnosis of 
cancer in the 
other kidney 
recipient) 
Explant Alive  26 
Case 
11 
Donor 10 
54 years 
female 
Kidney recipient 1 
39 years, male 
Transmitted 
adenocarcinoma 
of lung, 
disseminated 
849 Incidental (on 
biopsy performed 
to assess graft 
dysfunction) 
Explant Deceased Yes 51 
Kidney recipient 2 
53 years, male 
Data not available   No Alive  3 
Liver recipient 
57 years, male 
No cancer   No Alive  47 
Cases 
12 
and 
13 
Donor 11 
50 years 
female 
 
Kidney recipient 1 
46 years, female 
Transmitted 
lymphoma, 
localised 
14 Biopsy performed 
following post-
mortem 
examination of 
the donor 
No Alive  12 
Kidney recipient 2 
58 years, male 
Transmitted 
lymphoma, 
localised 
14 Biopsy performed 
following donor 
post-mortem  
No Alive  12 
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Donor 
age, 
gender 
Recipient age, 
gender 
Cancer extent: 
Localised to graft 
or disseminated 
Time of 
diagnosis 
(days) 
How the cancer 
was discovered 
 
Explant / 
excision 
Recipient 
outcome 
Death 
due to 
DTC 
Follow 
up 
(months) 
Case 
14 
Donor 12 
22 years 
male 
Liver recipient 
41 years, male 
Transmitted 
neuroendocrine 
tumour, 
disseminated 
265 Graft dysfunction No Deceased Yes 11 
Kidney recipient 
62 years, male 
Sarcoma of 
kidney (not a 
proven DTC) 
344  Explant Deceased No 60 
Case 
15 
Donor 13 
58 years 
male 
Liver recipient 
58 years, male 
Transmitted 
adenocarcinoma 
of colon, localised 
370 Incidental (focal 
abnormality on 
Ultrasound scan) 
Explant – re-
graft 
Alive  68 
Kidney recipient 1 
31 years, male 
No cancer   No Alive  93 
Kidney recipient 2 
25 years, male 
No cancer   No Alive  91 
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3.4.4 Donor factors associated with cancer transmission 
During the study period, 25697 organs were transplanted from 14986 donors. Organs from 
13 donors resulted in cancer transmission giving a cancer transmission rate of 0∙09% for 
donors (13 of 14986) and 0∙06% for organs transplanted (15 of 25697).  The cancer 
transmission rate was 0∙14% for DBD donors (9 of 6559), 0∙24% for DCD donors (4 of 1653). 
There was no case of cancer transmission from living donors. The donors resulting in cancer 
transmission were compared against the donors without cancer transmission. The results of 
univariate analysis are shown in Table 3.3.  Multivariate analysis showed that the risk of 
cancer transmission was significantly associated with donor age ≥45 years (Odds ratio [OR] 
9, 95% CI 1.2, 69.6). None of the other variables tested showed a significant association with 
transmission of cancer after adjusting for all other factors - donor gender (OR 2.2 for males, 
95%CI 0.7, 7.3), smoking history (OR 1.6 for smokers, 95% CI 0.5, 4.8), donor obesity (OR 2.2, 
95% CI 0.6, 7.3), donor type (OR 1.9 for DCD relative to DBD, 95% CI 0.6, 6.5).  
 
While it would have been helpful to assess the transmission rates from donors with a past 
history of a specific cancer, since none of the donors whose donated organs resulted in 
transmission had a history of cancer at the time of transplantation, it was not possible to 
assess cancer-specific transmission rates. 
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Table 3.3 Donor characteristics and the association with cancer transmission: results of univariate analysis 
  Donors who  
transmitted cancer 
Donors who did not 
transmit cancer 
Odds ratio 
(95% CI) 
p-value 
N  13 14973   
Mean age in 
years 
(95% CI) 
 50.7 
(44.6, 56.7) 
45.4 
(45.2, 45.7) 
 0.08 
Age group <45 years 1 (7.7%) 6586 (44%) 1 0.004 
≥45 years 12 (92.3%) 8387 (56%) 9.4 
(1.2, 72.5) 
Gender Female 4 (30.8) 7489 (50%) 1 0.16 
Male 9 (69.2%) 7484 (50%) 2.3 
(0.7, 7.3) 
Donor type 
 
DBD 9 (69.2%) 6550 (43.8%) 1 0.36 
DCD 4 (30.8%) 1649 (11.0%) 1∙8 
(0.5, 5.7) 
Mean BMI, 
kg/m2 
(95% CI) 
 30.3 
(22.9, 37.7) 
26.1 
(26.1, 26.2) 
 
 
0.23 
Obesity 
status 
 
Non-obese 8 (61.5%) 11594 (77.4%) 1 0.4 
Obese 4 (30.8%) 2405 (16.1%) 2.4 
(0.7, 8.0) 
Unknown 1 (7.7%) 974 (6.5%) 1∙5 
(0.19, 11.9) 
Past smoking 
 
No 6 (46.2%) 6276 (41.9%) 1 0∙4 
Yes 7 (53.8%) 4583 (30.6%) 1.6 
(0.5, 4.8) 
 
 3.4.5 Time of diagnosis of DTC and its relation to outcome 
In 11 recipients (of 15, 73%) the DTC were diagnosed within 6 weeks of 
transplantation.  These were diagnosed at a median time from transplant of 7 days 
(range 0 to 39). Nine of these (6 renal cell cancers and 3 lung cancers) were detected 
incidentally on histology and/or ultrasound scan performed for other reasons or in 
the explanted graft. In the remaining two cases (of lymphoma from the same donor), 
DTC were diagnosed on biopsies of the grafted kidneys performed following 
identification of cancer during post-mortem examination of the donor. None of the 
cases of DTC diagnosed within 6 weeks of transplantation had evidence of spread of 
cancer outside the graft. Surgical treatment (explant/excision) was recommended to 
all the 11 recipients DTC (except one recipient who had <1mm renal cell cancer 
which could not be localised on cross sectional imaging) and was accepted by 8 
recipients. The two recipients with donor transmitted lymphoma both refused 
surgery, and following chemotherapy, were well and cancer free 12 months post 
transplantation.  
 
Four recipients had DTC diagnosed after 6 weeks of transplantation, including lung 
cancer (two), neuroendocrine tumour and colon cancer (one each). These were 
diagnosed after a median duration of 318 days (range 192 to 849). In three of these 
cases the cancer had metastasised outside the graft at the time of diagnosis. 
 
3.4.6 Effect of DTC on recipient outcome 
Three (of 15, 20%) recipients with DTC died as a direct consequence of cancer and all 
three had DTC diagnosed after 6 weeks of transplantation. Out of seven kidney 
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recipients undergoing explantation, six returned to long-term dialysis and the other 
one underwent re-transplantation. Five-year survival of kidney recipients is shown in 
Figure 3.1. The survival was lower in recipients with transmitted cancer (83%) as 
compared to recipients without transmitted cancer (93%) and this difference 
approached but did not reach statistical significance (p=0.077). The trend towards 
higher survival among kidney recipients without a transmitted cancer as compared 
to the recipients with transmitted cancer (some of whom underwent explantation 
and returned to dialysis) may be attributable to the higher survival in transplanted 
patients than patients on dialysis. Kidney recipients with DTC had an increased risk of 
death within five years of transplantation compared to recipients without DTC but 
this difference was not statistically significant (p=0.116) after adjusting for age and 
gender (hazard ratio [HR] = 3, 95% CI 0.8, 12.1).  
 
 
 
 
 
 
 
 
 
137 
 
 
Figure 3.1: 5-year survival of kidney recipients with and without DTC 
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3.5 Discussion 
3.5.1 Clinical implications 
The incidence of DTC in this study (0.05%) is higher than the rate of 0.01% reported 
by the OPTN/UNOS study (Myron Kauffman et al., 2002). The OPTN/UNOS study 
analysed 108062 recipients from 34933 donors over 51 months and reported 15 
cases of DTC. There was only one case of transmitted renal cell cancer, which was 
diagnosed 37 months post transplantation. In contrast, I found six cases of 
transmitted renal cell cancer in the present study, diagnosed at a mean duration of 4 
days post transplantation (7% of all DTC in the OPTN/UNOS study compared with 
38% in my study). However a more recent report (Ison and Nalesnik, 2011) from 
OPTN/UNOS indicated that seven out of 20 (35%) DTC were renal cell cancers. In my 
study, all six cases of renal cell cancer were identified as incidental findings on 
biopsies performed routinely at the time of transplantation or to assess early graft 
dysfunction. There were two cases of transmitted lung cancer in the earlier 
OPTN/UNOS cohort compared to 5 cases in my cohort (13% of all DTC compared 
with 33% in my series). Two of the transmitted lung cancers in my cohort were 
identified on routine biopsies performed at the time of transplantation. Reasons for 
these differences may include different time periods, differing donor profiles, 
variations in reporting and in indications for biopsy. 
 
Although many countries have efficient and large national transplant registries, the 
number of DTC cases remains small and this highlights the importance of global 
initiatives, such as the NOTIFY project, in helping understand the extent of problem 
(NOTIFY, 2010). NOTIFY project is a joint venture of WHO and CNT, which aims to 
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improve the donor and recipient safety and increase the transparency in the practice 
of transplantation. Started in 2010, this project aims to collect data from 36 
countries on various complications of transplantation such as transmitted cancer, 
infection, clinical errors and reactions, with an intention provide evidence to 
facilitate risk reduction. Data collated from several countries are more likely to 
increase the robustness of the study and power of statistical analysis. However the 
limitations of such multi-national projects would include diverse demography of 
donors and recipients, varying inclusion/exclusion criteria for donors with known 
cancer and genetic differences which may result in heterogeneity in types of cancers 
and their biological behaviour.  
 
3.5.2 Strengths and limitations of the study 
The estimation of the risk of cancer transmission from a national cohort is useful in 
informing the transplant specialists and prospective recipients about the extent of 
the risk. This information enables better assessment of the risks involved with 
transplantation and a comparison with the risks of continuing without 
transplantation. This study identified the differences between early and late DTC in 
terms of the clinical presentation, extent of the disease, recipient management and 
outcome. These differences provide guidance for the management of the recipients 
with DTC. This study also provides evidence about the higher risk of DTC from older 
donors. Although the increased donor age was the only donor factor associated with 
an increased risk of cancer transmission, the effect of small numbers must be noted. 
There may be other donor factors associated with increased cancer transmission 
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risk, which did not reach statistical significance due to the small number of donors 
who transmitted cancer.  
 
This study has some important limitations. The reported incidence of DTC must be an 
underestimate. DTC were identified retrospectively and only those cases were 
included where donor origin was confirmed (or suspected in one case). It is possible 
that in some cases of cancers in the recipient, donor origin was not suspected or 
investigated and some recipients may have died with transmitted cancer that was 
not identified. I worked exhaustively in searching databases at individual transplant 
centres to identify for all cases of DTC but it is possible that not all cases were 
identified. The history of cancer in the donors was obtained from the cancer 
registries. The UK is widely recognised to maintain one of the most comprehensive 
cancer registration system in the world (UKACR, 2013). The cancer registries make 
constant efforts to register all diagnosed cancers to ensure a comprehensive register 
including regular cross verification with hospital/primary care records (Kaye et al., 
2000). However, it is possible that there may be some under-registration. 
A detailed and critical discussion of the strengths and the limitations of these data is 
included in sections 8.2 and 8.3.  
 
3.5.3 Reducing the risk of cancer transmission 
All donors undergo assessment to detect transmissible diseases prior to organ 
donation. This includes history, examination, chest X-ray and blood tests. The details 
of previous cancer are obtained by enquiry with family, carers and primary care 
physician.  In the UK, cross sectional imaging and tumour markers are not routinely 
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performed as a part of donor assessment but reports are reviewed, if available. As 
detailed in section 1.13 and Table 1.7, a history of several types of cancer in the 
donor is considered to pose a high-risk of transmission to the recipient. In my study, 
none of the donors whose organs resulted in cancer transmission was known to have 
a past history of cancer or active cancer at the time of donation. This highlights the 
difficulty in eliminating the risk of cancer transmission completely, despite a 
thorough assessment of the donor. A small but definite risk of transmission of occult 
donor cancer remains and should be considered an inherent risk of transplantation 
whilst assessing the overall benefit of transplantation to the recipient. 
 
In the UK, the donors are getting older. As shown in Figure 3.2, 59% of the donors in 
2013-14 were aged ≥ 50 years as compared to 43% in 2004-05 (NHSBT, 2014b). With 
increasing proportion of older donors, the likelihood of occult cancer in the donors is 
likely to increase, resulting in increased chance of cancer transmission to the 
recipients. 
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Figure 3.2. Increasing proportion of older organ donors in the UK 
 
 
 
 
 
 
 
 
 
 
Source: Transplant activity in the UK, 2013-2014, NHS Blood and Transplant
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3.5.4 Management of the recipients with transmitted cancers 
Based on the observations in the present study and those in the literature, it is 
possible to make some tentative recommendations. However, more robust evidence 
and wider discussion is needed before these observations can be translated into 
formal guidelines.  
 
3.5.4.1 Before transplantation  
All potential transplant candidates should be counselled about the benefits and the 
risks of transplantation in line with current practice. Informed consent should 
include the information about the risk of cancer transmission. As shown in this study 
with incidence of 0.05% and cancer-related death in 20% recipients developing DTC, 
it is important to highlight the rarity of transmission and also the possible outcome 
when such transmission does occur. Informed consent provides significant 
advantages in clinical management in that the transplant team and the recipient can 
be alert to the risk factors in the donor which may increase the risk of an occult 
cancer and also look out for manifestations of a transmitted cancer in the recipient. 
Comprehensive provision of information to the prospective recipient at the time of 
consent, apart from providing advantages in the clinical management of the 
recipient, also has medico-legal implications.  
 
3.5.4.2 After transplantation 
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Management of the recipient with transmitted cancer will be dependant on many 
factors, including the type and stage of cancer, organ transplanted, co-morbidities, 
time after implantation, immunosuppression and recipient’s wishes. As the number 
of recipients who developed transmitted cancer in this cohort was small and 
treatment varied, it is not possible to provide evidence-based guidelines. However 
some trends can be identified which may enable improved management of patients 
with a DTC.  
 
Excision of tumour or graft explantation is likely to benefit the kidney and pancreas 
recipients with transmitted cancer diagnosed in the early post–transplant period, 
and is likely to be most beneficial when there is no evidence of spread of cancer 
outside the graft. In presence of metastatic disease, explantation should be 
discussed: the outcome from cancer is likely to improve after stopping 
immunosuppression as the tumour is rejected (Wilson et al., 1968). However the 
ability of the transmitted cancer cells to be rejected by the host immunity may also 
be a reflection of the degree of tumour differentiation and expression of donor HLA. 
A higher degree of expression of HLA, its correlation with a higher degree of tumour 
differentiation and a higher degree of host immunological response has been 
demonstrated in several cancers including cancer of prostate (Levin et al., 1994), 
stomach (Ma et al., 1994), oesophagus (Hosch et al., 1997) and other cancers 
(Cordon-Cardo et al., 1991). In transplants other than kidney/pancreas transplants, 
the benefits of explantation should be weighed against the risks associated with re-
transplantation and the likelihood that the tumour may already have spread beyond 
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the donor organ. In cases where explantation is not an option, lowest possible 
immunosuppression should be used. As discussed in Section 1.7.5, mTOR inhibitors 
have inhibitory action against some cancers, therefore these agents may have a role 
in selected recipients with DTC, although conclusive evidence for this is limited.  
 
3.5.5 Management of the recipients of other organs 
When a recipient develops a transmitted cancer, recipients of other organs from this 
donor should be informed and investigated for cancer transmission. The risk of 
cancer transmission to these recipients is difficult to assess. This risk depends on the 
type, stage and grade of cancer in the index recipient, tumour biology and the organ 
transplanted. It is notable in the UK transplant recipients I studied, that transmission 
of cancer to multiple recipients was seen when the donor cancer was a lymphoma or 
small cell lung cancer. The recipients with no evidence of cancer transmission should 
undergo cancer surveillance. The benefits of graft explantation in such situations 
should be assessed based on the details of the cancer in the index recipient. In 
absence of high quality evidence, it is difficult to develop guidelines for management 
of all the other organ recipients from a donor who resulted in cancer transmission, 
however, the knowledge of common sites of metastases of different types of cancers 
may be useful in assessing the risk of cancer transmission to the recipients of 
different organs: for example, when the transmitted cancer is a breast cancer, the 
risk to the cardiothoracic organ recipients is likely to be higher than the risk to the 
kidney or pancreas recipients. Similarly, the risk of transmission of donor colon 
cancer to the liver recipient is likely to be higher than the risk to the heart recipient.  
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In summary, these data demonstrate that the incidence of DTC among the transplant 
recipients in the UK is 0.05%. There is no significant difference in the incidence of 
DTC between the recipients of different organ transplantation. Transmission 
exclusively occurred from donors without a known cancer indicating that, with 
continued implementation of standard donor assessment further reduction of the 
risk of cancer transmission cannot be achieved. This highlights the importance of 
informed consent of all prospective organ transplant recipients. (Desai et al., 2012) 
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CHAPTER 4 
DONORS WITH A HISTORY OF CANCER 
(Data and text from this chapter have been published  
(Desai et al., 2014)) 
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4.1 Introduction 
The guidelines from the Council of Europe (COE, 2010), described in Table 1.7, 
characterise some deceased organ donors with a previous history of cancer as having 
an unacceptable risk of cancer transmission. The guidelines recommend that organs 
from such donors should not be used unless in exceptional circumstances where a 
life-saving transplantation is needed. Whilst the terminology used to classify the 
donor risk itself can be misguiding (for example, an organ from a donor with 
“unacceptable risk” as per the classification may be lifesaving for a patient who is at 
a much higher risk of death due to organ failure), it is clear from the published 
literature, summarised in Table 1.6 that cancer transmission can occur from donors 
without a known history of cancer. As discussed in chapter 3, in all the 15 cases of 
DTC in the UK between 2001 and 2010, the donors whose organs transmitted cancer 
were standard risk donors. 
 
While offering transplantation to patients, an important priority is the reduction of 
risks associated with transplantation. The CoE guidelines focus primarily on 
reduction of the risk of cancer transmission. An inevitable consequence of reducing 
this risk by excluding some donors is further aggravation of the donor shortage and 
an increase in transplant waiting-list morbidity and mortality.  Every year, up to 16% 
of patients listed for heart transplantation, 13% of patients listed for liver 
transplantation, 15% of patients listed for lung transplantation and 6% of patients 
listed for kidney transplantation die or are withdrawn before a graft becomes 
available (NHSBT, 2014b). The number of patients dying whilst awaiting 
transplantation is considerably higher than the patients developing a DTC. In the UK, 
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in the same period between 2001 and 2010 in which there were 15 cases of DTC of 
whom three died, 4093 patients died whilst awaiting transplantation (NHSBT, 2013).  
  
The actual risk of cancer transmission posed by the donors who are classified as 
unacceptable risk has not been assessed in a large cohort. Such an assessment has 
the potential to verify the accuracy of present risk classification and also to explore 
the possibility of increasing the number of organ donors. In this Chapter, I present 
the findings of a study of organ donors with a history of cancer and the outcome of 
the recipients from these donors. 
 
4.2 Aims 
The aims of this chapter are 
1. To assess the proportion of actual and potential organ donors with a 
history of cancer  
2. To investigate the risk of cancer transmission from organs donors 
classified as unacceptable risk 
3. To identify a sub-group of donor cancers which are classed as 
unacceptable group by the CoE guidelines, who may actually have a lower 
risk of cancer transmission 
 
4.3 Methods 
Methods used for assessing cancer history in actual donors, their recipients and 
cancer history in potential donors are described separately. The definitions of actual 
and potential donors described in section 1.8.1 are used throughout this Chapter. 
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4.3.1 Actual donors and their recipients 
Actual donors were defined as donors where at least one solid organ (kidney, liver, 
heart, lung or pancreas) was transplanted. Using the UK Transplant Registry, living 
and deceased actual organ donors who donated between 1st January 1990 and 31st 
December 2008 and their recipients were identified. The details of cancer in organ 
donors and the recipients were obtained by matching their details with the National 
Cancer Data Repository, as described in section 3.2.1. This duration was selected, as 
the data from the National Cancer Data Repository were limited to this period. The 
cancer registration data for the donors and the recipients who lived outside England 
were not available in the National Cancer Data Repository, so the data were 
restricted to the donors and the recipients resident in England. Donors with 
insufficient data for matching with the National Cancer Data Repository (n=15) were 
excluded. All donor cancers diagnosed up to the day of donation were included. 
Donors registered with cancer after donation or in-situ carcinoma only were 
considered not to have had a history of cancer at donation. All recipient cancers 
diagnosed after transplantation were included. Actual and potential/possible donors 
with unacceptable risk of cancer transmission were identified according to the 
guidelines described in Table 1.7. 
 
4.3.2 Identifying cancer diagnosed at organ retrieval 
With a few exceptions, all cancers diagnosed at the time of organ retrieval are 
considered to pose an unacceptable risk of transmission. The exceptions include low-
grade CNS tumours, localised non-melanoma skin cancers and small low-grade renal 
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cell cancer. So, the risk of transmission of cancers diagnosed at the time of organ 
retrieval was studied separately to those donor cancers with a longer interval 
between diagnosis and organ donation. Using the data from the UK Transplant 
Registry it was not possible to identify donor cancers diagnosed at the time of organ 
retrieval. Therefore, donors diagnosed with an extra-cranial cancer within a day of 
donation were considered as diagnosed at the time of organ retrieval and these 
were studied separately.  
 
4.3.3 Potential donors 
In the UK Transplant Registry, the data for the potential/possible donors were not 
available for the entire duration between 1990 and 2008, as the potential donor 
audit did not exist prior to 2003 (NHSBT, 2014a). Furthermore, in October 2009, the 
data collection form for the potential donor audit was revised and definitions used 
were clarified to improve the data quality. For these reasons, the data for all 
potential/possible donors (defined below) in the UK, between 1st October 2009 and 
30th September 2012 were selected and those with cancers were identified. 
 
The following definitions (NHSBT, 2014a) were used: 
Possible DBD: suspected neurological death meeting the following criteria: apnoea, 
coma from known aetiology, ventilated, fixed pupils. 
Possible DCD: anticipated imminent death receiving ventilatory support and clinical 
decision to withdraw treatment. 
Potential DBD/DCD donor: possible DBD/DCD donor with no absolute/relative 
contraindication to donation.  
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4.3.4 Statistical analysis  
The mean donor age was compared between donors with and without a history of 
cancer using unpaired t-test, without assuming equal variances. Recipient survival 
was calculated using Kaplan-Meier estimate and compared using the log-rank test. 
Median survival times for the recipients were calculated, where possible. In some 
cases, less than 50% of the patients had died in the follow-up period. In these cases, 
the 25th percentile of distribution of survival time was used. Cox regression 
modelling was used to compare the hazard of death in single-organ recipients from 
donors in the two groups, using the following factors for risk adjustment: donor age, 
recipient age, donor sex, recipient sex, donor type, donor cause of death, primary 
disease (kidney, liver and heart recipients), HLA mismatch (kidney recipients) and 
ischemia time (cold ischemia for liver, total for heart/lung). An ‘unknown’ category 
was used to include the missing values. Recipients with missing ischemia time (liver: 
18%, heart: 40%, lung: 27%) were excluded from Cox regression. Additional life-years 
gained by using organs from donors with unacceptable/high risk were obtained as 
the average survival time up to 10 years, calculated from the area under survivor 
function curve up to 10 years after transplantation. 
 
All calculations were performed using SAS version 9.3 (SAS Institute, Cary). 
 
4.4 Results 
4.4.1 Cancers diagnosed at organ retrieval 
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Of the 17639 donors, 13 (0.07%) were diagnosed with cancer at organ retrieval. 
These donors donated 17 kidneys, two hearts, one liver, one lung and one pancreas 
to 22 recipients. The details of these donors and their recipients are shown in Table 
4.1.  
 
One of these donors resulted in transmission of cancer to the recipient. A 62-year-
old DBD donor was identified to have adenocarcinoma of the pancreas at the time of 
organ retrieval. Two kidneys and liver were transplanted from this donor into three 
recipients. One of the kidney recipients was diagnosed with transmitted cancer, two 
days after transplantation. The transmitted cancer was surgically excised. This 
recipient was followed up for 1.1 years without a recurrence of cancer, when he died 
following myocardial infarction. At the time of death he had a functioning graft. The 
liver recipient did not develop cancer transmission until his death, 2.6 years after 
transplantation. The cause of death was multi-organ failure. The recipient of the 
other kidney from this donor developed a graft failure on the day of transplantation 
due to post-operative vascular and ureteric complications. The long-term follow-up 
data for this recipient were not available. 
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Table 4.1 Donor cancers identified at organ retrieval and recipient outcome 
Donors 
Age in years, 
gender 
Cancer in the donor Recipients 
Age at transplant, 
gender 
Organ transplanted Transmission to 
recipient 
Outcome 
Donor 1 
44, male 
Non-Hodgkin’s lymphoma  
 
 
Recipient 1 
51, male 
Heart No Died on day 3 due to 
allograft dysfunction 
Recipient 2 
22, male 
Lung No Alive at 13 years 
Donor 2 
53, female 
Unspecified cancer Recipient 1 
30, male 
Kidney No Alive at 13.9 years 
Recipient 2 
30, male 
Kidney No Died after 6.4 years due 
to myocardial infarction 
Donor 3 
38, female 
Unspecified cancer Recipient 1 
69, female 
Kidney No Died after 17.2 years 
due to pneumonia 
Recipient 2 
48, male 
Kidney No Alive at 13.8 years 
Recipient 3 
48, male 
Heart No Died after 4 days due to 
pulmonary 
hypertension 
Donor 4 
51, female 
Adenocarcinoma-brain 
metastases 
Recipient 1 
58, male 
Kidney No Alive at 12.8 years 
Donor 5 
62, female 
Pancreas adenocarcinoma Recipient 1 
47, female 
Kidney No Graft failure on the day 
of transplant, no follow-
up data 
Recipient 2 
56, male 
Kidney Yes Died 1.1 year post-
transplantation due to 
myocardial infarction 
Recipient 3 
21, female 
Liver No Died after 2.6 years due 
to multi-organ failure 
156 
 
 
Donors 
Age in years, 
gender 
Cancer in the donor Recipients 
Age at transplant, 
gender 
Organ transplanted Transmission to 
recipient 
Outcome 
Donor 6 
57, male 
Renal cell carcinoma Recipient 1 
48, female 
Kidney No Died after 3.4 years due 
to pancreatitis 
Donor 7 
58, female 
Non-Hodgkin’s lymphoma Recipient 1 
34, female 
Kidney No Alive at 9.8 years 
Donor 8 
63, male 
Retroperitoneal 
liposarcoma 
Recipient 1 
49, female 
Kidney No Alive at 4.9 years 
Donor 9 
33, male 
 
 
Renal cell carcinoma Recipient 1 
58, female 
Kidney No Alive at 5.0 years 
Recipient 2 
60, male 
Kidney No Alive at 5.0 years 
Recipient 3 
30, female 
Pancreas  No Alive at 4.7 years 
Donor 10 
42, female 
Renal cell carcinoma Recipient 1 
46, male 
Kidney No Alive at 3.8 years 
Donor 11 
63, female 
Renal cell carcinoma Recipient 1 
65, female 
Kidney No Alive at 0.8 years 
Donor 12 
69, female 
Lung adenocarcinoma Recipient 1 
54, male 
Kidney  No  Alive at 3.0 years 
Recipient 2 
47, male 
Kidney No Alive at 3.0 years 
Donor 13 
53, male 
Renal cell carcinoma Recipient 1 
55, male 
Kidney No Alive at 2.9 years 
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4.4.2 Donors with a history of cancer 
Of the 17639 donors, 202 (1.14%) had a history of cancer. Figure 4.1 shows the number of 
donors with different types of cancer. The exploded slices of the pie chart indicate cancers 
which are currently classified as unacceptable risk of transmission according to the CoE 
guidelines (COE, 2010). 
 
Comparison of donors with and without history of cancer showed no significant difference 
in age (mean age 40.7 years [95%CI 38.5, 43.0] and 42.4 years [95%CI 42.2, 42.6] 
respectively, p=0.15) or gender (males 45.5% and 51.4% respectively, p=0.37). Significantly 
more DCD donors (24 of 1047, 2.3%) had a cancer history compared with DBD donors (164 
of 11047, 1.5%, p=0.04). Among the living donors 0.25% (14 of 5545) had a cancer history. 
 
 
 
 
 
 
 
 
 
 Figure 4.1 Donors with a history of cancer: exploded slices show cancers with unacceptable risk 
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4.4.3 Actual donors with unacceptable risk of cancer transmission and their recipients 
Of the 202 donors with cancer, 61 had cancers classed as unacceptable risk of transmission. 
These 61 donors donated 140 organs to 133 recipients (86 kidney, 22 liver, 10 heart, eight 
lung and seven multi-organ [four kidney-pancreas, two heart-lung and one kidney-heart]). 
Comparison of the survival of recipients of single organs from donors with unacceptable risk 
and standard/non-standard risk revealed no significant difference in unadjusted survival or 
risk-adjusted hazard of death. These results are shown in Table 4.2. There were insufficient 
data to assess the circumstances of acceptance of organs classed as unacceptable risk: I 
could not assess whether the data regarding the cancer in the donor were available to the 
transplanting team, whether there were discussions with the prospective recipients and 
their families regarding the risk of cancer transmission and if such organs were used 
because of the urgent need of transplantation. 
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Table 4.2 Recipient survival and risk-adjusted hazard of death in single-organ recipients from donors with unacceptable risk and standard/non-
standard risk of cancer transmission 
Recipient 
group 
Transplants from donors with an unacceptable 
risk of cancer transmission 
Transplants from donors with 
standard/non-standard risk of cancer 
transmission 
 Risk-adjusted hazard of 
death for recipients 
from donors with 
unacceptable risk† 
N Mean age in 
years 
Recipient survival in 
years 
N Mean age in 
years 
Recipient survival 
in years 
p-value Hazard ratio p-value 
Kidney  
 
86 47.4  
(43.7, 51.0) 
8.79 
(3.80, -)* 
23994 42.6 
(42.4, 42.8) 
10.96 
(10.69, 11.27) 
0.522 0.87 
(0.55, 1.39) 
0.566 
Liver 22 41.2 
(32.6, 49.9) 
5.37 
(0.11, -)* 
6560 39.4 
(39.0, 39.8) 
4.86 
(4.43, 5.42) 
0.807 1.07 
(0.43, 2.64) 
0.884 
Heart 10 34.3 
(22.8, 45.8) 
3.75 
(0.01, -)* 
2720 32.2 
(31.7, 32.7) 
3.56 
(2.72, 4.17) 
0.686 0.73 
(0.16, 3.18) 
0.670 
Lung 8 39.0 
(28.1, 49.9) 
0.43 
(0.04, 5.94) 
1245 36.6 
(35.8, 37.3) 
0.94 
(0.70, 1.29) 
0.400 2.85 
(0.94, 8.62) 
0.063 
Pancreas 0 - - 149 32.7 
(30.7, 34.6) 
6.20 
(5.84, 10.32) 
- - - 
Values in parentheses indicate 95% confidence intervals. *Upper confidence limit for survival of recipients was not under 75%, therefore not 
estimable.  Comparison of recipient survival (logrank test), † Cox regression modeling 
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At ten years after transplantation, the additional survival benefit of transplanting the organs 
from donors with unacceptable risk was 944 life-years (95%CI 851, 1037) with mean survival 
of 7.1 years (95%CI 6.4, 7.8) per recipient. Eight of these recipients developed post-
transplant cancers but none had the same type of cancer as their donor indicating these 
were de novo cancers. These results are shown in Table 4.3. 
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Table 4.3 Post transplant cancers* in the recipients from donors with unacceptable risk cancers 
Donor cancer Time of donor 
cancer 
diagnosis prior 
to donation 
Organ 
transplanted 
Recipient cancer Time from 
transplant to 
diagnosis of 
recipient cancer 
Haemangiosarcoma 3 days Kidney Glioma 307 days 
Medulloblastoma 0 days Kidney Small cell cancer liver secondaries 339 days 
Hodgkin’s lymphoma 4715 days Kidney Colon adenocarcinoma 828 days 
Glioblastoma 2 days Kidney Thyroid adenocarcinoma 933 days 
Medulloblastoma 0 days Heart Acute myeloid leukaemia 1371 days 
Glioblastoma 2 days Kidney Melanoma 3751 days 
Neuroectodermal tumour 2 days Heart Prostate adenocarcinoma 3930 days 
Glioblastoma 1 day Liver Non-Hodgkin’s lymphoma 3994 days 
*excluding primary liver tumours found in the explant, non-melanoma skin cancer and in-situ carcinoma 
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4.4.4 Factors associated with non-transmission of donor cancer 
In spite of being classed as having unacceptable risk of cancer transmission, some donor 
cancers did not transmit to the recipients. These donor cancers were assessed for 
identification of factors, which may be associated with non-transmission of cancer. Table 4.4 
shows factors associated with non-transmission of donor cancers. 
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Table 4.4 Donors with unacceptable risk cancer (excluding CNS cancers): features associated with non-transmission of cancer 
Donor cancer 
type 
No of 
donors 
No of recipients 
(organs) 
Duration from cancer 
to organ donation 
(completed months) 
Treatment of donor cancer 
(where known) 
Other features 
Melanoma 3 3 (kidney) 106, 107 and 15 Surgery in one case Superficial spreading subtype in 2 
cases 
Breast 10 20  
(14 kidney, 4 liver, 
1 lung, 1 
kidney+pancreas) 
97, 115, 118, 73, 196, 
161, 65, 115, 102 and 
190 
Surgery +/- radiotherapy in 8 cases 
(surgery details unknown in the 
remaining 2 cases) 
Hormone therapy in 6 cases 
Adenocarcinoma in 9 cases 
Medullary carcinoma 
in 1 case 
Ovary 2 3 
(1 kidney, 1 liver, 1 
kidney+pancreas) 
142 and 156 Surgery in one case Mucinous cystadenocarcinoma in 
both cases 
Colon/rectum 3 5 (kidney) 20, 78 and 101 Surgery in all cases 
Chemotherapy in 1 case 
Adenocarcinoma in all cases 
Rectum in one case 
Ascending colon in 2 cases 
Lymphoma 5 8 
(5 kidney, 1 liver, 1 
lung, 1 heart) 
70, 154, 49, 12 
months 
1 day* 
 
Surgery 1 case 
Radiotherapy 1 case 
Radiotherapy + chemotherapy in 1 
case 
2 Hodgkin’s  
2 Non-Hodgkin’s 
1 Unspecified 
Sarcoma 4 10 
(6 kidney, 1 liver, 1 
heart, 1 lung, 1 
kidney+pancreas) 
0, 1 and 3 days in 3 
cases* 
172 months in one 
case 
Surgery 1 case 1 haemangiosarcoma 
1 liposarcoma 
1 embryonal rhabdomyosarcoma 
1 Ewing’s sarcoma 
*Information regarding recently diagnosed lymphoma/sarcoma in the donor was not available to the team transplanting the organs 
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4.4.5 Possible/potential donors excluded based on their history of cancer 
Data from 23376 possible donors were examined including 3996 DBD and 19380 DCD 
donors. Six cases were identified with a history of cancer classed as unacceptable risk and 
no other contraindication to donation: 3 cases with treated breast cancer without 
recurrence at 5, 10 and 15 years, 2 cases with treated colorectal cancer without recurrence 
for 12 and 18 years and one case of melanoma treated 15 years prior, without evidence of 
recurrence. All 6 were possible DCD donors. At present in the UK, the average number of 
organs retrieved are 2.6 per DCD donor and 4.0 per DBD donor (NHSBT, 2014b). Thus, these 
6 donors would be anticipated to have donated 15 additional organs for transplantation (5 
additional organs per year).  
 
4.5 Discussion  
This study points to a potential overall benefit in recipient survival if organs from selected 
donors with a history of cancer are used for transplantation. A small, yet real risk of cancer 
transmission is present, of which the recipient should be advised. Notably, although the risk 
can be reduced by careful assessment, it cannot be abolished.  
 
4.5.1 Balancing the cancer transmission risk against the risk of waiting-list mortality 
In the UK, the proportion of patients annually removed from or dying on the waiting list for 
transplantation ranges from 6% for kidney, 13% for liver, 16% for heart and 15% for lung 
candidates (NHSBT, 2014b). When organs from a donor with past history of cancer are 
offered for transplantation, the risk of cancer transmission has to be balanced against the 
consequence of declining such organs. The present study found that the recipients of organs 
from donors with unacceptable risk cancer had no different survival and risk of death as 
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recipients of organs from standard/non-standard risk donors. In addition, there was no 
cancer transmission from 61 donors with unacceptable risk cancers. It must be noted that 
the cohort of such donors was small and these organs were transplanted after careful risk 
assessment. Nonetheless, this evidence indicates that there is a proportion of donors with a 
cancer history currently classified as unacceptable risk, whose organs can be transplanted 
without a negative impact on the recipient survival and with very low rates of cancer 
transmission. Therefore, it is likely that strict adherence to present guidelines may have 
resulted in inappropriate exclusion of some donors whose organs could have been 
transplanted with very low risk of cancer transmission.  
 
4.5.2 Strengths and limitations of this study 
Most donors with an unacceptable cancer transmission risk would be excluded from organ 
donation. Non-transmission of cancer from such donors must be demonstrated in a 
substantial cohort of recipients in order for the results to be reliable. In the present study, 
0.35% donors (61 of 17639) had a history of unacceptable risk cancer. Evidence for non-
transmission of cancer was demonstrated in 133 recipients. The data from the Cancer 
Registry included useful data such as date of diagnosis of cancer, details of treatment of 
primary cancer and date and cause of death. These details were useful in showing the 
association between non-transmission and factors such as curative surgery and cancer-free 
period prior to donation. Therefore, the size of the cohort and the degree of detail of data 
of individual cases were strengths of this study. 
  
The quality of the data held by the cancer registries is rigorously verified to maintain the 
accuracy. Cancer registries make every effort to record all malignancies by use of a range of 
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data sources, in order to ensure that the most accurate information is captured. The 
number of cancer registrations that each registry records is closely monitored for 
discrepancies between the actual number of registrations and the expected number of 
registrations. The national cancer registration data have also been compared to 
independently collected data held within the General Practice Research Database, and it 
was shown that no significant difference was noted in registration of breast cancer (Kaye et 
al., 2000). In spite of these measures, it is possible that there has been some under-
registration of cancer, which in turn may result in under-estimation of cancer transmission 
for organ donors to their recipients.  
 
Among the recipients from high risk donors, 133 (86%) recipients (residents of England) 
were included in our study; from the same donors, there were 22 (14%) other recipients 
who lived outside England and cancer transmission to these recipients was not assessed. An 
occult transmitted cancer may have gone undiagnosed in cases where the recipient died 
soon after transplantation. Extending recurrence rates of dormant cancers from the 
immunocompetent population to recipients of non-renal transplants (where stopping 
immunosuppression is not an option) is also likely to result in imprecise risk estimation. For 
these reasons, this study may underestimate the cancer transmission risk. The donors in this 
study represent a carefully selected cohort and caution must be used while extrapolating 
our conclusions to all potential donors with history of cancer. 
 
A more detailed discussion of the strengths and the limitations of this research is included in 
sections 8.2 and 8.3.  
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4.5.3 Existing evidence and the need to consider modifications to present guidelines 
Evidence supporting the present classification of cancer transmission risk was from non-
consecutive case series, transplant registry reports, survival data in non-transplant patients 
and expert opinion (COE, 2010, Nalesnik et al., 2011). The published reports preferentially 
highlight the cases of cancer transmission as opposed to the cases of non-transmission: an 
OPTN/UNOS report (Kauffman et al., 2007) included 440 transplants from high risk donors 
and apart from one case of transmitted melanoma, none of the other recipients developed 
transmitted cancer. In the present study there were 133 recipients from 61 donors with 
unacceptable risk cancer and none of the cancers were transmitted. Therefore, this 
evidence offers an opportunity for exploring methods of safe expansion of the donor pool 
by modifying the present guidelines.  
 
4.5.4 Donors with cancer of CNS 
A study by Watson and colleagues (Watson et al., 2010) assessed donors with CNS cancers 
in England, Wales and Northern Ireland between 1985 and 2001. This cohort was partly 
overlapping with and larger than the cohort I studied. Watson reported no case of 
transmission of CNS cancer from 177 donors to any of their 448 recipients. These included 
24 donors with glioblastomas and 9 with medulloblastomas. Several of these patients had 
undergone cerebrospinal fluid shunt. This study concluded that organs from donors with 
CNS cancers should be considered for transplantation. A further analysis of the same data 
(Warrens et al., 2012) demonstrated that using organs from the donors with CNS cancer 
provided additional survival benefit of 8 years for a kidney recipient, 3 years for a liver 
recipient, 2 years for a heart recipient and 1 year for the lung recipient.  
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4.5.5 Donors with non-CNS cancers – features associated with non-transmission 
In the present study 6 types of non-CNS cancers that were classed as unacceptable risk, did 
not result in transmission to the recipients: melanoma, lymphoma, sarcoma and cancers of 
the breast, colon and ovary. There are similar reports in the published literature where 
donors with these cancers have not resulted in cancer transmission. These reports were 
studied to identify features associated with non-transmission.  
 
4.5.5.1 Donors with past melanoma: 
Prolonged dormancy followed by late recurrence of melanoma is well recognised in non-
transplant patients (Crowley and Seigler, 1990) with recurrence rates up to 2% after 15 
years (Tsao et al., 1997). Recurrence rates depend on Breslow tumour thickness – 
recurrence rates between five and ten years after diagnosis are 0.3% for tumours thinner 
than 1mm, 1.5% for tumours between 1mm and 3.55mm and 3.5% for tumours more than 
3.55mm thick (Dicker et al., 1999). A higher degree of suspicion should be adopted when a 
potential donor with past melanoma has an unclear cause of death. In particular, when the 
cause of brain death is cerebral haemorrhage or an apparently primary brain tumour 
diagnosed without histology, the possibility of cerebral metastasis from melanoma should 
be considered (Penn, 1996b). Cerebral metastasis of amelanotic melanoma can be 
misdiagnosed as primary oligodendroglioma resulting in underestimation of transmission 
risk. In early stages, superficial spreading subtype of melanoma is known to spread laterally 
and outwards (rather than deeper) resulting in early identification. Superficial spreading 
melanoma subtype is reported to contain smaller proportion of ‘thick’ (>2mm) melanoma 
compared to other subtypes (Carli et al., 2004). In the present study, organs from two 
donors with superficial spreading subtype of melanoma diagnosed 8∙9 years before 
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donation (in both cases), did not transmit the cancer. So organs from donors with past 
melanoma but no features of recurrence for five or more years can be considered for 
transplantation. Superficial spreading subtype and tumour thickness less than 1mm are 
likely to have low transmission risk.  
 
4.5.5.2 Donors with past breast cancer: 
Breast cancer is also noted for late recurrence in non-transplant population with recurrence 
rates of 5 to 7% after five years (Bosco et al., 2009, Brewster et al., 2008) and annual 
recurrence rate of 0∙5% after ten years (Lousberg et al., 2011). Late recurrence of breast 
cancer depends on stage/grade, hormone receptor status and the treatment of the primary 
tumour. Stage I tumours (<2cm diameter without nodal spread) have a lower recurrence 
rates after five years (7%) compared with stage III (>5cm or infiltrating locally or with 
ipsilateral nodal spread) tumours (13%) and the risk is lower for hormone receptor negative 
tumours, localised tumours and those receiving curative surgery (Lousberg et al., 2011, 
Cheng et al., 2012).  
 
In the UNOS/OPTN cohort (Kauffman et al., 2007), there were 126 transplants using organs 
from donors with past breast cancer (of whom 73% had the cancer more than five years 
before donation) and no cases of transmission. In the series I studied, there were ten donors 
with past breast cancer (minimum 5∙5 years before donation, eight undergoing surgical 
resection) and there was no transmission of cancer to recipients of their 21 donated organs. 
Therefore, it can be recommended that organs from donors with stage I breast cancer 
treated with curative surgery at least five years before donation can be considered for 
transplantation. Recipient selection should include careful assessment of risks-benefits and 
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informed consent. Hormone receptor negative status is likely to be associated with low 
recurrence risk.  
 
4.5.5.3 Donors with past ovarian cancer: 
Ovarian cancer often presents late with 60% women in stage III/IV at diagnosis and 29% 
cases present as an emergency (CancerResearchUK, 2013). Both advanced stage and 
emergency presentation are associated with poor outcome. Therefore, there are limited 
data about late recurrence of ovarian cancer. In the non-transplant population recurrence 
of ovarian cancer after 46 months of diagnosis is reported (Gadducci et al., 2007).  
Transmission of ovarian cancer to a kidney recipient is reported (Bellati et al., 2009)  but the 
donor had no history of cancer. In the cohort I studied, two donors with mean cancer-free 
period of 12.4 years donated four organs to three recipients without transmission of cancer. 
In the OPTN/UNOS cohort (Kauffman et al., 2007), there were 75 transplants (and no 
transmission) from donors with ovarian cancer of which 85% donors had been cancer-free 
for 10 or more years. Based on this evidence it can be recommended that organs from 
donors with past ovarian cancer, cancer-free for more than ten years can be considered for 
transplantation following informed consent.  
 
4.5.5.4 Donors with past colon cancer 
Recurrence of colon cancer following curative surgery is uncommon after five years 
although long-term follow-up data are sparse as most surveillance programmes stop after 
five years. Late recurrence in 1.6% of all surgically treated colorectal cancers is reported 
(Cho et al., 2007). Cancer of the left colon/rectum accounted for 95% of recurrences. Two 
cases of transmission of colon cancer from donors with brain death due to cerebral 
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metastases are reported (Buell et al., 2004). In addition to the data from the UK Transplant 
Registry presented in this chapter, at least two other registry reports (Kauffman et al., 2007, 
Birkeland and Storm, 2002) have reported no transmission of colon cancer from donors 
after a minimum cancer-free period of five years. Based on this evidence, it can be 
recommended that organs from a donor with non-metastatic colon cancer surgically 
resected at least five years prior to donation can be considered for transplantation after risk 
assessment and informed consent.  
 
4.5.5.5 Donors with past sarcoma/lymphoma 
Three of the four donors with sarcoma and one donor with lymphoma in my study were 
diagnosed within the week before donation and this information was not available to the 
transplanting team. Therefore, it is not possible to suggest changes to the current 
recommendations about the transmission risk of lymphoma/sarcoma. 
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Table 4.5 Suggested changes to present guidelines: donor cancers proposed to have a low 
risk (NHSBT, 2014c) 
Cancer type Characteristics 
Melanoma Superficial spreading subtype 
Tumour (Breslow) thickness < 1mm 
Curative Surgery 
Minimum cancer-free period of 5 years 
Breast cancer Stage I 
Hormone receptor negative 
Curative surgery 
Minimum cancer-free period of 5 years 
Ovarian cancer Curative surgery 
Minimum cancer-free period of 10 years 
Colon cancer Curative surgery 
Minimum cancer-free period of 5 years 
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4.5.6 Impact on the number of organs available for transplantation 
The information obtained from the potential/possible donors demonstrates that an increase 
in the number of donor organs can be achieved by including selected donors with past 
cancer. The details of the cancers among potential/possible donors recorded on the UK 
Transplant registry was significantly less than the data recorded by the Cancer registries. 
There were also many potential/possible donors who were recorded as having ‘medical 
contraindication to donation’ in some of whom the medical contraindication may have been 
a past history of cancer. Therefore, the estimated number of additional organs of 5 per year 
is likely to be an underestimate. Considering the high mortality of patients on the transplant 
waiting list, these additional organs are likely to make a real difference to the outcomes 
especially in cases where an urgent life-saving transplantation is needed.  
 
4.5.7 Role of informed consent 
In the UK, the guidelines for consenting potential adult recipients for transplantation are 
published by NHSBT and the British Transplantation Society (NHSBT, 2011). These specify 
that the risks of transplantation should be explained to the recipient at two stages: at the 
time of listing for transplantation and at the time of the offer of an organ. The risk of cancer 
transmission (0.05% in the UK, as discussed in Chapter 3) should be explained at the time of 
listing. A list of donor details, which the recipient is entitled to know, is specified including 
whether the donor has high risk of cancer transmission. Although the risk of cancer 
transmission is small, the outcome for the recipient when a transmission occurs is poor in 
terms of graft loss and/or recipient survival, hence informed consent is vital.  
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In conclusion, it is clear that there is an overall benefit in survival if organs from selected 
donors with a history of cancer are used for transplantation. Surgeons are faced with 
difficult decisions when offered an organ from a higher risk donor. Guidelines, designed to 
facilitate making these decisions, may have the unintended consequence of reducing the 
survival of those listed for transplantation. The data presented in this chapter confirm that 
surgeons make balanced and appropriate judgement although it is not possible to 
accurately estimate how many donor organs with similar risk are declined. There is a real 
but small risk of cancer transmission so the potential recipients need to be advised of these 
risks and understand that, while risks can be reduced by careful assessment, they cannot be 
abolished. (Desai et al., 2014) 
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CHAPTER 5 
RECURRENCE OF CANCER IN ORGAN TRANSPLANT RECIPIENTS  
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5.1 Introduction 
Although organ transplantation is highly effective in improving both the quality and the 
length of life in patients with end-stage organ failure, because of the relative shortage of 
organs, the offer of transplantation is limited to patients who would benefit the most: for 
example in the UK, a predicted survival of less than 50% at 5 years is generally a 
contraindication for liver transplantation (NHSBT, 2012). Co-morbid conditions in the 
recipient are among the important factors influencing the overall benefit from 
transplantation. An increased risk of cancer in patients with liver and kidney disease 
compared with a matched general population is recognised: 18% increase in standardised 
risk of all cancers among patients with renal failure and 100% increase in patients with 
cirrhosis (Sorensen et al., 1998, Maisonneuve et al., 1999). Five to 10% of patients on the 
transplant waiting list are known to have a history of cancer (Mosconi et al., 2011, 
Fischereder and Jauch, 2005). Furthermore, as the age of transplant candidates is 
increasing, the probability of a history of cancer will be greater.  
 
All recipients of organ transplantation are at an increased risk of de novo cancer compared 
with the matched general population. In addition, those recipients with a history of cancer 
treated prior to transplantation are at an added risk of recurrence of such cancers after 
transplantation. The clinical course of cancer is shown to be more aggressive in the 
immunosuppressed transplant recipient (Barrett et al., 1993, Veness et al., 1999, Martinez 
et al., 2003). Therefore, a thorough understanding is essential, of the risk of recurrent 
cancer in determining access to transplantation, follow-up and surveillance after 
transplantation and, potentially, the choice of immunosuppression. 
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 However, there are limited data regarding rates of recurrence following transplantation of 
cancers treated prior to transplantation. The IPITTR (Penn, 1993, Penn) remains the most 
widely used database on which the present recommendations for listing are based, but 
these data are not comprehensive and may be subject to important bias. The IPITTR is a 
registry of cases reported voluntarily, so it does not include all cases of transplantation 
performed.  So the denominator to calculate the rates of cancer is incomplete. Additional 
information regarding the cancer recurrence following transplantation and the outcome 
following recurrence in recipients of different organs will be useful in ensuring just selection 
of prospective recipients for transplantation and equitable use of scarce donor organs. In 
this chapter, the outcomes of solid organ allograft recipients with a history of cancer with 
respect to recurrence of cancer are discussed. 
 
5.2 Aims 
The aims of this chapter are: 
1. To identify the proportion of transplant recipients with a history of cancer prior to 
transplantation 
2. To study which of these recipients developed a recurrence of cancer following 
transplantation 
3. To study the outcome of transplant recipients with a recurrence of cancer 
 
5.3 Methods 
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5.3.1 Data 
The recipients of first solid organ transplantation from deceased and living donors who were 
transplanted between 1st January 1985 and 31st December 2010 were identified from the 
UK Transplant Registry. Although the data for primary diagnosis of cancer are recorded by 
all the cancer registries in the UK, the practice of recording the data regarding the 
recurrence of cancers is not uniform across different cancer registries. The data were 
restricted to recipients residing in the West Midlands region of the UK (which had a 
population 5.6 million in 2011) as the data regarding recurrence of cancer were recorded by 
the West Midlands Cancer Intelligence Unit for the duration of this study. The cases of 
recurrence of cancer were recorded following confirmation by histology, imaging and/or 
clinical evidence. The details of the recipients undergoing transplantation during the study 
period were obtained from the UK Transplant Registry (name, dates of birth and death, 
gender, address, NHS number) and matched with the data held by the West Midlands 
Cancer Intelligence Unit. Those recipients who were diagnosed to have new or recurrent 
cancer (excluding non-melanoma skin cancer, as these data were unavailable) were 
identified. The cancers diagnosed before the date of transplantation and recurrences after 
transplantation were included. The 51 liver recipients transplanted with cancer of the liver 
(including hepatocellular cancer, hepatoblastoma, cholangiocarcinoma or embryonal 
sarcoma) were excluded.  
 
For recipients with multi-organ transplantation, recipients of kidney-pancreas (n=75), 
kidney-liver (n=13) and kidney-heart (n=2) were included with kidney recipients. The 
recipients of liver-pancreas, liver-heart and liver-lung (n=1 each) were included with liver 
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recipients. The recipients of heart-lung (n=74) were included with heart recipients. The 
recipients of pancreas only (n=7) were excluded. 
 
5.3.2 Statistical Analysis 
The survival of recipients with and without a pre-transplant cancer was analysed using 
Kaplan-Meier estimates and compared using the log rank test. All calculations were 
performed using Statistical Analysis Software, version 9.3 (SAS Institute, Cary). 
 
5.4 Results 
5.4.1 Study cohort 
The study cohort of 4835 recipients included 3321 (69%) kidney, 821 (17%) liver, 495 (10%) 
heart and 198 (4%) lung recipients. A history of cancer was noted in 64 (of 4835, 1.32%) 
recipients including one recipient with two cancers. Table 5.1 shows the age, gender and 
survival of these recipients. 
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Table 5.1 Recipients with and without a pre-transplant cancer: comparison of age, gender and survival of recipients of different organs 
 Recipients with pre-transplant cancer Recipients without pre-transplant cancer 
 Number 
(%) 
Mean age in 
years 
(95% CI) 
Gender 
M (%) 
Median survival in 
years 
(95% CI) 
Number 
(%) 
Mean age in 
years 
(95% CI) 
Gender 
M (%) 
Median survival in 
years  
(95% CI) 
Kidney 35 (1) 57.0 
(54, 63) 
19 (54) 11.76 
(9.23,-) 
3286 (99) 43.0 
(42, 44) 
2041 (62) 20.28 
(18.67, 22.97) 
Liver 16 (2) 53.5 
(50, 62) 
7 (44) 7.53 
(0.05, -) 
805 (98) 47.0 
(44, 48) 
395 (49) 17.50 
(15.27, 20.76) 
Heart 8 (2) 34.5 
(14, 61) 
5 (63) 5.75 
(0.01, 5.75) 
487 (98) 46.0 
(44, 47) 
380 (78) 8.62 
(7.16, 10.59) 
Lung 5 (3) 56.0 
(33, 58) 
4 (80) - 193 (97) 53.0 
(50, 54) 
111 (58) 3.35 
(1.51, 6.40) 
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5.4.2 Recipients with recurrence of cancer after transplantation 
Of the 64 recipients with a history of cancer, 5 developed recurrence with a rate of 
recurrence within 10 years of transplantation of 11.9% (95%CI 0.4, 23.5). For each of these 
five recipients, the time from diagnosis of primary cancer to transplantation and the time 
from transplantation to recurrence of cancer are shown in Table 5.2. Melanoma was the 
most common cancer to recur (3 cases) followed by leiomyosarcoma and testicular germ 
cell cancer (1 each). In all five cases, the recipients died as a direct consequence of recurrent 
cancer. 
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Table 5.2 Recipients with recurrence of cancer after transplantation 
Recipient 
No 
Type of cancer Time from diagnosis 
of primary cancer to 
transplantation 
(days) 
Time from 
transplantation 
to recurrence 
(days) 
Outcome 
1 Melanoma 5 4294 Death due to 
cancer 
2 Melanoma 745 421 Death due to 
cancer 
3 Melanoma 559 573 Death due to 
cancer 
4 Leiomyosarcoma 190 1199 Death due to 
cancer 
5 Germ cell tumour of 
testis 
1627 2100 Death due to 
cancer 
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5.4.3 Recipients without recurrence of cancer after transplantation 
There were no cases of cancer recurrence among 59 recipients with a history of cancer at a 
median follow-up of 4.0 years (95%CI 2.9, 5.8). Of these, 38 (65%) had been cancer-free for 
more than 5 years at the time of transplantation, 9 (15%) had been cancer-free for less than 
2 years and in the remaining 12 recipients (20%) the cancer-free period was between 2 and 
5 years (Table 5.3). Of the 9 recipients undergoing transplant within 2 years of cancer 
diagnosis, 4 received liver transplants (1 urgent), 2 received heart transplants (both urgent) 
and the remaining 3 received kidney transplants. 
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Table 5.3 Recipients without cancer recurrence (numbers is brackets indicate the number of recipients with cancer) 
Cancer-to-transplant duration > 5 years Cancer-to-transplant duration 2 - 5 years Cancer-to-transplant duration < 2 years 
Bladder - transitional cell cancer (3) Bladder cancer (1) Acute myeloid leukaemia (3) 
Osteosarcoma (1) Osteosarcoma (1) Chronic myeloid leukaemia (1) 
Breast – adenocarcinoma (6) Breast adenocarcinoma (1) Parathyroid carcinoma (1) 
Cervix – adenosquamous carcinoma (1) Colorectal adenocarcinoma (2) Breast adenocarcinoma (1) 
Colorectal cancer (4) Prostate adenocarcinoma (2) Colorectal adenocarcinoma (1) 
Acute leukaemia  
(myeloid 1, lymphoid 1) 
Thyroid adenocarcinoma (1) Renal cell carcinoma (2) 
Lymphoma 
(Hodgkin’s 3, Non-Hodgkin’s 3) 
Renal cell carcinoma (1)  
Kidney: Renal cell carcinoma (2), Nephroblastoma (2) Nephroblastoma (1)  
Nasopharyngeal carcinoma (1) Hepatoblastoma (1)  
Oral cavity: adenocarcinoma (1) Lung (1)  
Penis: squamous cell carcinoma (1)   
Prostate: adenocarcinoma (2)   
Melanoma (1)   
Testis: endodermal sinus tumour (1)   
Thyroid: adenocarcinoma (2)   
Uterus: adenocarcinoma (3)   
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5.4.4 Impact of immunosuppression on the risk of recurrence 
The available immunosuppression data were limited to the agent the recipients were 
receiving at the time of transplantation, at 3 months and 12 months post-transplantation. 
The data were available for azathioprine (77% recipients), ciclosporin (70%), tacrolimus 
(14%) and MMF (42%).  Cox regression analysis was performed to assess the use and non-
use of these agents individually, with correction for age and gender. This analysis showed no 
association between immunosuppressive agent and the risk of cancer recurrence. These 
results are shown in Table 5.4. 
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Table 5.4 Impact of individual immunosuppressive agents on the risk of recurrence of cancer 
after transplantation 
  Number of recipients Hazard ratio 
(95% CI) 
p-value 
 
With 
cancer 
recurrence 
 
Without 
cancer 
recurrence 
Azathioprine Not used 1 16 1  
Used 3 29 1.00  
(0.08, 12.55) 
0.998 
No data 1 14 0.35  
(0.01, 11.60) 
0.55 
Ciclosporin Not used 2 17 1  
Used 2 23 0.24 
(0.02, 3.41) 
0.29 
No data 1 19 0.15 
(0.01, 3.70) 
0.25 
Tacrolimus Not used 1 7 1  
Used 0 1 -  
No data 4 51 0.22  
(0.02, 2.50) 
0.22 
MMF Not used 1 11 1  
Used 0 15 -  
No data 4 33 3.30  
(0.19, 57.08) 
0.41 
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5.5 Discussion 
5.5.1 Summary of findings and comparison with literature 
In this study, a majority of the recipients with a pre-transplant cancer (59 of 64, 92%) did 
not develop a recurrence after transplantation, including 50 recipients (78%) with at least 2-
year wait between the diagnosis of cancer and transplantation.  
 
In the IPITTR report (Penn, 1993), of the 185 recipients with recurrence of cancer, 53% had 
waited for transplant for less than 2 years after cancer, 34% had waited for transplant 
between 2 and 5 years after cancer. There were 13% cases of recurrence in recipients who 
had waited for transplantation for more than five years after cancer whereas in the cohort I 
studied, there were no cases of recurrence among 38 recipients.  The reasons for the 
differences between the two studies are likely to include the differences in the recipient 
cohort, time of the study, method of reporting and the definition of a recurrence. The IPITTR 
report was based on voluntary reporting from transplant centres around the world, over a 
period of 24 years.  Whilst the number of patients is a clear strength, interpretation of the 
findings is limited by the nature of the registry in that the denominator (the number of all 
the transplantations performed during the study period) is not known, hence the study was 
not comprehensive and it is not possible to calculate the rate of recurrence accurately. 
Furthermore, as the authors acknowledged (Penn, 1993), they could not distinguish true 
recurrences from de novo post-transplant cancers. The other limitation in interpreting the 
recurrence rates reported in the IPITTR study is that it included post-transplant recurrences 
of both post-transplant cancers as well as cancers diagnosed before transplantation.  
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In the literature, there are other reports describing recurrence of cancer among transplant 
recipients: these are summarised in Table 5.5.  
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Table 5.5 Published cases of transplant recipients with a history of cancer 
Author, year Transplant Recipients with pre-transplant cancer Cancer-free 
period at 
transplantati
on 
(mean, 
range) 
Post-transplant recurrence 
Cancer type Cancer-free period 
at transplantation  
Outcome 
Dillon, 1991 
(Dillon et al., 
1991) 
Heart 7 
(breast [2], endometrium, bladder, 
testis, leukaemia and skin:basal cell 
cancer) 
6.4 years 
(20 days to 
14 years) 
Basal cell 
cancer* 
 No death 
related to 
cancer 
recurrence 
Ladowski, 
2006 
(Ladowski et 
al., 2006) 
 
Heart 13 
(breast[4], uterus, bladder [2], testis, 
sarcoma, lymphoma [2], leukaemia 
and skin:basal cell cancer) 
6.2 years 
(0 to 26 
years) 
None   
Metcalfe, 
2010 
(Metcalfe et 
al., 2010) 
 
Lung / 
Heart-lung 
23 
(skin:basal cell [3], skin:squamous cell 
[2], lung[5], cervix [3], breast [2], 
melanoma [2], prostate, 
myxosarcoma, uterus, leukaemia, 
renal, bladder 
7.4 years 
(0 to 27 
years) 
Myxosarcoma, 
breast 
Myxosarcoma: 1.7 
years 
Breast: 7.2 years 
Death due to 
cancer in both 
cases 
Saigal, 2001 
(Saigal et al., 
2001) 
 
Liver 18 
(myeloproliferative disorder[6], colon 
[4], lymphoma, breast, bladder, 
melanoma, skin:basal cell, renal, 
thyroid, uterus) 
 
 
 
2.6 years 
(0 to20 
years) 
NHL NHL: 23 months 
 
Alive at 31 
months 
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Author, year Transplant Recipients with pre-transplant cancer Cancer-free 
period at 
transplantati
on 
(mean, 
range) 
Post-transplant recurrence 
Cancer type Cancer-free period 
at transplantation  
Outcome 
Benten, 2008 
(Benten et 
al., 2008) 
 
Liver 37 (myeloproliferative disorder[7], 
NHL[3], leukaemia, leiomyosarcoma, 
ovary, cervix[2], vulva, uterus, 
breast[2], oral, melanoma[3], 
skin:basal cell[2], tests[2],prostate, 
renal, colon [3], rectum, 
osteoclastoma, oligodendroglioma, 
desmoid tumour, neurofibroma),  
3.7 years 
(0 to 26 
years) 
Colon Colon cancer: 
found incidentally 
at transplantation 
 
Death due to 
cancer 
Kelly, 1998 
(Kelly et al., 
1998) 
Liver 29 (skin:squamous cell, skin: basal 
cell[5], Hodgkin’s lymphoma [5], 
palate [4], colon [3], thyroid [3], 
breast [2], larynx [2], melanoma [2], 
uterus, gall bladder, lung, gastric 
carcinoid)   
8.7 years 
(0.5 to 35 
years) 
Breast (2), 
palate, thyroid 
(papillary) 
Breast: 5 and 7 
years (stage III), 
palate: 8 months, 
thyroid: 4 years 
Breast cancer: 
death due to 
cancer 
Dousset,1995 
(Dousset et 
al., 1995) 
Liver 5 2.5 years 
(0 to 4 years) 
None   
Chapman, 
2001 
(Chapman et 
al., 2001) 
Kidney 210 NS Kidney, 
melanoma, 
cervix(2 each), 
bladder, 
prostate   
NS NS 
*Authors acknowledged that this could be a de novo caner related to Sun exposure 
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In contrast to the IPITTR report (Penn, 1993), other published reports shown in Table 5.5 
and the results of the cohort I studied demonstrate a lower rate of recurrence. The factors 
contributing to these differences are likely to include the criteria used for selection of 
recipients, choice of immunosuppressive agent and post-transplant cancer surveillance and 
reporting bias. Among the cases listed in Table 5.5, with the exception of three cases of 
breast cancer (that recurred in spite of a pre-transplant cancer free period of 5, 7 and 7.2 
years) all the other cases which recurred post-transplantation had been treated within 5 
years before transplantation. 
 
Present guidelines for selection of transplant candidates include the guidelines from 
American Society of Transplantation (Kasiske et al., 2001) European best practice guidelines 
for renal transplantation (Europeanguidelines, 2000) and the UK Renal Association 
guidelines (Renalassociation, 2011). These guidelines recommend that most patients with a 
previous cancer would benefit from a two-year wait before transplantation. Some cancers 
such as non-melanoma skin cancers, in-situ cancers and small renal cell cancers (under 5cm) 
discovered incidentally do not require a waiting period before transplantation and some 
cancers with a high risk of recurrence such as large (over 5cm) or invasive renal cell cancers, 
breast cancer, colon cancer (other than Dukes A or B1) or melanoma require a minimum 
waiting period of 5 years before transplantation. However, it is evident from the data 
presented in Table 5.2 that selected recipients can benefit with recurrence-free post-
transplant survival even when the wait between cancer and transplant is shorter, although 
emphasis should be placed on the need for rigorous pre-transplant assessment, careful 
selection and close post-transplant monitoring.  
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5.5.2 Impact of immunosuppression 
The mechanism of action of different immunosuppressive agents, their side effects and the 
impact of immunosuppression on post-transplant cancer has been discussed in Sections 1.6 
and 1.7. There is limited evidence assessing the impact of immunosuppression on the risk of 
cancer recurrence following transplantation. The impact of different immunosuppressive 
agents varies. This is discussed here. 
 
5.5.2.1 Calcineurin inhibitors – ciclosporin and tacrolimus 
These are used in nearly all regimens (Kapturczak et al., 2004). Both ciclosporin (Hojo et al., 
1999) and tacrolimus (Maluccio et al., 2003) amplify the growth and metastatic potential of 
cancer cells in mouse models, primarily by increasing TGF-1 expression. The risk of cancer 
in patients using ciclosporin is higher than the risk of cancer in patients using azathioprine in 
several epidemiological studies (Shuttleworth et al., 1989, Kyllonen et al., 2000, Hiesse et 
al., 1997, Marcen et al., 2003, Tremblay et al., 2002) but studies comparing ciclosporin 
against tacrolimus have been inconclusive. While animal models suggest that ciclosporin is 
associated with more aggressive tumour growth, this has been seen less clearly in humans 
(Webster et al., 2005, Bustami et al., 2004, Caillard et al., 2005). 
 
5.5.2.2 mTOR inhibitors – Sirolimus and everolimus 
Sirolimus and everolimus exert their immunosuppressive effect by blocking the mTOR 
pathway and subsequent blockage of IL-2 mediated T cell activation. Several clinical studies 
have shown a lower risk of de novo cancer after transplantation when sirolimus is used as 
primary immunosuppression (Alberu et al., 2011, Mathew et al., 2004, Campistol et al., 
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2006). However, there is limited evidence supporting use of sirolimus to reduce the risk of 
recurrence of previously treated cancer.  
 
The data presented here must be treated with some caution. Although the results of my 
study compare favourably with other series, the number recipients is relatively small so 
misleading conclusions may be drawn by generalisation of conclusions. The conclusions 
from this cohort in the West Midlands of the UK may not be directly applicable to transplant 
candidates in other countries. The patients who underwent organ transplantation were 
carefully evaluated prior to transplant and so are likely to represent a selected cohort and 
any conclusions drawn from this analysis may not be directly applicable to all candidates. 
The data regarding immunosuppression were limited to the name of immunosuppressive 
agents at three time points within the first year of transplantation. Most transplant 
recipients receive varying immunosuppressive agents in varying doses during their post-
transplant period and such limited data would not capture the degree of 
immunosuppression accurately. It is therefore difficult to develop robust evidence-based 
guidelines to help identify patients with pre-existing cancer who may not benefit with 
transplantation because of lack of data, with small number of patients reported, 
inconsistency of reporting, the diversity in the type, stage and treatment of cancer and the 
immunosuppressive regimen. Prospectively and rigorously collected data by national 
transplant registries including data on type, stage, treatment of pre-transplant cancer, 
immunosuppression, surveillance, details of recurrence and outcome after recurrence 
would be useful.  
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CHAPTER 6  
CYTOMEGALOVIRUS AND CANCER RISK AFTER TRANSPLANTATION 
(Data and text from this chapter have been published (Desai et al., 2015)) 
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6.1 Introduction 
CMV infection is common affecting 50 to 80% of adult population (CDC, 2010). The initial 
infection, which usually occurs in childhood, is either subclinical or characterised by mild 
non-specific self-limiting symptoms. This is followed by a state of life-long chronic viral 
carriage. In an immunocompetent host, the CMV infection is generally well controlled but in 
the immunosuppressed, it is often associated with significant morbidity. Some viruses, such 
as HPV, HBV, HCV, EBV and HHV-8 have an established role in the development of cancer 
both in the immunocompetent and the immunosuppressed organ transplant recipient 
populations. There is limited evidence assessing the association of CMV and cancer. While 
CMV antigens have been identified in cells of certain tumours such as cancers of the colon, 
prostate, lymphoma and glioblastoma (Soderberg-Naucler, 2006), it is not known if the 
presence of CMV is an epiphenomenon or whether there is a causative association. 
Epidemiological studies investigating the association between CMV and post-transplant 
cancer have shown conflicting evidence: some have shown a protective effect (Couzi et al., 
2010) whereas others, an increased risk (Courivaud et al., 2012). These studies have 
important limitations including relatively small cohort size and lack of long-term follow-up 
data. 
 
Although survival after transplantation is increasing, recipients of solid organ 
transplantation remain at increased risk of premature death (Lindholm et al., 1995, Morales 
et al., 2012, Pruthi et al., 2001, Blankenberg et al., 2001, Muhlestein et al., 2000). Important 
causes of this increased mortality are cardiovascular disease, cancer, infection and recurrent 
disease. While some studies, both in the normal and the transplant population, have found 
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an increased risk of cardiovascular disease and death in CMV infected individuals 
(Blankenberg et al., 2001, Thomas et al., 2009, Zhou et al., 1996, Li et al., 2007), this has not 
been confirmed by all (Zhu et al., 1999, Johnson et al., 2009, Kaufman et al., 2001, Arthurs 
et al., 2007). However, all the studies in the transplant population have been relatively short 
term (less than five years).  
 
In this chapter, the risk of development of post-transplant cancer and its association with 
the CMV status of the organ donor and the recipient are discussed. 
 
6.2 Aims 
The aims of this chapter are: 
1. To assess the CMV status of organ donor (D) and recipient (R) and association of the 
CMV status with the risk of post-transplant cancer 
2. To study the impact of D/R CMV status on the post-transplant recipient survival 
3. To study the association of D/R CMV status with the cause of death among 
transplant recipients 
 
6.3 Methods 
6.3.1 Study cohort 
Using the data held by the UK Transplant Registry, the recipients of first solid organ (kidney, 
liver, heart, lung) transplantation between 1st January 1987 and 31st December 2007 who 
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were resident in England, Wales or Scotland were identified. This duration was selected, as 
the available registry CMV data were limited to this period. The transplants where the CMV 
IgG status was not recorded for the donor or the recipient were excluded (n=12228, 35% of 
all the transplant recipients). Recipients of combined kidney-pancreas (n=764) were 
grouped with the kidney recipients and recipients of double-lung or heart-lung transplants 
(n=553) were grouped with the lung recipients. The recipients were divided into four groups 
based on the combination of donor and recipient CMV IgG status at the time of 
transplantation: both donor and recipient CMV positive (D+R+) or negative (D-R-), CMV 
positive donor with CMV negative recipient (D+R-) and CMV negative donor with CMV 
positive recipient (D-R+). 
 
6.3.2 Data  
Transplant and CMV data were obtained from the UK Transplant Registry. Cancer 
registration data were obtained from the Office for National Statistics by matching the 
details of the recipients (name, gender, date of birth/death, address and NHS number). All 
types of cancers other than non-melanoma skin cancer (for which data were unavailable) 
were included. The data for the first diagnosed cancer following transplantation were 
included. To exclude the cancers which may have been present at the time of 
transplantation, all cancers other than Hodgkin’s lymphoma or Non-Hodgkin’s lymphoma 
diagnosed within a month of transplantation were excluded.  
  
6.3.3 Statistical analysis  
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Kaplan-Meier analysis and logrank test were used to assess the long-term post-
transplantation patient survival. The risk-adjusted hazard of death was calculated using Cox 
proportional hazards model, correcting for the those risk factors that have been identified 
by NHSBT as having a significant impact on survival (NHSBT, 2010). Risk adjusted hazard of 
death for different solid organ recipients are shown separately because the risk adjustment 
varies. The risk factors included were: donor age, recipient age, donor sex, recipient sex, 
donor type (kidney and lung recipients), donor cause of death (kidney and heart recipients), 
transplant year, primary disease (kidney, liver and heart recipients), HLA mismatch (kidney 
recipients) and ischemia time (cold ischemia for liver, total for heart/lung). For this 
assessment, death of the recipient within ten years (or one year, when 1-year survival was 
assessed) was considered as an event and the recipients who were alive at ten years (or one 
year, when 1-year survival was assessed) from transplantation and those who were lost for 
follow-up were censored. 
 
During Cox regression, missing data for a categorical covariate were grouped together as 
‘unknown’ category. The recipients with missing ischemia time (12% of liver recipients, 35% 
of cardiothoracic recipients) were excluded from multivariate analysis using Cox regression 
only. The times to diagnosis of cancer in the four CMV groups were compared using the 
logrank test. Cox proportional hazards modelling was also used to assess the time to a 
diagnosis of cancer in various CMV groups with censoring at 10 years for those who survived 
to that time without the diagnosis of cancer. The factors used for risk-adjustment in this 
analysis were recipient age and gender. For this assessment, a diagnosis of cancer within ten 
years of transplantation was considered as an event and times to any other end-point in 
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absence of a diagnosis of cancer, such as death or end of follow-up were considered as 
censored survival times.  
 
While comparing the hazard of multiple types of cancers in different CMV groups the 
Bonferroni correction was used to assess statistical significance in order to avoid inflating 
the overall type I error above its nominal level for each test. This involved using a 
significance level of 0.05/n, where n is the number of comparisons, to give an overall 5% 
significance level. The causes of death between the D-R- groups and other recipient group 
were compared using the chi square test. All data were analysed using SAS version 9.3 (SAS 
Institute, Cary). 
 
6.4 Results 
A total of 22461 recipients were studied, including 13215 (59%) kidney recipients, 4814 
(21%) liver recipients, 2686 (12%) heart recipients and 1746 (8%) lung recipients. The 
baseline characteristics of the recipients in different CMV groups are shown in Table 6.1. 
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Table 6.1 Characteristics of recipients in different CMV groups 
CMV status Recipient details 
N Mean age 
In years 
(95% CI) 
Male Median follow-up 
in years (95% CI) 
D+R+ 6666 
(30%) 
47.6 
(47.3, 47.9) 
3985 (60%) 8.0 
(7.9, 8.1) 
D+R- 4520 
(20%) 
41.3 
(40.8, 41.8) 
2926 (65%) 7.6 
(7.2, 7.8) 
D-R+ 5754 
(26%) 
46.7 
(46.3, 47.1) 
3415 (59%) 7.8 
(7.6, 7.9) 
D-R- 5521 
(25%) 
37.6 
(37.1, 38.0) 
3528 (64%) 8.0 
(7.9, 8.3) 
Total 22461 
(100%) 
43.6 
(43.4, 43.9) 
13854 (62%) 7.9 
(7.8, 7.9) 
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6.4.1 Risk of cancer among recipients in different CMV groups 
The unadjusted incidence of all cancers was 8.8% (95% CI 7.9, 9.6) among D+R+ group, 7.0% 
(6.0, 7.9) among D+R- group, 9.1% (8.1, 10.1) among D-R+ group and 6.4% (5.5, 7.3) among 
D-R- group and this difference was statistically significant (p<0·0001). However, there was 
no statistically significant difference in the risk-adjusted hazard of all cancers between these 
groups following correction for age and gender. In this assessment, along with adjustment 
of risk for age (which is a recognised risk factor for cancer), I also adjusted for gender 
because male gender was found to be an independent risk factor for cancer even after 
excluding those cancers which are gender specific such as cancer of cervix, ovary uterus and 
prostate (HR for male 1.36, p<0.0001).  
 
The risk-adjusted hazard ratios and 95% confidence intervals are shown in Figure 6.1. 
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Figure 6.1 Risk-adjusted hazard of cancer within 10 years of transplantation, among 
different CMV groups compared with the D-R- group 
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6.4.2 Risk of individual types of cancer among recipients in different CMV groups  
The risk of 23 different types of cancer was compared between the recipients in different 
CMV groups. Table 6.2 shows the frequency and unadjusted incidence of 23 types of 
cancers among the recipients in different CMV groups. The risk-adjusted hazard of different 
types of cancers is shown as forest plots in Figure 6.2.  
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Table 6.2 Frequency and unadjusted incidence of different types of cancers in the recipient groups based on CMV status 
 Number of recipients (% incidence ± 95%CL) 
Cancer type D+R+ D+R- D-R+ D-R- p-value Total 
Anus 7  
(0.13 ±0.12) 
2  
(0.06 ±0.087) 
4  
(0.07 ±0.095) 
5  
(0.12 ±0.12) 
0.78 18  
(0.10 ±0.06) 
Bladder 13  
(0.29 ±0.16) 
7 
(0.24 ±0.18) 
8  
(0.22 ±0.16) 
10  
(0.28 ±0.18) 
0.91 38  
(0.26 ±0.09) 
Breast 21 
(0.45 ±0.20) 
5 
(0.17 ±0.16) 
19 
(0.52 ±0.25) 
12 
(0.31 ±0.18) 
0.097 57  
(0.38 ±0.10) 
Cervix 4 
(0.18 ±0.18) 
2 
(0.21 ±0.28) 
3 
(0.18 ±0.20) 
1 
(0.12 ±0.24) 
0.77 10 
(0.17 ±0.11) 
Colon 37 
(0.92 ±0.31) 
19 
(0.60 ±0.28) 
26 
(0.69 ±0.27) 
21 
(0.58 ±0.25) 
0.50 103 
(0.71 ±0.14) 
Hodgkin’s lymphoma 4 
(0.10 ±0.10) 
3 
(0.12 ±0.14) 
4 
(0.14 ±0.14) 
6 
(0.17 ±0.14) 
0.81 17 
(0.13 ±0.06) 
Kaposi’s sarcoma 4 
(0.08 +0.08) 
0 3 
(0.06 ±0.0.07) 
1 
(0.02 ±0.02) 
0.30 8 
(0.04 ±0.03) 
Kidney 28 
(0.64 ±0.25) 
13 
(0.49 ±0.27) 
23 
(0.72 ±0.31) 
10 
(0.30 ±0.50) 
0.076 74 
(0.54 ±0.13) 
Leukaemia 2 
(0.05 ±0.07) 
2 
(0.05 ±0.07) 
4 
(0.08 ±0.08) 
4 
(0.10 ±0.10) 
0.72 12 
(0.07 ±0.04) 
Lip 11 
(0.28 ±0.17) 
2 
(0.07 ±0.10) 
13 
(0.41 ±0.23) 
4 
(0.11 ±0.11) 
0.035 30 
(0.23 ±0.08) 
Liver 7 
(0.13 ±0.10) 
12 
(0.35 ±0.21) 
10 
(0.23 ±0.15) 
4 
(0.11 ±0.11) 
0.048 33 
(0.19 ±0.07) 
Lung 54 
(0.12 ±0.34) 
23 
(0.80 ±0.33) 
39 
(0.11 ±0.34) 
24 
(0.71 ±0.29) 
0.037 140 
(0.97 ±0.17) 
Myeloma 4 
(0.08 ±0.08) 
5 
(0.17 ±0.15) 
9 
(0.26 ±0.17) 
4 
(0.10 ±0.09) 
0.30 22 
(0.14 ±0.06) 
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 Number of recipients (% incidence ± 95%CL) 
Cancer type D+R+ D+R- D-R+ D-R- p-value Total 
Non-Hodgkin’s lymphoma 77 
(1.8 ±0.41) 
46 
(1.4 ±0.43) 
78 
(2.0 ±0.45) 
60 
(1.6 ±0.41) 
0.35 261 
(1.7 ±0.21) 
Oesophagus 6 
(0.13 ±0.26) 
1 
(0.03 ±0.05) 
5 
(0.13 ±0.12) 
6 
(0.16 ±0.13) 
0.49 18 
(0.12 ±0.06) 
Oral cavity 3 
(0.06 ±0.07) 
8 
(0.26 ±0.18) 
6 
(0.15 ±0.12) 
7 
(0.20 ±0.16) 
0.19 24 
(0.16 ±0.07) 
Ovary 3 
(0.15 ±0.17) 
1 
(0.08 ±0.15) 
5 
(0.37 ±0.34) 
4 
(0.27 ±0.26) 
0.59 13 
(0.22 ±0.13) 
Pancreas 4 
(0.09 ±0.10) 
4 
(0.17 ±0.17) 
6 
(0.17 ±0.14) 
4 
(0.08 ±0.08) 
0.82 18 
(0.12 ±0.06) 
Prostate 22 
(0.79 ±0.34) 
13 
(0.71 ±0.40) 
17 
(0.84 ±0.41) 
18 
(0.80 ±0.39) 
0.95 70 
(0.79 ±0.19) 
Skin: melanoma 12 
(0.25 ±0.15) 
9 
(0.30 ±0.20) 
6 
(0.16 ±0.13) 
6 
(0.17 ±0.15) 
0.43 33 
(0.22 ±0.08) 
Stomach 11 
(0.25 ±0.15) 
1 
(0.04 ±0.07) 
6 
(0.17 ±0.14) 
4 
(0.10 ±0.09) 
0.11 22 
(0.15 ±0.06) 
Thyroid 4 
(0.09 ±0.09) 
1 
(0.03 ±0.05) 
6 
(0.17 ±0.14) 
2 
(0.06 ±0.09) 
0.29 13 
(0.09 ±0.05) 
Uterus 2 
(0.09 ±0.12) 
2 
(0.15 ±0.21) 
7 
(0.49 ±0.37) 
1 
(0.06 ±0.12) 
0.09 12 
(0.20 ±0.12) 
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Figure 6.2 Comparison of risk-adjusted hazard (with 95% CI) of developing different types of cancers within 10 years of transplantation in 
different CMV groups, compared against the D-R- group 
 
 
 
209 
 
 
  
 
 
210 
 
 
 
 
 
 
 
 
211 
 
 
These graphs show that, there was no significant difference in the hazard of developing any 
of the 23 different types of cancer between the recipients in different CMV groups.  
 
6.4.3 CMV and post-transplant recipient survival 
Survival curves for the recipients of organ transplantation are shown in Figure 6.3. At ten 
years from transplantation, recipient survival of D-R- group (73·6% [95%CI 72·3, 74·9]) was 
significantly higher (p<0·0001) compared with the combined survival of all the other 
recipients (66·1% [65·3, 66·9]). The donor-recipient CMV matching was associated with 
significant survival advantage for CMV negative recipients (ten year survival: 73·6% [72·3, 
74·9] for D-R- group and 68·4% [66·9, 69·9] for D+R- group) but not for CMV positive 
recipients (ten year survival: 64·6% [63·3, 65·8] for D+R+ group and 66·1% [64·7, 67·5] for D-
R+ group).  
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Figure 6.3 Comparison of 10-year recipient survival between four groups based on CMV 
status 
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Table 6.3 shows the risk-adjusted hazard of death within one-year and ten-years from 
transplantation, assessed separately for the recipients of kidney, liver, heart and lung 
transplantation. 
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Table 6.3 1-year and 10-year patient survival and risk-adjusted hazard of death 
Organ  CMV status p-value for 
patient survival D+R+ D+R- D-R+ D-R- 
Kidney  N 4072 2797 3120 3226  
1-year survival% ± 95%CL 95.2±0.7 95.0±0.8 95.6±0.7 97.6±0.5 <0.0001 
Risk adjusted 
hazard of death 
within 1 year 
HR 1.27 (0.96, 1.67) 1.74 (1.30, 2.31) 1.26 (0.95, 1.68) 1  
p-value 0.10 0.0002 0.11   
10-year survival% ± 95%CL 70.9±1.6 76.8±1.8 73.4±1.8 82.5±1.5 <0.0001 
Risk adjusted 
hazard of death 
within 10 years 
HR 1.11 (0.99, 1.25) 1.14 (1.00, 1.30) 1.05 (0.93, 1.19) 1  
p-value 0.08 0.044 0.44   
Liver  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N 1445 896 1375 1098  
1-year survival% ± 95%CL 87.7±1.7 85.3±2.3 86.2±1.8 89.3±1.8 0.036 
Risk adjusted 
hazard of death 
within 1 year 
HR 0.99 (0.77, 1.28) 1.20 (0.92, 1.57) 1.15 (0.89, 1.47) 1  
p-value 0.94 0.18 0.29   
10-year survival% ± 95% CL 63.2±2.8 63.4±3.5 66.1±2.8 71.3±3.0 0.002 
Risk adjusted 
hazard of death 
within 10 years 
HR 1.03 (0.88, 1.22) 1.13 (0.94, 1.34) 0.99 (0.84, 1.17) 1  
p-value 0.71 0.19 0.87   
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Organ  CMV status p-value for 
patient survival 
D+R+ D+R- D-R+ D-R- 
Heart  N 696 499 789 702  
1-year survival% ± 95%CL 80.2±3.0 79.1±3.6 84.1±2.6 83.4±2.7 0.037 
Risk adjusted 
hazard of death 
within 1 year 
HR 1.16 (0.83, 1.61) 1.34 (0.96, 1.87) 0.91 (0.65, 1.27) 1  
p-value 0.38 0.08 0.57   
10-year survival% ± 95% CL 55.3±3.8 56.2±4.7 57.6±3.7 64.1±3.8 0.009 
Risk adjusted 
hazard of death 
within 10 years 
HR 1.31 (1.05, 1.65) 1.34 (1.06, 1.70) 1.09 (0.87, 1.36) 1  
p-value 0.019 0.014 0.47   
Lung  N 453 328 470 495  
1-year survival% ± 95%CL 73.6±4.1 69.9±5.0 77.1±3.8 76.8±3.6 0.054 
Risk adjusted 
hazard of death 
within 1 year 
HR 1.29 (0.93, 1.80) 1.41 (1.02, 1.96) 1.02 (0.73, 1.43) 1  
p-value 0.12 0.04 0.89   
10-year survival% ± 95% CL 28.8±4.5 29.9±5.6 34.6±4.8 35.4±4.8 0.01 
Risk adjusted 
hazard of death 
within 10 years 
HR 1.27 (1.03, 1.57) 1.35 (1.09, 1.68) 1.04 (0.84, 1.29) 1  
p-value 0.028 0.0058 0.72   
 
 
 
216 
 
 
6.4.4 Causes of death among transplant recipients 
A total of 6213 recipients died within ten years from transplantation. The recipients who 
died within 30 days of transplantation (n=897) were excluded, as CMV is not likely to have 
contributed to death in this group. A majority of these (471, 53%) died within 8 days of 
transplantation and the cause of death in this group is more likely to be related to peri-
operative complications than CMV.  
 
The causes of death were studied in the remaining 5316 recipients after dividing them into 
D-R- group and ‘others’ group and the results are shown in Figure 6.4. The cardiac and 
vascular group included cardiac causes, cerebral causes and thromboembolic causes. Others 
included miscellaneous, unspecified and unknown causes.  
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Figure 6.4 Causes of death (in %) among 6213 recipients of all organs who died within 10 
years of transplantation, divided into D-R- recipients and all other recipients 
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6.5 Discussion 
This study showed no association between the risk of post-transplant cancer and the CMV 
status of the organ donor-recipient. However, the study did show an increased mortality 
among recipients of kidney, heart and lung, exposed to CMV as compared to CMV naïve. 
Although these results are significant, the limitations of the study must be acknowledged. 
Further detailed discussion of the strengths and weaknesses of the research presented in 
this thesis is included in sections 8.2 and 8.3.  
 
6.5.1 Strengths and limitations of this study 
Missing data is one of the important limitations of retrospective registry studies. In this 
study, the CMV data were not available for 12228 (35%) recipients and these were 
excluded. The CMV status was recorded at the time of transplantation and any recipients 
with post-transplantation acquisition of de novo CMV infection were not identified. In a 
significant proportion of patients (35%), no cause of death was specified. The risk of cancer 
would be underestimated in cases where the recipient had multiple cancers as the data for 
the first diagnosed post-transplantation cancer only were included. The risk of cancer would 
also be underestimated, as there may be some recipients with undiagnosed cancer, who 
may have died of other causes. The cause of death data were obtained from the Office for 
National Statistics, which is the UK’s largest independent producer of official statistics and is 
the most widely recognised national statistical institute in the UK. Multiple robust internal 
and external quality control measures are in place, in order to maintain the high quality of 
data produced by the Office for National Statistics. In spite of this some inaccuracy of data 
may be inevitable.  
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6.5.2 Impact of CMV on the risk of post-transplantation cancer 
The cancer risk of a transplant recipient is influenced by complex interactions between 
recipient factors (age, ethnicity, social status, pre-malignant conditions, pre-existing 
infections, smoking, alcohol intake, possibly genetic factors), donor factors (diseases 
transmitted from donor organ) and post-transplant factors (the intensity and the duration 
of immunosuppression, de novo infections, engagement with screening of post-transplant 
cancer). The recipient factors which are associated with an increased risk of cancer such as 
age, social status and smoking, are also associated with higher CMV sero-prevalence (Dowd 
et al., 2009) and it can be difficult to tease out any independent effect exerted by CMV. A 
higher risk of cancer among CMV positive recipients as compared to D-R- recipients 
observed on univariate analysis of our cohort may also be explained by the fact that the 
CMV positive recipients were older than CMV negative recipients. This difference in the risk 
was not statistically significant following risk adjustment for recipient’s age and gender, 
indicating that the donor-recipient CMV status have no independent association with the 
risk of post-transplantation cancer in general or with the specific risk of developing 23 types 
of post-transplantation cancers.  
 
The size of the cohort is likely to be the reason for the differences in findings between the 
results of the cohort I studied and the two other recent reports assessing a similar question 
(Couzi et al., 2010, Courivaud et al., 2012). Couzi and colleagues (Couzi et al., 2010) 
retrospectively studied a cohort of 105 kidney recipients with a median follow-up of 5 years, 
23 of whom had developed a post-transplant cancer. They concluded that CMV naïve 
recipients had a 5·28 times increased risk of post-transplant cancer as compared to 
recipients exposed to CMV before or after transplantation and attributed this to CMV 
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mediated increase in the number of a subset of  T lymphocytes which possess anti–
tumour activity.  In contrast, Courivaud and colleagues (Courivaud et al., 2012) reported 
from a cohort of 455 recipients of kidney transplantation that both pre-transplant exposure 
(HR = 1·8) and post-transplant replication (HR = 2·17) of CMV were associated with an 
increased risk of post-transplant cancer as compared to CMV naïve recipients and attributed 
this to immune exhaustion related to exposure to CMV. Compared to these studies, the 
cohort I studied was substantially larger resulting in increased statistical power to detect 
any association between CMV and post-transplantation cancer. As shown in Table 6.2, in 
spite of the cohort size, the number of individual types of cancers is relatively small; so 
studies with a smaller cohort would have very small numbers of individual types of cancer 
and are likely to produce results which cannot be generalised to all transplant recipients.  
 
6.5.3 Impact of CMV on post-transplant recipient survival  
This study showed that the use of organs from donors who are CMV positive for recipients 
who are CMV negative is associated with an increased long-term post-transplant mortality 
in kidney, heart and lung transplant recipients. In the published literature, the effect of CMV 
on post-transplant patient survival has been studied among the recipients of different 
organs with conflicting results. The published reports assessing patient survival after 
transplantation include studies of kidney recipients (Johnson et al., 2009) (no effect), 
kidney-pancreas recipients (Kaufman et al., 2001) (no effect), liver recipients (Arthurs et al., 
2007) (no effect) and heart recipients (Li et al., 2007) (7·05 times increased hazard of 
mortality at one year among CMV infected patients). Most of these studies have assessed 
short-term survival, often limited to less than five years from transplantation. The data 
assessing the long-term survival are limited. One of the larger reports is the study by 
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Johnson and colleagues (Johnson et al., 2009), which included 8228 recipients of deceased 
donor kidney transplantation in the UK between 2000 and 2007, partly overlapping with the 
cohort I studied. Johnson demonstrated no effect of CMV on the post-transplant patient 
survival at one, three and five years. In comparison, the results of my study showed an 
increased risk of patient death at ten years after transplantation among the recipients of 
kidney as well as heart and lung transplantation. This difference is likely to be due to larger 
numbers and longer follow-up. A direct comparison between the cohort I studied and the 
cohort studied by Johnson could not be performed due to inherent differences between the 
two cohorts, such as different inclusion criteria and unspecified duration of follow up. The 
results of my analysis showed an increased mortality in the D+R- group at ten years (14% 
increase in risk of death in comparison to D-R- group among kidney recipients, 34% increase 
among heart recipients and 35% increase among lung recipients) possibly highlighting the 
effect of the ‘new’ CMV infection acquired during transplantation. An increased mortality 
was also observed among D+R+ group of heart recipients (31% increase) and lung recipients 
(27% increase).  
 
6.5.4 Possible reasons for increased mortality among CMV exposed recipients  
It is difficult to explain the processes by which CMV may be contributing to increased post-
transplantation mortality in a retrospective registry study, such as the one I conducted. The 
most common causes of death within 10 years after transplantation included cardiovascular 
events, cerebrovascular events, infections and single or multi-organ failure. The analysis of 
causes of death showed a small (2%) increase in cardiovascular death among CMV-infected 
recipients, however, it should also be noted that causes of death in more than a third of 
recipients were unspecified or ‘others’. CMV infection has been shown to be associated in 
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the non-transplantation population with an increased cardiovascular mortality (Blankenberg 
et al., 2001, Muhlestein et al., 2000, Zhou et al., 1996). Among solid organ transplantation 
recipients, CMV has been shown to be associated with a variety of conditions such as acute 
rejection (Nett et al., 2004),  tubulointerstitial nephritis and glomerulopathy after kidney 
transplantation (Rane et al., 2012), hepatic artery thrombosis and accelerated HCV infection 
(Bosch et al., 2012) after liver transplantation, allograft vasculopathy after heart 
transplantation and bronchiolitis obliterans after lung transplantation (Thomas et al., 2009), 
bacterial, fungal and viral infections (George et al., 1997, Arthurs et al., 2008) and new onset 
diabetes mellitus (Leung Ki et al., 2008). The rates of these complications and their impact 
on post-transplantation mortality could not be assessed in the present cohort due to lack of 
relevant data. The increased mortality observed among CMV infected transplantation 
recipients in the cohort I studied may be interplay of some or all of these diseases.  
 
In the general population, especially the healthy elderly population, CMV is described as a 
driver of age-associated immune alterations leading to a reduction in naïve T cells (Sansoni 
et al., 2014). Reactivation of CMV may result in increased levels of pro-inflammatory 
cytokines such as IL-6 and TNFα. C-Reactive Protein (CRP) levels also increase as a 
consequence of leakage of the virus from host cells, via the action of IL-6. These 
inflammatory markers have been linked to both all-cause and cardiovascular disease related 
mortality. Savva and colleagues (Savva et al., 2013), found in a cohort of 511 healthy 
individuals aged at least 65 years followed for 18 years, that CMV infection was associated 
with an increased mortality rate and a near doubling cardiovascular death whereas there 
was no increase in mortality from other causes. Simanek AM et al. (Simanek et al., 2011), in 
a large and younger American population, aged 25 and older with up to 18 years of follow-
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up, showed that CMV seropositivity was independently associated with an increased all-
cause mortality (adjustment for CRP level did not attenuate this relationship). However, 
after confounder adjustment, they failed to associate CMV serostatus with cardiovascular 
mortality. Another study by Courivaud et al. (Courivaud et al., 2013) showed that CMV 
exposure was an independent risk factor for atherosclerotic events whereas post-
transplantation CMV replication was independent risk factor for both atherosclerotic events 
and death in kidney transplant recipients. Their results suggested that CMV was associated 
with immune exhaustion and inflammation in favour of an indirect effect of CMV on 
atherosclerotic progression. These results, along with the results of my study provide 
evidence towards a complex interaction between aging, CMV infection and cardiovascular 
disease/death both in general population as well as recipients of organ transplantation.  
 
In summary, in this large cohort of solid organ transplant recipients, there was no 
association between the donor-recipient CMV status and the risk of post-transplantation 
cancer as a whole, or the risk of 23 individual types of cancers. The results also showed a 
negative impact of the D+R- CMV mismatch on the long-term survival of the recipients of 
kidney, lung or heart transplantation but not the recipients of liver transplantation. (Desai et 
al., 2015) 
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CHAPTER 7  
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS 
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7.1 Introduction 
PTLD include a group of conditions characterised by unregulated proliferation of 
lymphocytes in the recipients of solid organ or bone marrow transplantation. PTLD, along 
with non-melanoma skin cancer is one of the two most common cancers after solid organ 
transplantation (Collett et al., 2010, Buell et al., 2005).  
 
7.1.1 Risk factors and pathogenesis of PTLD 
A majority of PTLD are the result of EBV induced proliferation of lymphocytes facilitated by 
immunosuppression. EBV is an oncogenic Υ herpes virus, first discovered in 1964 (Epstein et 
al., 1964) in Burkitt’s lymphoma cells. It was subsequently shown to be associated with 
nasopharyngeal carcinoma, NHL and HL (zur Hausen et al., 1970, Jones et al., 1988, Weiss et 
al., 1989). The initial infection with EBV often occurs in the childhood and by the age of 40, 
about 90%of the population is infected (Cohen, 2000). This initial infection may remain 
asymptomatic or present with infectious mononucleosis. This is followed by lifelong latent 
infection, which is kept under control by intact T-lymphocyte mediated immunity. A 
majority of PTLD involve B lymphocyte proliferation, cases with proliferation of T 
lymphocyte account for around 15% (Hanson et al., 1996, Ravat et al., 2006, Rajakariar et 
al., 2004) and cases involving natural killer cell proliferation are rare (Draoua et al., 2004). 
EBV associated PTLD accounts for more than 80% of PTLD cases involving B-lymphocytes 
and a smaller proportion of cases involving T-lymphocytes (Caillard et al., 2006). The 
incorporation of EBV DNA into the lymphocyte genome results in resistance to apoptosis by 
bcl-2 induction and an unregulated proliferation of lymphocytes. Other viruses such as CMV 
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and HCV have also been shown to be associated with an increased risk of PTLD in smaller 
studies but this association has not been conclusively established (Rabkin et al., 2002, 
Hausfater et al., 2001).  
 
In the immunocompetent, there are several studies showing association between 
lymphoma and the HLA. Some HLA types are associated with an increased risk: HLA-A68 and 
DR11(5)  (Huang et al., 2011), HLA-A1, B5 and B18 (Hors and Dausset, 1983) and some like 
HLA-A2, with a reduced risk (Niens et al., 2007). The association between HLA and the risk of 
lymphoma is further complicated by the EBV status: several HLA types are reported to be 
associated with an increased risk of Hodgkin’s disease and one specific HLA allele has been 
shown to be protective allele against Hodgkin’s disease in EBV negative patients and a 
susceptibility allele in EBV positive patients (Huang et al., 2012). The association between 
PTLD and HLA types has not been assessed in larger cohorts. 
 
Immunosuppressive agents increase the risk of post-transplant cancer including PTLD by 
different mechanisms including reduced immune surveillance and increased risk of infection 
with oncogenic viruses. Immunosuppressive regimen change continuously as a result of 
introduction of newer agents, discontinuation of older agents, side effects of a particular 
agent, comorbidities, preferences of the recipient and the medical team and the availability 
of new evidence. As a result, it is difficult to tease out the effect of individual agents on the 
risk of cancer. However, there is good evidence demonstrating the association between 
more intensive immunosuppressive regimen and an increased risk of cancer including PTLD 
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(Dantal et al., 1998, Vivarelli et al., 2002, Swinnen et al., 1990). A detailed discussion of the 
individual immunosuppressive agents and their impact on the risk of PTLD is included in 
Sections 1.7.1 to 1.7.5 of the thesis and is summarised here. The use of ATG is associated 
with an increased risk of PTLD, with an odds ratio of 1.6. The use of azathioprine is 
associated with a four-fold increased risk of PTLD and the risk is enhanced by concomitant 
use of CNI agents. Several studies comparing the risk of PTLD among the recipients on 
ciclosporin or tacrolimus have shown an increased risk among recipients on tacrolimus but 
this difference was only evident among recipients not receiving ATG induction.  
 
7.1.2 Incidence of PTLD 
The incidence of PTLD is highest in the first post-transplant year followed by a long tapered 
incidence rate that continues for decades after transplantation. The incidence is higher in 
paediatric recipients, EBV negative recipients and recipients of heart or lung 
transplantation. The cumulative incidence of PTLD after 5 years post-transplantation ranges 
from 1 to 3% for kidney recipients, 2 to 10% for liver recipients up to 20% for heart or lung 
transplant recipients (Opelz and Dohler, 2004). The age-gender-year standardised incidence 
rate of post transplant NHL, compared to matched non-transplant population is 12.5 for 
kidney recipients, 13.3 for liver recipients, 19.8 for heart and 30.0 for lung recipients. The 
organ of involvement of PTLD varies among recipients of different organ transplantation 
with predilection to the transplanted organ. While PTLD can involve different sites such as 
central nervous system, lymph nodes, gastrointestinal tract or multiple organs, 10 to 30% of 
kidney recipients, 22 to 33% of liver recipients, 50 to 80% of lung (or heart-lung) recipients 
and 10% heart recipients have predominant involvement of the transplanted organ (Mucha 
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et al., 2010). The involvement of tonsils and the Waldeyer’s ring is commoner in children 
than in adults. 
 
7.1.3 Classification of PTLD 
The WHO classification of PTLD is most widely used (Campo et al., 2011). PTLD is classified in 
to four types: 
Early lesions – plasmacytic hyperplasia 
           - infectious mononucleosis like PTLD 
Polymorphic PTLD 
Monomorphic PTLD (B-cell, T-cell and NK-cell type) 
Classical Hodgkin’s lymphoma type PTLD 
 
Among these, the early lesions and polymorphic PTLD tend to have the least degree of 
cellular atypia and are often seen in children and young people with primary EBV infection. 
These are also often associated with better prognosis. Monomorphic PTLD includes all T-
cell, NK-cell lymphomas and a majority of B-cell (non-Hodgkin’s) lymphomas.  This group 
also includes less common types of PTLD such as Burkitts lymphoma, multiple myeloma and 
extra-medullary plasmacytoma.   
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7.1.4 Clinical features and diagnosis of PTLD 
PTLD often presents with varied, non-specific clinical features including graft dysfunction, 
infections, fever, lymphadenopathy and malaise. The differential diagnoses include a variety 
of infections, graft rejection, adverse effects of immunosuppressive agents and other dugs, 
and other types of cancers. While a majority of PTLD present within the first year after 
transplantation, it can present from weeks to decades after transplantation. The diagnostic 
work up of PTLD is a multidisciplinary process. The diagnostic tests are histopathological and 
immunophenotypical tests while clinical examination, endoscopy and cross-sectional 
imaging can guide in identifying the involved organ. A rising level of EBV in the serum or the 
presence of EBV in the tissue samples can be a useful circumstantial evidence of PTLD.  
 
7.1.5 Management and prognosis of PTLD 
The treatment of PTLD is varied and individualised, depending on the age and comorbidities 
of the recipient, symptoms, EBV status, organ transplanted, degree of graft dysfunction, 
location of PTLD, immunosuppressive agents used and the preference of the patient and the 
medical team. The general principles of management of PTLD include three types of 
interventions: reduction of immunosuppression, treatment of EBV and tumour reduction 
interventions, which can be pharmacological or surgical. There is universal agreement with 
the benefits of reduction of immunosuppression in patients PTLD however substitution of 
agents is not supported by good evidence. Often azathioprine and MMF are withdrawn and 
the doses of corticosteroids and CNI agents are reduced. Substitution with the proliferation 
signal inhibitors such as sirolimus or everolimus is sometimes considered but this is not 
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based on established evidence. The option of graft excision should be considered in a kidney 
or pancreas recipient with PTLD localised to the graft but a surgical option for a similar 
tumour in recipients of liver, heart or lung transplantation is more complicated. The 
chemotherapy options include CHOP (cyclophosphamide, doxorubicin, vincristine and 
prednisolone) and rituximab, an anti-CD20 monoclonal antibody. In those with primary EBV 
infection and a high EBV titre, treatment with acyclovir or gancyclovir is likely to be 
beneficial. The immunotherapeutic agents include interferon, anti-IL6 or anti-B-cell 
antibodies which selectively remove EBV-infected B-cells.  
 
PTLD has a poor prognosis. The one-year mortality following diagnosis of PTLD is 37 to 54% 
for recipients of kidney or liver transplantation and 50% for recipients of heart 
transplantation (Opelz and Dohler, 2004, Leblond and Choquet, 2004). Larger studies 
assessing prognosis of PTLD patients across different eras of transplantation show no 
significant change in prognosis of PTLD (Opelz and Dohler, 2004). 
 
In this chapter, the incidence of PTLD among recipients of solid organ transplantation across 
three decades among adult and paediatric recipients, factors associated with development 
of PTLD including HLA types and recipient survival following diagnosis of PTLD are discussed. 
 
7.2 Aims 
The aims of this chapter are: 
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1. To assess the incidence of PTLD in different eras of transplantation among the 
recipients of different organs 
2. To study the recipient survival following PTLD and compare this in recipients of 
different organs over different time periods 
3. To study the association of PTLD with the immunosuppressive agents 
4. To study the association of PTLD with different HLA types 
 
7.3 Methods 
7.3.1 Study cohort 
Using the data held by the UK Transplant Registry, the recipients of first solid organ (kidney, 
liver, heart, lung) transplantation performed between 1st January 1980 and 31st December 
2007 who were resident in England, Wales or Scotland were identified. This duration was 
selected, as the availability of PTLD data was limited to this period. Recipients of combined 
kidney-pancreas transplantation (n=764) were included in the kidney recipient group and 
the recipients of combined double-lung and heart-lung transplants (n=553) were grouped 
with the lung recipients. 
 
7.3.2 Data  
Transplant data were obtained from the UK Transplant Registry. The data regarding 
registration of PTLD were obtained from the Office for National Statistics by matching the 
details of the recipients (name, gender, date of birth/death, address and NHS number). The 
Office for National Statistics received the PTLD data from the cancer registries in the UK. The 
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cancer registries did not register lymphoproliferative conditions other than HL and NHL. So 
the data were unavailable regarding lymphoproliferative disorders other than HL or NHL. 
 
7.3.3 Statistical analysis  
The SIR was used to compare the incidence of PTLD in different recipient groups. The SIR for 
a specific age group and gender is the ratio of the observed number of PTLD cases in that 
group to the expected number of PTLD cases assuming the incidence rates in the general 
population prevailed. The Office for National Statistics published incidence rates of cancers 
in the population of England (ONS, 2014). The same incidence rates were assumed to be 
applicable to the recipients from Wales and Scotland. For those years where the national 
incidence rates were not available, the incidence rates were calculated assuming a log linear 
relationship between the published incidence rates and estimated incidence rates. The 
expected number of PTLD cases for each age-gender-year group was calculated by working 
out the number of person-years in each age-gender-year group at risk of developing PTLD in 
the post-transplant period. Age groups were of 5 years each between 0 and 85 years of age, 
and a group aged above 85 years. The number of person-years in each age-gender-year 
group was multiplied by the corresponding incidence rate obtained from the Office for 
National Statistics publications of incidence rates of cancers in the population of England. 
This was performed for each year between 1980 and 2007. The recipient survival after the 
diagnosis of PTLD was assessed using Kaplan-Meier survival curve and compared using the 
log-rank test. Cox regression analysis was used to assess the risk-adjusted hazard of death. 
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The analyses of the impact of immunosuppression and HLA type on PTLD were restricted to 
kidney recipients transplanted after 1st January 2000 as the immunosuppression data and 
the HLA data were missing in 65% of the recipients transplanted prior to this date.  The 
details of the immunosuppression data were limited to whether a recipient was receiving 
azathioprine, MMF, tacrolimus and ciclosporin at the time of transplantation, 3 months and 
12 months after transplantation. The association of 46 different HLA antigens with PTLD was 
assessed, including 10 types of HLA-A (A1, A2, A3, A9, A10, A11, A19, A28, A36, A80), 25 
types of HLA-B (B5, B7, B8, B12, B13, B14, B15, B16, B17, B18, B21, B22, B27, B35, B37, B40, 
B41, B42, B46, B47, B48, B53, B70, B78, B82) and 11 types of HLA-DR antigens (DR1, DR2, 
DR3, DR4, DR5, DR6, DR7, DR8, DR9, DR10, DR103). Logistic regression was used to assess 
the association of different HLA antigens and PTLD with risk-adjustment for recipient age 
and gender. While comparing the association of multiple HLA antigens with PTLD, the 
Bonferroni correction was used to assess the statistical significance in order to avoid 
inflating the overall type I error above its nominal level for each test. SAS version 9.3 was 
used for data analysis (SAS Institute, Cary). Person-years at risk and incidence were 
calculated using SAS Macros function (Macaluso, 1992). 
 
7.4 Results 
7.4.1 Recipient characteristics 
There were 37617 recipients in the study cohort, including 25104 (67%) kidney, 6846 (18%) 
liver, 3609 (10%) heart and 2058 (5%) lung recipients. The recipients were divided into three 
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groups based on their decade of transplantation. Table 7.1 shows the baseline 
characteristics of these recipients. 
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Table 7.1. Recipient characteristics in different organ recipients over 3 decades 
 
 
 
 
 
 
 
 
 
 
 
Transplant 
Decade 
 Recipient group  
Total Kidney Liver Heart Lung 
1980 – 
1989 
Number 5454 159 401 77 6091 
Mean age at transplant in 
years (95% CI) 
37.1  
(36.7, 37.5) 
37.2  
(34.2, 40.2) 
42.8  
(41.4, 44.1) 
26.2  
(23.3, 29.1) 
38 
Male % 61 36 85 51 62 
Median follow up in years 
(95% CI) 
16.6 
(16.2, 17.0) 
18.3 
(18.1, 18.6) 
17.2 
(16.5, 18.2) 
14.6 
(11.8, 17.2) 
 
1990 – 
1999 
Number 11050 3122 2092 1090 17354 
Mean age at transplant in 
years (95% CI) 
43.0  
(42.7, 43.3) 
41.5  
(40.8, 42.1) 
45.3  
(44.7, 46.0) 
40.8  
(39.9, 41.6) 
46 
Male % 63 48 82 54 62 
Median follow up in years 
(95% CI) 
9.8 
(9.7, 9.9) 
9.3  
(9.1, 9.5) 
9.5  
(9.3, 9.8) 
5.0 
(4.5, 5.6) 
 
2000 – 
2007 
Number 8600 3565 1116 891 14172 
Mean age at transplant in 
years (95% CI) 
45.2  
(44.9, 45.5) 
44.7  
(44.1, 45.3) 
40.1  
(39.0, 41.2) 
44.4  
(43.3, 45.4) 
48 
Male % 61 57 73 54 61 
Median follow up in years 
(95% CI) 
3.2 
(3.1, 3.3) 
3.1 
(3.0, 3.2) 
3.1 
(2.9, 3.4) 
2.1 
(1.8, 2.4) 
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7.4.2 Incidence and SIR of HL and NHL 
A total of 620 (1.65%) recipients developed PTLD, including 55 (0.15%) with HL and 565 
(1.50%) with NHL. The SIR for NHL was 13.8 (95% CI 12.7, 15.0) and for HL was 7.8 (5.9, 
10.2). Table 7.2 shows the observed and expected number of cases of HL and NHL among 
recipients of different organs and the SIRs. Table 7.3 shows the observed and expected 
number of cases of HL and NHL among paediatric (under 18 years of age at the time of 
transplantation) and adult (over 18) recipients of different organs and the SIRs. Table 7.3 
also shows the median time from transplantation to the diagnosis of PTLD in each group. 
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Table 7.2 SIRs for NHL and HL among recipients of different organs 
 Non-Hodgkin’s lymphoma Hodgkin’s lymphoma 
Organ 
transplanted 
Observed 
number 
Expected 
number 
SIR 
(95% CI) 
p-value Observed 
number 
Expected 
number 
SIR  
(95% CI) 
p-value 
Kidney 353 28.7 12.3  
(11.1, 13.7) 
<0.001 38 5.2 7.4  
(5.2, 10.1) 
<0.001 
Liver 80 6.2 13.0  
(10.3, 16.1) 
<0.001 8 0.9 8.6 
(3.7, 16.9) 
<0.001 
Heart  99 5.1 19.5  
(15.8, 23.7) 
<0.001 8 0.7 11.5 
(5.0, 22.7) 
<0.001 
Lung 33 1.1 31  
(21.3, 43.5) 
<0.001 1 0.2 4.2 
(0.1, 23.5) 
0.30 
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Table 7.3 SIRs for NHL and HL among children and adult recipients 
   Non-Hodgkin’s lymphoma Hodgkin’s lymphoma 
Organ 
transplanted 
Recipient 
age-
group 
Median 
time to 
PTLD, 
days 
(range) 
Observed 
number 
Expected 
number 
SIR 
(95% CI) 
p-value Observed 
number 
Expected 
number 
SIR  
(95% CI) 
p-value 
Kidney Under 18 3896 
(168, 
7449) 
27 0.3 84.3  
(55.5,122.7) 
<0.001 2 0.5 4.2 
(0.5, 15.2) 
0.15 
18 and 
over 
2689 (47, 
9280) 
326 28.3 11.5  
(10.3, 12.8) 
<0.001 36 4.7 7.7 
(5.4, 10.6) 
<0.001 
Liver Under 18 530 (61, 
4422) 
8 0.1 119.9  
(51.6,236.3) 
<0.001 1 0.1 10.6 
(0.1, 59.2) 
0.17 
18 and 
over 
1394 (21, 
6692) 
72 6.1 11.8  
(9.2, 14.9) 
<0.001 7 0.8 8.3 
(3.3, 17.2) 
<0.001 
Heart  Under 18 2308 (91, 
7805) 
18 0.03 523.8 
(310.3,827.8) 
<0.001 2 0.05 39.5 
(4.4,142.5) 
0.02 
18 and 
over 
2636 
(142, 
7751) 
81 5 16.1 
(12.8, 20.0) 
 
<0.001 6 0.6 9.3  
(3.4, 20.3) 
<0.001 
Lung Under 18 594 (74, 
4020) 
5 0.01 470.9 (151.8, 
1099.0) 
<0.001 0 0.02 0 - 
18 and 
over 
747 (75, 
6125) 
28 1.1 26.6  
(17.6, 38.4) 
<0.001 1 0.2 4.6 
(0.1, 25.6) 
0.29 
 7.4.3 SIR of lymphoma among transplant recipients over 3 decades 
Chronological change in SIR of HL and NHL over three decades was assessed among kidney, 
liver, heart and lung recipients. The SIRs for kidney recipients and liver recipients are shown 
in figures 7.1A and B, 7.2A and B. The SIR for heart recipients and lung recipients are shown 
in Table 7.4. 
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Figure 7.1A SIR for NHL among kidney recipients (p = 0.20) 
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Figure 7.1B SIR for HL among kidney recipients (p = 0.08) 
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Figure 7.2A SIR for NHL among liver recipients (p = 0.61) 
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Figure 7.2B SIR for HL among liver recipients (p = 0.70) 
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Table 7.4 SIR for HL and NHL among heart recipients and lung recipients  
Recipient 
group 
 SIR (95% CI) p-value 
1980 - 1989 1990 - 1999 2000 - 2007 
Heart HL 13.9  
(1.6, 50.3) 
13.4  
(4.9, 29.1) 
0 0.42 
NHL 14.5  
(8.4, 23.2) 
22.0  
(17.3, 27.6) 
14.0  
(5.6, 28.9) 
0.16 
Lung HL 0 6.7  
(0.1, 37.3) 
0 0.61 
NHL 85 (27.4, 
198.3) 
28.3 (17.3, 
43.8) 
26.6 (11.5, 
52.4) 
0.47 
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7.4.4 Recipient survival after the diagnosis PTLD  
Among the recipients with PTLD, the overall 1-year survival was 52.4% (95%CI 47.3, 57.5) for 
kidney recipients, 49.1% (95%CI 38.5, 59.7) for liver recipients, 53.4% (95%CI 43.9, 62.9) for 
heart recipients and 47.1% (95%CI 30.32, 63.88) for lung recipients. 
 
The recipient survival and the risk-adjusted hazard of death after the diagnosis of PTLD were 
compared among the recipients undergoing transplantation in three decades. Figures 7.3, 
7.4, 7.5 and 7.6 show Kaplan-Meier survival curves among kidney, liver, heart and lung 
recipients respectively. Table 7.5 shows the median recipient survival after the diagnosis of 
PTLD and the risk-adjusted hazard of death for these recipients. 
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Figure 7.3 Kidney recipient survival after the diagnosis of PTLD (log rank p=0.84) 
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Figure 7.4 Liver recipient survival after the diagnosis of PTLD (log rank p=0.76) 
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Figure 7.5 Heart recipient survival after the diagnosis of PTLD (log rank p=0.58) 
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Figure 7.6 Lung recipient survival after the diagnosis of PTLD (log rank p=0.49) 
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Table 7.5 Recipient survival and risk-adjusted hazard of death among organ transplant 
recipients with PTLD over three decades 
  Decade N Median survival in 
years (95% CI) 
Hazard ratio 
(95% CI) 
p-value 
Kidney 1980-89 118 1.67 (0.55, 3.35) 1  
 1990-99 221 1.10 (0.50, 1.94) 0.90  
(0.61, 1.33) 
0.60 
 2000-07 52 0.94 (0.29, -) 0.59 
(0.33, 1.04) 
0.07 
Liver 1980-89 2 2.21 (0.57, 3.84) -  
 1990-99 58 1.06 (0.63, 3.60) 1  
 2000-07 28 0.61 (0.16, 3.59) 0.56  
(0.17, 1.85) 
0.34 
Heart 1980-89 19 2.16 (0.11, -) -  
 1990-99 80 0.97 (0.44, 1.33) 1  
 2000-07 7 1.80 (0.09, -) 1.45  
(0.02, 119.9) 
0.86 
Lung 1980-89 5 0.91 (0.01, -) -  
 1990-99 21 0.52 (0.11, -) 1  
 2000-07 8 - 21.85  
(0, -) 
1.00 
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7.4.5 Immunosuppression and post-transplant NHL 
The impact of immunosuppression on the SIR of NHL was assessed among kidney recipients 
transplanted between 1st January 2000 and 31st December 2007. There were 8490 
recipients in this group after excluding 110 recipients whose immunosuppression data were 
not available.  
 
7.4.5.1 Impact of induction agent on the SIR of NHL 
Of the 8490 kidney recipients, 8326 (98.07%) did not receive any induction agent. Of the 
remaining 164, ALG only was used in 139 recipients, AKT3 only in 8 recipients and both ALG 
and OKT3 were used in the remaining 17 recipients. The SIR for NHL among kidney 
recipients based on their induction agent is shown in Table 7.6. 
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Table 7.6 SIR for NHL among kidney recipients based on their induction agent 
Induction Number of 
recipients 
Observed 
number 
Expected 
number 
SIR (95% CI) p-value 
Received 164 1 0.08 13.1  
(0.2, 72.9) 
0.996 
Not received 8326 50 4.2 11.9 
(8.8, 15.7) 
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7.4.5.2 Impact of ciclosporin and tacrolimus on the SIR of NHL 
Of the 8490 recipients, 4270 (50.3%) received tacrolimus, 3112 (36.7%) received ciclosporin, 
1050 (12.3%) received both ciclosporin and tacrolimus, and the remaining 58 (0.7%) 
received neither. The SIR for NHL were compared among these four recipient groups and 
the results are shown in Table 7.7. 
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Table 7.7 SIR for NHL among kidney recipients on ciclosporin or tacrolimus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number of 
recipients 
Observed 
number 
Expected 
number 
SIR (95% CI) p-value 
Ciclosporin 
group 
3112 25 2.1 11.8  
(7.7, 17.5) 
0.69 
Tacrolimus 
group 
4270 21 1.6 13.1  
(8.1, 20.1) 
Both 1050 5 0.5 9.4  
(3, 21.9) 
Neither 58 0 0.03 0 
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7.4.5.3 Impact of azathioprine and MMF on the SIR of NHL 
Of the 8490 recipients, 2510 (29.6%) received azathioprine, 3692 (43.5%) received MMF, 
1140 (13.4%) received both azathioprine and MMF and 1146 (13.5%) received neither.  The 
SIR for NHL were compared among these four recipient groups and the results are shown in 
Table 7.8. 
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Table 7.8 SIR for NHL among kidney recipients on azathioprine or MMF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number of 
recipients 
Observed 
number 
Expected 
number 
SIR (95% CI) p-value 
Azathioprine 
group 
2510 18 1.6 11.2  
(6.7, 17.7) 
0.40 
MMF 
group 
3692 18 1.4 13.0  
(7.7, 20.6) 
Both 1140 9 0.6 16.1  
(7.4, 30.6) 
Neither 1146 6 0.7 8.2  
(3.0, 17.8) 
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7.4.6 HLA and PTLD 
Table 7.9 shows the odds ratios for PTLD among recipients with different HLA antigens. 
None of the 46 antigens showed a significant association with PTLD, considering a 
Bonferroni corrected p value of less than 0.001. This p value was calculated using a 
significance level of 0.05/n, where n is the number of comparisons (n=46 in this instance), to 
give an overall 5% significance level. 
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Table 7.9 HLA antigens and their association with PTLD among kidney recipients  
 
HLA Univariate Multivariate 
OR (95% CI) p-value OR (95% CI) p-value 
A1 1.23  
(0.70, 2.15) 
0.48 1.24  
(0.71, 2.18) 
0.45 
A2 1.16  
(0.67, 2.10) 
0.59 1.16  
(0.67, 2.00) 
0.60 
A3 1.15  
(0.63, 2.11) 
0.64 1.14  
(0.62, 2.07) 
0.68 
A9 1.08  
(0.54, 2.16) 
0.82 1.10  
(0.50, 2.19) 
0.78 
A10 1.11  
(0.44, 2.81) 
0.82 1.06  
(0.42, 2.67) 
0.91 
A11 1.75  
(0.88, 3.51) 
0.11 1.78  
(0.89, 3.56) 
0.10 
A19 0.43  
(0.19, 0.95) 
0.04 0.42  
(0.19, 0.94) 
0.03 
A28 0.72 
(0.22, 2.31) 
0.58 0.71  
(0.22, 2.28) 
0.56 
A36 0 >0.99 0 >0.99 
A80 0 >0.99 0 >0.99 
B5 0.76  
(0.27, 2.12) 
0.60 0.76  
(0.27, 2.12) 
0.60 
B7 0.93  
(0.48, 1.75) 
0.83 0.91  
(0.49, 1.71) 
0.77 
B8 1.74 
(0.99, 3.07) 
0.05 1.82  
(1.03, 3.21) 
0.04 
B12 1.38  
(0.79, 2.41) 
0.26 1.34  
(0.77, 2.34) 
0.30 
B13 0.47  
(0.07, 3.44) 
0.46 0.49  
(0.07, 3.54) 
0.48 
B14 1.13  
(0.41, 3.13) 
0.82 1.12  
(0.40, 3.11) 
0.83 
B15 1.05  
(0.47, 2.33) 
0.90 1.03  
(0.46, 2.29) 
0.94 
B16 0.35  
(0.05, 2.54) 
0.30 0.34  
(0.05, 2.44) 
0.28 
B17 0.42  
(0.10, 1.74) 
0.23 0.44  
(0.11, 1.81) 
0.26 
B18 0.75  
(0.23, 2.42) 
0.63 0.74  
(0.23, 2.39) 
0.62 
B21 1.25 
(0.39, 4.03) 
0.71 1.20  
(0.37, 3.87) 
0.76 
B22 1.29  
(0.40, 4.14) 
0.67 1.22  
(0.38, 3.92) 
0.74 
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HLA Univariate Multivariate 
OR (95% CI) p-value OR (95% CI) p-value 
B27 0.20  
(0.03, 1.47) 
0.11 0.21  
(0.03, 1.49) 
0.12 
B35 1.49  
(0.75, 2.97) 
0.26 1.50  
(0.75, 2.99) 
0.25 
B37 0.71  
(0.10, 5.15) 
0.73 0.70  
(0.10, 5.11) 
0.73 
B40 0.70  
(0.28, 1.76) 
0.45 0.70  
(0.28, 1.76) 
0.45 
B41 0 >0.99 0 >0.99 
B42 0 >0.99 0 >0.99 
B46 0 >0.99 0 >0.99 
B47 0 >0.99 0 >0.99 
B48 0 >0.99 0 >0.99 
B53 0 >0.99 0 >0.99 
B70 0 >0.99 0 >0.99 
B78 0 >0.99 0 >0.99 
B82 0 >0.99 0 >0.99 
DR1 0.80  
(0.39, 1.63) 
0.53 0.76  
(0.37, 1.57) 
0.46 
DR2 0.58  
(0.29, 1.16) 
0.12 0.57  
(0.29, 1,14) 
0.12 
DR3 1.32  
(0.73, 2.37) 
0.34 1.39  
(0.78, 2.49) 
0.27 
DR4 1.08  
(0.62, 1.91) 
0.78 1.09  
(0.62, 1.92) 
0.77 
DR5 0.67  
(0.29, 1.58) 
0.36 0.65  
(0.28, 1.54) 
0.33 
DR6 1.47  
(0.82, 2.66) 
0.20 1.46  
(0.81, 2.63) 
0.21 
DR7 1.25  
(0.69, 2.26) 
0.45 1.25  
(0.69, 2.25) 
0.47 
DR8 0 >0.99 0 >0.99 
DR9 0 >0.99 0 >0.99 
DR10 0 >0.99 0 >0.99 
DR103 2.51  
(0.90, 7.00) 
0.08 2.41  
(0.86, 6.74) 
0.09 
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7.5 Discussion 
7.5.1 Brief summary of findings 
1. The SIRs of NHL were significantly higher among the recipients of kidney, liver, heart and 
lung transplantation compared with the matched non-transplant population.  The SIRs of HL 
were significantly higher among the recipients of kidney, liver and heart but not lung 
transplantation. 
2. The SIRs of NHL were significantly higher among paediatric transplant recipients than 
among adult recipients. 
3. The SIRs of NHL did not significantly change over the three decades of transplantation 
among the kidney, liver, heart and lung transplantation recipients. 
4. The recipient survival after the diagnosis of PTLD remained poor and did not change 
significantly over the three decades of transplantation. 
5. The use of induction agent, ciclosporin, tacrolimus, azathioprine or MMF was not 
associated with post-transplant NHL among the recipients of kidney transplantation. 
6. Among the recipients of kidney transplantation, none of the 46 HLA antigens tested, 
showed a significant association with PTLD. 
 
7.5.2 Strengths and limitations of the study 
The size of the cohort and the duration of the study are its strengths.   The cancer data were 
obtained from the Office for National Statistics, which in turn received the cancer data from 
the Cancer Registries. The Cancer Registries have several continuous quality control 
mechanisms in place to ensure a high degree of completion in registering cases with cancer. 
These measures are likely to increase the accuracy of the data and the conclusions drawn 
from the analysis. This study also has several important limitations. The EBV data were not 
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available resulting in inability to analyse the impact immunosuppression and HLA among 
EBV positive and negative subgroups. The data regarding the use of EBV chemoprophylaxis 
were not available. Also, the data regarding the site of involvement of PTLD, histological 
type or treatment of PTLD were not available. The immunosuppression and HLA data were 
only available for a subgroup of the cohort. Furthermore, the immunosuppression data 
were not comprehensive, limited to three time points within the first year after 
transplantation. The cancer registration data were limited to the first registered cancer after 
transplantation so in some recipients who may have had another type of cancer first, 
followed by PTLD, the diagnosis of PTLD would not be captured resulting in an 
underestimation of the risk of PTLD. Although the Cancer Registries in the UK adopt several 
internal and external audit mechanisms to maintain a comprehensive registry (as detailed in 
sections 3.5.2 and 4.5.2) some under-registration is possible.  
 
A further detailed assessment of strengths and limitations of this research is included in 
sections 8.2 and 8.3. 
 
7.5.3 SIR of PTLD 
Overall SIR for NHL of 13.8 in the UK transplant cohort I studied was higher than the rates 
reported from transplant registries in Sweden (SIR 6.0) (Adami et al., 2003), Finland (SIR 4.8) 
(Kyllonen et al., 2000) and Canada (SIR 8.8) (Villeneuve et al., 2007). The Swedish study 
(Adami et al., 2003) included 5931 recipients of kidney, liver, heart, lung and pancreas 
transplantation performed between 1970 and 1997 whereas the Finnish study (Kyllonen et 
al., 2000) included 2890 kidney recipients transplanted between 1964 and 1997, and the 
Canadian study (Villeneuve et al., 2007) included 11155 kidney recipients transplanted 
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between 1981 and 1988. The reasons for the difference in SIR may include the differences in 
the prevalence of EBV, the choice and intensity of immunosuppression, cancer registration 
methods and the geographic variation in the incidence of lymphoma in the non-transplant 
population. 
 
The data I analysed showed no significant change in the SIR of NHL among transplantation 
recipients over three time periods, 1980 to1989, 1990 to 1999 and 2000 to 2007. Similar 
findings were reported from other large studies. Opelz and colleagues studied (Opelz and 
Dohler, 2004) the Collaborative Transplant Study database which includes data from over 
400 transplant centres from 45 countries and analysed the differences in the incidence of 
PTLD among 195,938 recipients of solid organ transplantation over three time periods, 1985 
to 1989, 1990 to 1994 and 1995 to 2001. Similar to the UK data, there was no significant 
difference in the incidence of PTLD among the kidney recipients.  
 
In the cohort I studied, the SIR of NHL was higher among heart and lung recipients as 
compared with kidney or liver recipients, and among paediatric recipients than adult 
recipients. Similar findings of higher incidence of NHL among cardiothoracic recipients and 
among younger recipients were found in other large national studies from Sweden (Adami 
et al., 2003) and Canada (Villeneuve et al., 2007).  
 
7.5.4 PTLD and recipient survival 
The recipient survival after the diagnosis of PTLD was poor in the cohort I studied. The 
mortality within the first year of diagnosis of PTLD ranged between 47.6% for kidney 
recipients and 52.6% for lung recipients. The survival rates did not improve during the three 
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decades of transplantation. These findings were similar to the findings from the other large 
registry data (Opelz and Dohler, 2004).   
 
7.5.5 PTLD and immunosuppression 
Post-transplant immunosuppression plays a key role in the pathogenesis of PTLD. The 
analysis of the association of immunosuppression with PTLD faces several challenges in the 
methodology and statistical modelling. In the post-transplant period, the 
immunosuppressive agents and their doses vary between the recipients and within an 
individual recipient, with time. An accurate record of these data is often a challenge to 
maintain but when maintained, can be critical in reaching useful conclusions. In a large 
retrospective cohort such as the one I studied, the data are often significantly limited. In this 
study, the fact the immunosuppression data were limited to 3 fixed time points within the 
first year after transplantation is likely to be the main reason for the results showing no 
association between immunosuppressive agents and PTLD. A detailed discussion of the 
published evidence showing association of various immunosuppressive agents with PTLD is 
included in sections 1.7.1 to 1.7.5. 
 
7.5.6 PTLD and HLA 
T-lymphocytes play a key role in immune-surveillance of cancer cells and EBV-infected cells 
and protection against PTLD. Effective functioning of T-lymphocytes depends on HLA 
antigens (discussed in section 1.4.2) and is influenced by several of the immunosuppressive 
agents used after transplantation (discussed in sections 1.6.1 and 1.6.2). The association of 
HLA types with PTLD has been studied in few studies. Subklewe and colleagues studied 
(Subklewe et al., 2006) 155 solid organ transplant recipients with PTLD from eight European 
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and North American transplant centres and compared them with a control group of 1996 
recipients from Berlin. Of the 33 HLA antigens studied, a statistically significant association 
with PTLD was demonstrated for four antigens - HLA-A03 (OR 0.61, p=0.02), HLA-B18 (OR 
1.76, p<0.006), HLA-B21 (OR 2.08, p=0.02) and HLA-DR7 (OR 0.46, p<0.004). There are 
several important limitations in the methodology used in this study. In spite of including 33 
different HLA groups in the analyses, the p-value assumed to indicate statistical significance 
was not corrected for multiple comparisons. The cohort of PTLD patients was put together 
by including relatively smaller number of patients from individual centres, ranging from 2 
patients from Munich to 40 patients from Paris. These were diagnosed with PTLD over a 
period of 26 years, between 1977 and 2003. Inherent differences in the risk of PTLD among 
patients from such diverse background over such a long duration of time were not adjusted 
during the statistical analysis. The EBV data were available for 144 patients only, 32 from 
serology and 112 from histology. No data on immunosuppression were included in the 
analysis. The other large published study (Lustberg et al., 2014) included 106 PTLD cases and 
1392 controls from a single centre, Ohio State University. This showed a significant 
association between PTLD and HLA-B40 (OR 8.38) among EBV negative recipients and HLA-
B8 (OR 3.2) among EBV positive recipients. The limitations of this study included lack of 
immunosuppression data and the single centre nature of the study. The discordance 
between the results from the two studies discussed here and the results from the cohort I 
analysed highlight the importance of further data from large multicentre prospective 
studies including all the relevant confounding factors. 
 
In summary, the incidence of PTLD among the recipients of solid organ transplantation in 
the UK and their survival following the diagnosis of PTLD showed no statistically significant 
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change between the time periods of 1980-89, 1990-99 and 2000-07. This study showed no 
association between the risk of PTLD and the immunosuppressive agents or HLA antigens. 
However, significant limitations detailed in Section 7.5.2 and later in section 8.3 must be 
considered before drawing conclusions from this study. Further work from larger 
prospective multicentre cohorts with comprehensive data are needed to verify the 
conclusion of this study.  
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CHAPTER 8 
SUMMARY AND CONCLUSIONS 
(Some data and text from this chapter have been published  
(Desai et al., 2012, Desai et al., 2014, Desai et al., 2015)) 
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8.1 Summary of research findings 
In this chapter, a summary of the findings discussed in the previous chapters is made and 
the strengths and weaknesses of this research are discussed.  
 
Cancer is one of the important complications of solid organ transplantation. Along with 
infection and cardiovascular disease, cancer is one of the three common causes of death 
among long-term survivors of organ transplantation (USRDS, 2012, Pruthi et al., 2001, 
Rabkin et al., 2001, Jung et al., 2011). Cancer in the organ transplant recipient could be 
classified as: 
donor origin cancer (including donor-derived cancer and donor-transmitted cancer) 
de novo cancer   
recurrent cancer  
 
8.1.1 Setting the scene 
Chapter 1 included a brief overview of the history of solid organ transplantation, the 
development of surgical and anaesthetic techniques, experimentation with 
xenotransplantation and finally the successful human allotransplantation.  
 
The challenges that arose following the technical success of transplantation related to 
maintaining the health of the allograft and the recipient such that the graft continued to 
function and the recipient benefitted with improved length and the quality of life. Perhaps 
the greatest advance in the long-term post-transplant management was the development 
of effective immunosuppression. Whilst the immunosuppression improved the graft 
function by reducing the consequences of rejection, new challenges arose in the form of 
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adverse effects immunosuppression including agent-specific side effects, increased rates of 
infection and cancer. At present in the UK, 5-year post-transplant patient survival rates 
range from 88 to 96% (depending on the type of the donor) for kidney recipients, 80% for 
liver, 78% for heart and 55% for lung recipients (NHSBT, 2014b). The incidence of cancer is 
increased in the UK transplant recipients compared with the matched non-transplant 
population by 2.2 times in the liver recipients, 2.4 times in the kidney recipients, 2.5 times in 
the heart recipients and 3.6 times in the lung recipients (Collett et al., 2010). The highest 
increased risk is noted for NMSC (6 to 16 times increased risk depending on the type of 
transplant), cancers of the lip (20 to 65 times increased risk), the anus (3 to 20 times 
increased risk) and non-Hodgkin’s lymphoma (12 to 30 times increased risk). It should be 
noted, however, that for some of these cancers, such as anus, the absolute risk remains very 
low. 
 
Cancer transmission from donors has been reported since early years of transplantation 
(Martin et al., 1965, Wilson et al., 1968). Major published reports assessing the burden of 
DTC include the reports from the IPITTR (Penn, 1997) and OPTN/UNOS (Myron Kauffman et 
al., 2002).  The IPITTR report (Penn, 1997) included 117 recipients with 13 types of 
transmitted cancers. Of the 117 recipients, the cancer was localised to the allograft in 45 
recipients (6 died due to the transmitted cancer), locally spread in 6 recipients (no deaths 
due to cancer) and had distant metastasis in 66 recipients (44 deaths due to cancer). The 
OPTN/UNOS study (Myron Kauffman et al., 2002) reported 15 (0.01%) cases of DTC among 
108,062 recipients. Since the OPTN/UNOS report in 2002, the donor profile has changed 
(NHSBT, 2014b). The donors are older and have higher rates of obesity. The proportion of 
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DCD donors has increased. It is likely that these changes in donor characteristics may have 
an impact on the risk of cancer in the donor and its transmission by transplantation.  
 
The main reason why I chose this topic for research is its potential to improve the clinical 
practice of transplantation. Every organ offered for transplantation carries some risk of 
cancer transmission. When an organ is offered, the transplant surgeon, in discussion with 
the prospective recipient and their family, assesses the risks of accepting the organ for 
transplantation and compares this with the risks of not accepting. So far, there had not been 
a national study of the organ donors and the recipients in the UK to assess the extent of 
cancer transmission. The results of this research, in addition to enabling the estimation of 
the risk of cancer transmission, have also provided data on the risk factors associated with 
cancer transmission and the outcome of the recipients with transmitted cancer. Using the 
data from this research, I have contributed to the development of national guidelines for 
stratification of the risk of cancer transmission from organ donors. These guidelines are now 
published (SABTO, 2014). 
 
8.1.2 Donor-transmitted cancer in the transplant recipient 
In Chapter 3, the data from a nationwide survey of all the transplant recipients assessing the 
donor-origin cancer were presented. This survey covered a total of 30765 transplant 
recipients undergoing transplantation between 1st January 2000 and 31st December 2010. In 
this group, 18 (0.06%) cases of donor origin cancers were identified, including 3 (0.01%) DDC 
and 15 (0.05%) DTC. Three DDC included one transitional cell cancer in a kidney recipient, 
one renal cell cancer in a kidney recipient and one lymphoma in a liver recipient. Of the 15 
cases of DTC, 6 were renal cell cancers (all in kidney recipients), 5 were lung cancers (one 
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lung recipient and 4 kidney recipients), two were lymphoma (both kidney recipients) and 
one each of neuroendocrine tumour (liver recipient) and colon cancer (liver recipient).  
 
The rate of cancer transmission to the recipients was 0.05% (15 of 30765 recipients). These 
15 recipients had received organs from 13 donors. The rate of cancer transmission from the 
donors was 0.09% (13 of 14986 donors resulted in cancer transmission). Among the donors 
resulting in transmission of cancer, at the time of transplantation, none of the donors were 
known to have cancer or a past history of cancer. According to the guidelines from the 
Council of Europe (COE, 2010) which classify the donors based on their risk of cancer 
transmission (summarised in Table 1.7), the donors with no known cancer are classed as 
standard risk donors. So the transmission of cancer had exclusively occurred from standard 
risk donors.  
 
As none of the donors resulting in cancer transmission had a history of cancer, the risk of 
cancer transmission cannot be eliminated by strict adherence to these guidelines. This 
research has established that a small risk of cancer transmission persists despite all 
precautions. This emphasizes the need to include an explanation of this unavoidable but 
small risk of cancer transmission whilst taking consent from a prospective recipient.  
 
In this study, among the donor factors, older age was significantly associated with the risk of 
cancer transmission. Donors older than 45 years of age at the time of donation had a 9 
times higher risk of cancer transmission than the donors younger than 45 years. The mean 
age of the donor in the UK has been increasing and at present 59% of the donors are older 
than 50 years of age (NHSBT, 2014b). A higher proportion of older donors is likely to 
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translate into a higher risk of cancer transmission to the recipients from these donors, 
although it must be noted that the absolute risk for all the donors remains very small at 
0.09% (13 of 14986 donors resulted in cancer transmission).  
 
A diagnosis of the transmitted cancer within 6 weeks of transplantation was associated with 
localised disease, suitability for curative treatment and no deaths attributable to 
transmitted cancer. On the other hand, later diagnosis of transmitted cancer was more 
likely to be associated with disseminated disease and death due to transmitted cancer. 
 
Individual cases of cancer transmission often receive coverage in the media (BBCNews, 
2011, MailOnline, 2013, CNN, 2009) but these do not help in the assessment of the risk for 
the patients considering a transplantation. The results of this national survey provide a 
context to the extent of the problem and enable explanation of the actual risk of 
transmission of cancer to the prospective recipient and its comparison to the risk of death 
on the waiting list if the prospective recipient wishes to decline the offer of an organ. An 
explanation of risks and benefits, as accurately as possible, is an essential component of 
informed consent. Therefore, the data from this study provide important additional 
information which can be explained to the prospective recipients while consenting them for 
transplantation.(Desai et al., 2012) 
 
 The data discussed in chapter 3 showed that the donors resulting in cancer transmission 
were not known to have cancer at the time of accepting the organs for transplantation. This 
led to the next research question: what is the outcome of the transplantation from the 
donors with a previous history of cancer? This was discussed in chapter 4.  
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8.1.3 Donors with a history of cancer 
The guidelines from the Council of Europe (Table 1.7) classify the risk of transmission of 
cancer from the donor, based on the donor’s history of cancer. The guidelines, being revised 
at this time, divide the donors in to three categories: standard risk, non-standard risk and 
unacceptable risk. While the effort to stratify the risk among the donors is worthwhile, the 
terminology used for the donor risk categories is misleading. In particular, the ‘unacceptable 
risk’ seems to indicate that the donors in this category pose a risk of cancer transmission 
that is not acceptable for transplantation regardless of the risk of non-transplantation to the 
prospective recipient. Considering that the evidence supporting this classification comes not 
from high quality evidence but from case reports and retrospective registry reports, such 
categorical terminology used to classify the risk among donors appears to be potentially 
misleading. For example, in a patient with acute liver or heart failure listed for 
transplantation on super-urgent priority, the risk assessment would be considerably 
different from another patient needing transplantation for chronic organ failure. Whilst the 
annual rates of removal from and death on the waiting list are as high as 4% and 2% for 
kidney, 10% and 6% for heart, 5% and 10% for lung and 8% and 5% for liver transplant lists 
respectively (NHSBT, 2014b), the consequences of not accepting an organ must be carefully 
considered particularly when the actual risk of cancer transmission posed by an organ is 
likely to be very small. 
 
Thus, strict non-critical adherence to the guidelines may result in non-availability of organs 
for transplantation to some critically ill patients and also may result in wastage of some 
donor organs. To my knowledge, in the published literature, there has not been a study of 
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organ donors based on their classification of the risk of cancer transmission and the 
assessment of outcomes of the recipients of such organs. 
 
Over a period of 19 years (1990 - 2008), 17639 actual organ donors from England were 
assessed for a history of cancer diagnosed before organ donation. A total of 202 (1.15%) 
donors had a history of cancer diagnosed prior to organ donation including 61 (0.35%) 
donors belonging to the types classed as ‘unacceptable risk’ of cancer transmission by the 
Council of Europe guidelines. The cancer was diagnosed at the time of organ retrieval in 13 
(0.07%) donors. The cancers diagnosed at retrieval included renal cell cancer (5 donors), 
NHL (2), unspecified (2), metastatic adenocarcinoma, sarcoma, cancer of the pancreas and 
lung (1 each). Of these, the cancer of the pancreas was transmitted to the kidney recipient. 
The recipient was treated with excision of the transmitted cancer and was alive at 1 year 
following excision.  
 
From these 61 donors with cancers belonging to the types classed as ‘unacceptable risk’ of 
cancer transmission, 140 organs had been transplanted into 133 recipients. The survival 
analysis confirmed no significant difference in the recipient survival between the recipients 
from the donors with an ‘unacceptable risk’ and the recipients from donors with 
standard/non-standard risk. At 10 years of follow-up, transplant recipients had benefitted 
by an additional 944 person-years of survival as a result of using organs from the 
‘unacceptable risk’ donors. None of the recipients from the donors with an ‘unacceptable 
risk’ of cancer transmission developed a transmitted cancer. 
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After assessing the features of these donor cancers which did not transmit and similar 
reports in the literature of cancer non-transmission, I made the recommendations that the 
organs from a sub-group of the donors with a history of cancer may be considered for 
transplantation after careful assessment of risks to the recipient and an informed consent.  
 
The factors associated with caner non-transmission are:  
cutaneous melanoma, curative treatment with a cancer-free period of more than 5 years,  
stage 1 breast cancer with curative treatment and a cancer-free period of more than 5 
years,  
ovarian cancer with curative treatment and a cancer-free period of more than 10 years,  
colon cancer with curative treatment and  a cancer-free period of more than 5 years. 
 
It is important that these recommendations should be used with careful risk assessment of 
the recipient and an informed consent. These recommendations have been included in the 
UK national guidelines for classification of cancer transmission risk from organ donors 
(SABTO, 2014) (Desai et al., 2014). 
 
8.1.4 Recurrent cancer after transplantation 
The outcome of the recurrence after transplantation of a cancer treated prior to 
transplantation is poor, often fatal (Penn, 1993). So the assessment of the risk of such 
recurrence is one of the important factors considered while listing patients for 
transplantation. The largest published report assessing this risk (Penn, 1993) has several 
limitations including reporting bias due to voluntary reporting, incomplete denominator due 
to non-inclusion of all cases of transplantation and lack of differentiation of recurrent 
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cancers from de novo post-transplant cancers. In chapter 5, the data from 4835 solid organ 
transplant recipients from the West Midlands region of the UK were presented. These 
recipients were assessed for a history of cancer prior to transplantation and a recurrence of 
cancer after transplantation. Of the 4835 recipients, 64 (1.32%) recipients had a history of 
cancer prior to transplantation. There were five cases of recurrence of cancer after 
transplantation including 3 cases of melanoma, one case each of leiomyosarcoma and 
testicular germ cell cancer. In all the five cases, the recurrent cancer proved fatal. Of the 59 
recipients who did not develop a recurrence of cancer, 50 had been transplanted at least 2 
years following the diagnosis of cancer. There were no significant associations between 
individual immunosuppressive agents and the risk of recurrence of cancer, although the 
effect may not be apparent due to small numbers. 
 
Although the results indicated a favourable outcome for the patients transplanted following 
a minimum of 2-year wait after the diagnosis of cancer, these outcomes should be 
considered with caution. The number of patients transplanted with a previous history of 
cancer was small and the numbers of patients with individual types of cancer were very 
small indicating a high degree of selection of recipients. So the outcomes noted in this study 
may not be generalised to all patients undergoing transplantation. These limitations are 
discussed further in section 8.2.3. 
 
8.1.5 CMV and the risk of post-transplant cancer 
There is conflicting evidence in the published literature assessing the impact of CMV on the 
risk of cancer after transplantation. Couzi and colleagues followed up a cohort of 131 
recipients of kidney transplantation for 8 years and reported a 5-fold higher risk of cancer 
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among CMV naïve recipients (Couzi et al., 2010). In contrast, Courivaud and colleagues 
reported from a cohort of 455 kidney transplant recipients, an increased risk of cancer 
among the recipients exposed to CMV before transplantation (HR 1.83, p=0.009) and among 
the recipients with post-transplant CMV replication (HR 2.17, p=0.044) (Courivaud et al., 
2012). A common limitation of both these studies is small cohort size. 
 
In chapter 6, I presented the risk of post-transplant cancer in a cohort of 22461 solid organ 
transplant recipients over a period of 10 years. The recipients were divided into four groups 
based on the donor and recipient CMV IgG status at the time of transplantation: D-R-, D-R+, 
D+R+ and D+R-. There was no significant difference in the risk of cancer between these four 
groups. Furthermore, no significant difference in the risk of developing 23 different types of 
cancer was noted. The survival analysis showed that as compared to the other groups, the 
10-year recipient survival was significantly lower (and the risk-adjusted hazard of death was 
higher) among D+R- recipients of kidney, lung and heart but not the liver transplantation. 
The analysis of the cause of death showed that the proportion of recipients with 
cardiovascular death was significantly higher among the D+R- recipients. Although it was not 
possible to assess the mechanisms by which CMV may be increasing the mortality, the 
discussion of the chapter 6 included several reports from the published literature where 
CMV has been shown to be associated with increased rates of graft dysfunction, 
atherosclerosis and cardiovascular disease. (Desai et al., 2015) 
 
8.1.6 Post-transplant lymphoproliferative disorders 
PTLD, along with non-melanoma skin cancer is one of the two most common cancers after 
solid organ transplantation (Collett et al., 2010, Buell et al., 2005). In chapter 7, an 
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assessment was made of the incidence of PTLD, survival of the recipients after the diagnosis 
of PTLD and the factors influencing the incidence and the survival. A cohort of all the 
recipients of first solid organ transplantation in the UK between 1980 and 2007 included a 
total of 37617 transplant recipients.  Among these, 620 (1.65%) cases of PTLD were 
identified. SIR was used to compare the risk-adjusted incidence rates in different subgroups. 
The SIR for NHL was 12.3 among kidney recipients, 13.0 among liver recipients, 19.5 among 
heart recipients and 30.0 among lung recipients. Chronological changes in the incidence 
were assessed over 3 decades: 1980 to 1989, 1990 to 1999 and 2000 to 2007. Over these 
three decades, there was no significant change in the SIR of NHL or HL among the kidney, 
liver, heart or lung recipients. The recipient survival following the diagnosis of PTLD was 
poor: among the recipients with PTLD, the overall 1-year survival was 52.4% for kidney 
recipients, 49.1% for liver recipients, 53.4% for heart recipients and 47.1% for lung 
recipients. The recipient survival following the diagnosis of PTLD did not change significantly 
over the three decades. The impact of various immunosuppressive agents and HLA antigens 
on the incidence of PTLD was assessed among 8490 recipients of kidney transplantation. No 
significant association with PTLD was found for any of the immunosuppressive agents 
(induction agent, ciclosporin, tacrolimus, azathioprine or MMF) or the HLA antigens. The 
limitations of the immunosuppression data, discussed in section 8.3 must be considered 
while interpreting these results. 
 
8.2 Strengths of this research 
Much of this research is based on a collaboration of the data from two comprehensive 
national databases: the UK Transplant Registry and the Cancer Registries. Additional data 
supplementing these are from the recipient databases maintained at the individual 
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transplant centres and the Office for National Statistics. This research draws its strengths 
from the direct impact of the new evidence identified, on the clinical practice of 
transplantation and from the strengths of the data utilised in this research. 
 
8.2.1 New evidence with impact on clinical practice 
This research presents the results of the first national comprehensive survey of all organ 
recipients to identify cases with donor-transmitted cancer. The survey involved searching 
for the cases of transmitted cancers from multiple sources including patient databases at 
transplant centres across the country, the UK Transplant Registry and the clinical 
governance records at NHSBT. The detailed nature of this search is likely to have resulted in 
identification of most of the cases of cancer transmission by transplantation in the UK.  
 
The results of this survey have enabled the calculation, for the first time in the UK, of the 
rate of transmitted cancer among the recipients of solid organ transplantation. This rate of 
cancer transmission has provided vital information for the transplant team and for the 
prospective recipient to understand the extent of the risk of cancer transmission. Apart 
from improving clinical management, the understanding of the risk of cancer transmission 
has also enabled informed consent to be more comprehensive. 
 
This study provides some data regarding the management and outcome of the recipients 
with transmitted cancer.  It also identified the differences between the clinical features, 
management and the outcomes of recipients with early DTC compared against the 
recipients with late DTC. The differences highlighted by this study, between the recipients 
diagnosed with a DTC soon after transplantation as opposed to those with a late diagnosis 
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of DTC, in terms of the extent of cancer, amenability to curative excision and also 
differences in DTC related mortality, will provide guidance for the management of the 
recipients with DTC.  
 
A higher risk of DTC from older donors was identified by this research. This is likely to 
forecast an increased risk of cancer transmission in the coming years, in view of the 
increasing average donor age in the UK. However, it must be noted that the absolute risk of 
cancer transmission is very low.  
 
The study of the donors with a history of cancer (chapter 4) demonstrated non-transmission 
of cancer from such donors in a substantial cohort of recipients. As a result of this research 
a sub-group of donors with a previous history of certain type of cancers with a very low risk 
of cancer transmission has been identified. This evidence has contributed to the 
development of national guidelines for transplantation of organs from deceased donors 
with cancer or a history of cancer (SABTO, 2014). These guidelines are now in use and have 
the potential to increase the number of organs used for transplantation resulting in valuable 
additional survival for the recipients. 
 
A common limitation of the published studies assessing the impact of CMV on the risk of 
post-transplant cancer is the small number of recipients included. With a cohort size of 
22461, which in my knowledge is the largest study assessing this question, my research 
overcomes this limitation. Consequently, the absence of association between CMV and the 
risk of post-transplant cancer shown in this research is likely to be a reliable result as 
opposed to the conflicting associations between CMV and cancer shown in studies with 
280 
 
 
smaller cohorts. In addition, this research showed a poorer long-term post-transplant 
survival among the CMV negative recipients of kidney, heart or lung transplantation who 
received an organ from a CMV positive donor. These results provide evidence for matching 
the CMV status of the donor and the recipient.  
 
8.2.2 Quality of data: the UK Transplant Registry 
The UK Transplant Registry is a comprehensive database, which records the data from all 
organ donation and transplantation activity in the UK. Data are regularly collected and 
included to the UK Transplant Registry by a variety of professionals including Specialist 
Nurses for Organ Donation, National Organ Retrieval Service personnel, transplant doctors, 
recipient transplant coordinators, data managers at individual transplant centres and other 
hospital staff. Maintenance of a reliable database is a high priority and a dedicated 
Information Services team oversees the accuracy of the data. The Information Services team 
runs a process called ‘Stats for Verification’ which checks, at quarter-yearly intervals, that 
the organ usage is recorded correctly on the registry. The CUSUM analysis is used to check 
allograft failure and recipient deaths. There is regular cross verification of the transplant 
registry data against the independent recipient follow-up data held by the transplant 
centres and any discrepancies identified are rectified.  
 
The procedures of data management adopted by the Information Services team are 
regularly audited internally to ensure high degree of accuracy. The UK Transplant Registry 
practices double-data entry enabling comparison and validation of data entry processes to 
ensure accurate input. 
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In accordance with the specification of the Human Tissue act, all retrieved organs are 
tracked, accounted for and signed for at the point of retrieval and the point of use/non-use. 
These forms are used to crosscheck the data on the UK Transplant Registry. 
 
As a consequence of these comprehensive and continuous quality control interventions, the 
data held by the UK Transplant Registry achieves a high degree of accuracy. The conclusions 
drawn from the analyses of such high-quality data, such as the conclusions of my research 
are likely to be valid although, as discussed below in section 8.3, there are caveats. 
 
8.2.3 Quality of data: the cancer registries 
The UK Association of Cancer Registries is widely regarded to maintain a highly reliable 
database (UKACR, 2013). Cancer registries in the UK collect a wide range of data items 
including patient demographics, tumour details, treatment modalities and death details. 
These records are coded by experienced registrars trained to the UK Association of Cancer 
Registries standards, using internationally recognised ICD10 topography and ICD-O-3 
morphology codes. All data are captured locally and inputted into regionally held databases 
that are then merged to form the National Cancer Data Repository. The quality of the data 
held by the cancer registries is rigorously verified to maintain the accuracy, both prior to 
and after combining of these local databases. Cancer registries make every effort to record 
all malignancies by use of a range of data sources, in order to ensure that the most accurate 
information is captured. The data sources that are commonly used by cancer registries 
include hospital patient information systems, hospital episode statistics, cancer waiting time 
data, pathology reports, medical records departments, radiotherapy systems, hospices, 
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general practices, private hospitals, cancer screening programmes, nursing homes, autopsy 
reports and death certificates.  
 
The number of cancer registrations that each registry records is closely monitored for 
discrepancies between the actual number of registrations and the expected number of 
registrations. The results of such comparison are released internally usually, and 
occasionally in the published literature. One such study assessed the national cancer 
registration data for breast cancer and compared these to independently collected data 
held within the General Practice Research Database and showed no significant difference 
between the rates of registration (Kaye et al., 2000). Another study to test the hypothesis 
that under-registration of malignancies in England and Wales was associated with poorer 
survival following a cancer diagnosis in England and Wales compared to other European 
countries, noted that it was implausible that under-registration occurred to a significant 
level, and to an extent that would adversely affect the reported survival rates (Woods et al., 
2011).  
 
The quality control measures undertaken by the cancer registries would improve the quality 
of these data and consequently, strengthen the reliability of the conclusions drawn from the 
research detailed in this thesis. 
 
8.3 Limitations of this research 
This research has some important limitations. The reported incidence of DTC must be an 
underestimate. DTC were identified retrospectively and only those cases were included 
where donor origin was confirmed or suspected. It is probable that in some cases of cancers 
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in the recipient, a donor origin was not suspected or investigated. In spite of my exhaustive 
efforts in searching databases at individual transplant centres to identify all cases of DTC, it 
is probable that not all cases were identified. (Desai et al., 2012) 
 
The history of cancer in the donors was obtained from the cancer registries. The efforts 
undertaken by the cancer registries in order to maintain an accurate record of all cases of 
cancer diagnosed, have been detailed in section 8.2.3. All these measures would have 
contributed to minimization of missed cases. However, it is possible that there may be some 
under-registration affecting the accuracy of the conclusions drawn from this research. 
 
Although the increased donor age was the only donor factor associated with an increased 
risk of cancer transmission, the effect of small numbers must be noted. There may be other 
donor factors associated with increased cancer transmission risk, which did not reach 
statistical significance due to the small number of donors who transmitted cancer.  
 
Therefore the estimated risk of transmission of cancer from the donors with a previous 
history of cancer is likely to be an underestimate. Because of the limitations of the data 
recorded by the registry, I was able to assess only the risk of cancer transmission to 
recipients resident in England: among the recipients from the donors with a high risk of 
cancer transmission, 133 (86%) recipients (residents of England) were included in my study; 
from the same donors, there were 22 (14%) other recipients who lived outside England and 
cancer transmission to these recipients was not assessed. An occult transmitted cancer may 
have gone undiagnosed in cases where the recipient died soon after transplantation. 
Extending the recurrence rates of dormant cancers from the immunocompetent population 
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to recipients of non-renal transplants (where stopping immunosuppression is not usually a 
viable therapeutic option) is also likely to result in imprecise risk estimation. For these 
reasons, this study will underestimate the cancer transmission risk. (Desai et al., 2014) 
 
The teams facilitating donation-transplantation applied a high level of screening in donor 
selection by carefully assessing the donor factors and balancing them with the clinical 
situation of the recipients. The acceptance and the use of organs from a donor with a 
history cancer was assumed to imply that the tumour was correctly treated, appropriately 
followed-up, and that the retrieving surgeon performed thorough laparotomy and 
thoracotomy looking for evidence of recurrence. For these reasons, the donors in this study 
represent a carefully selected cohort and caution must be used while extrapolating the 
conclusions of this research to all potential donors with a history of cancer. (Desai et al., 
2014) 
 
While assessing the risk of recurrence of cancer treated prior to transplantation (chapter 5), 
despite the reassuring results showing low rates of recurrence, the limitations of the data 
must be considered. Numbers are relatively small so misleading conclusions may be drawn. 
In spite of a large initial cohort, the number of recipients who had a history of cancer was 
small indicating a high degree of selection. Moreover, the patients who underwent 
transplantation were carefully evaluated prior to transplantation and so represent a 
carefully selected cohort and any conclusions drawn from this analysis will not be directly 
applicable to all candidates. It is therefore difficult to develop robust evidence-based 
guidelines to help identify patients with pre-existing cancer who may not benefit with 
transplantation because of lack of data, with small number of patients reported, 
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inconsistency of reporting, the diversity in the type, stage and treatment of cancer and the 
immunosuppressive regimen. It is difficult to confirm if the lack of association between the 
risk of cancer recurrence and the immunosuppressive agents is real because of the relatively 
small number of recipients and also because the immunosuppression data were not 
comprehensive as they were limited to the agent at three time points within the first year of 
transplantation.  
 
Missing data is another important and inevitable limitation encountered whilst assessing 
the data retrospectively from a large national transplant registry. The CMV data were not 
available for a large proportion (35%) of recipients and these were excluded. The CMV 
status was recorded at the time of transplantation and any recipients with post-
transplantation acquisition of CMV infection were not identified. Furthermore, in a 
significant proportion (36% of the 6213) of patients, the cause of death was not specified. 
The data regarding pharmacological prophylaxis against CMV infection were not available. 
The risk of cancer would be underestimated in cases where the recipient had multiple 
cancers, as the data for the first diagnosed post-transplantation cancer only were included. 
(Desai et al., 2015) 
 
With regards to the data assessing the incidence and survival of the recipients with PTLD 
several important limitations are likely to influence the conclusions drawn. EBV is one of the 
important risk factors associated with the development of PTLD. The EBV data were not 
available for the entire cohort, resulting in inability to analyse the impact 
immunosuppression and HLA among EBV positive and negative subgroups. The data 
regarding the use of EBV chemoprophylaxis were also not available. Also, the data regarding 
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the site of involvement of PTLD, histological type or treatment of PTLD were not available. 
The immunosuppression and HLA data were only available for a subgroup of the cohort. 
Furthermore, the immunosuppression data were not comprehensive, limited to three time 
points within the first year after transplantation. The cancer registration data were limited 
to the first registered cancer after transplantation so in some recipients who may have had 
another type of cancer first, followed by PTLD, the diagnosis of PTLD would not be captured 
resulting in an underestimation of the risk of PTLD. 
 
Finally, the practice of donation-transplantation is evolving: the profile of the donor is 
changing, with more donors becoming older and heavier; both factors are likely to increase 
the risk of cancer. The evaluation of the potential donor is improving so cancer and other 
risks are becoming better identified; the improved training of the retrieval teams is likely to 
lead to a more systematic examination of the abdomen and chest, so possibly identifying 
more cancers in the donor. The immunosuppressive regimens are also changing: some of 
the newer agents, such as mTOR inhibitors, have an anti-neoplastic effect, and so may 
modify the likelihood and impact of cancers. Finally, the greater awareness of cancer in the 
allograft recipient may lead not only to earlier diagnosis but also greater emphasis on 
reducing cancer risk, such as reinforcing the need to stop smoking or avoiding excess 
alcohol.   
 
Thus conclusions based on historical data must be extrapolated with caution. 
 
8.4 Conclusions 
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The research detailed in this thesis provides new evidence with a direct impact on the 
clinical practice of transplantation. Donor-transmitted cancer is a rare complication of solid 
organ transplantation but frequently results in graft loss and death. The risk of cancer 
transmission cannot be completely eliminated because the transmission occurred from 
standard-risk donors. This information should be included in informed consent for 
prospective recipients. The recipients with a transmitted cancer that is localised to the graft 
are likely to benefit with explantation or excision but in transplants other than kidney or 
pancreas, the benefits of explantation should be balanced against the risks of 
retransplantation.  
 
Organs from carefully selected donors with a history of cancer can be used for 
transplantation with a low risk of cancer transmission, whilst providing valuable additional 
survival benefit to the recipients. Strict implementation of present guidelines is likely to 
result in overestimation of cancer transmission risk in some donors.  (Desai et al., 2014) 
 
Recurrence after transplantation of cancers treated prior to transplantation is a rare 
complication among the recipients selected after careful assessment of risks, after a 
minimum of 2-year wait between the diagnosis of cancer and transplantation. The outcome 
of cancer recurrence is poor, frequently fatal.  
 
CMV does not influence the risk of post-transplant cancer. There is no chronological change 
in the incidence of or the survival after a diagnosis of PTLD among the recipients of solid 
organ transplantation in the UK. 
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CHAPTER 9  
FUTURE WORK 
(Some data and text from this chapter have been published  
(Desai et al., 2012, Desai et al., 2014, Desai et al., 2015)) 
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Future developments in several areas have the potential to contribute towards better 
estimation of the risk of cancer transmission from organ donors, reducing the risk of post-
transplant cancer and improving the management and outcomes for the recipients with 
cancer. These are discussed here.  
 
9.1 Improvements in data 
There are several areas related to DTC where there is a scarcity of good quality evidence. 
The fact that several large national cohorts have found a small number of cases of DTC 
highlights the importance of international collaboration. Data from larger cohorts of 
recipients with DTC are likely to enable identification of trends, which can guide the 
management of future cases of DTC, both in terms of risks/benefits of surgical resection and 
the choice of immunosuppression. It is also useful to identify the donor characteristics 
associated with cancer transmission. The risk of cancer transmission is different from donors 
with different types of cancers and also depends on the duration between successful cancer 
treatment and organ donation. These characteristics can be more reliably assessed in a 
larger cohort. (Desai et al., 2014) 
 
The outcomes for the recipients of organs from donors with a history of cancer were not 
routinely reported to the UK Transplant Registry. Since the development of the guidelines to 
which this research has contributed, it is now recommended that NHSBT should maintain a 
register of the outcomes of such recipients (SABTO, 2014). Mandatory reporting of all cases 
of DTC is now required under each Transplant Unit’s licence from the Human Tissue 
Authority. This reporting is crucial in creating a comprehensive database which can provide 
evidence for the selection of donors with lower risk of cancer transmission, exclusion of 
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donors with a higher risk, specific transmission rates of different types of donor cancers and 
the management of other organ recipients from the same donor when recipient of one 
organ develops a DTC. (Desai et al., 2014) 
 
My research centred around a collaboration of the data from the UK Transplant Registry and 
the data from the cancer registries in the UK. An important limitation of the methods used 
was that the data were matched between the two databases, at one point of time. 
Conclusions were drawn and recommendations were made for the patients undergoing 
transplantation in future, based on the historical data. Further analysis of similar data in 
future transplant recipients is necessary to confirm the findings and improve the validity of 
the conclusions. A regular and ongoing linkage (annual, for example) between the 
transplant and the cancer databases will have several advantages. Such linkage would 
facilitate regular assessment of the incidence and types of cancer in the organ donors and 
transplant recipients. This linkage will also enable identification of DTC.  Changing trends in 
the incidence, outcomes and transmission risks of different cancers would be identified and 
this information would contribute towards improving the recommendations. The US 
Transplant Cancer Match Study (Transplantmatch, 2015) is one such example of ongoing 
linkage between the national transplant registry data in the USA and the cancer registration 
data from 16 states of the USA. 
 
The NOTIFY project is an important initiative in collaborating international data regarding 
multiple outcomes following transplantation with a common theme of improving safety and 
reducing the risks (NOTIFY, 2010). The NOTIFY project is a joint venture of WHO and CNT, 
which aims to improve the donor and recipient safety and increase the transparency in the 
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practice of transplantation. Started in 2010, this project aims to collect data from 36 
countries on various complications of transplantation such as transmitted cancer, infection, 
clinical errors and adverse reactions, with an intention provide evidence to facilitate risk 
reduction. Data collated from several countries are more likely to increase the robustness of 
the study and the power of the statistical analysis. However the limitations of such multi-
national projects would include diverse demography of donors and recipients, varying 
inclusion/exclusion criteria for donors with known cancer and genetic differences which 
may result in heterogeneity in the types of cancers and their biological behaviour. The 
Council of Europe guidelines for the classification of donor’s risk of cancer transmission 
(COE, 2010) are currently under review. The next edition is likely to include the results of the 
NOTIFY project as well as the results of the research detailed in this thesis. (Desai et al., 
2012) 
 
9.2 Improvements in donor selection and assessment 
Whilst assessing the potential donor’s suitability for safe organ donation, several additional 
interventions such as cross-sectional imaging of the donor, urgent histological assessment 
of any suspicious lesions, urgent autopsy and tumour markers  can be considered in order to 
improve the detection of occult cancers. The detection of occult cancers enables risk 
assessment and informed decision regarding the use or non-use of the donated organ. The 
other advantage of using additional interventions to detect and confirm occult cancers 
would be to avoid inappropriate non-acceptance of donors who may be classed as high-risk 
of cancer transmission by conventional assessment whereas additional investigation may 
indicate that the risk of cancer transmission is low. However, along with the advantages, the 
disadvantages of such interventions must also be considered. These are discussed here.      
292 
 
 
 
9.2.1 Cross-sectional imaging 
The gap between the supply and the demand for donor organs continues to increase 
resulting in search for avenues to find additional organs. In recent years, the organs from 
older donors and donors with co-morbidities have been accepted for transplantation and 
this trend is likely to continue. The rising age of the organ donor is likely to increase the 
chances of a donor organ carrying an occult cancer, resulting in transmission of cancer to 
the recipient. At present in the UK, it is not a mandatory practice to perform cross-sectional 
imaging of the donor prior to donation. Cross-sectional imaging is more likely to find an 
occult cancer, facilitating a thorough assessment of the donated organ and non-use of 
organs considered to be at high-risk of containing a transmitted cancer. There are 
advantages of identifying the occult cancer in the donor, even after the donated organ has 
been transplanted. The recipient will be informed, investigated and additional interventions 
such as excision of the tumour from the allograft, reduction or cessation of 
immunosuppression, explantation or close monitoring can be considered.  
 
There are several challenges and disadvantages in implementing a routine use of cross-
sectional imaging during donor assessment. Most hospitals in the UK have access to CT scan, 
in working hours as well as out-of-hours, however access to other types of imaging may be 
limited. In some cases when a lesion is identified on a CT scan, it may need further 
characterisation by a magnetic resonance imaging (MRI) scan or a positron emission 
tomography (PET) scan before its malignant nature is ascertained. Availability of these 
specialised imaging modalities is limited particularly in smaller peripheral hospitals, 
particularly during out-of-hours period. Even if a scan can be performed out-of hours, the 
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on-call radiologist may not have the expertise necessary to report a MRI or a PET scan with a 
degree of accuracy needed to make a decision regarding accepting the organ for donation.  
 
A routine use of cross-sectional imaging in the assessment of all organ donors is likely to be 
inappropriate and impractical.  The use of cross-sectional imaging needs to be targeted to 
high-risk donors such as older donors, donors with significant risk factors such as smoking, 
alcohol use and infection with viruses known to predispose to cancer. The routine use of 
cross-sectional imaging in low-risk donors (such as children or young victims of traffic 
accidents) is likely to be counter-productive and burden the health care system with 
wastage of financial and technical resources and the donor’s family with avoidable anguish.  
 
9.2.2 Histopathology: biopsy and autopsy 
In cases where a suspicious lesion is identified during the assessment of a potential donor, 
the availability of an expert histopathology opinion on an urgent basis can make a significant 
difference. Such histopathology opinion, in combination with cross-sectional imaging and 
blood test results, has the potential to enable the transplant team to differentiate benign 
lesions from malignant ones with a high degree of accuracy. However, at present in many 
hospitals in the UK, the availability of histology services is limited to daytime working hours. 
The Royal College of Pathologists which monitors and regulates the pathology services in 
the UK, has set out key performance indicators (RCPath, 2010) to provide a direction for 
future development of pathology services. This document listed out a number of targets to 
be achieved by the pathology services in the coming years. According to this report, by April 
2014, a target of 90% of the diagnostic biopsy samples should be reported within 7 days of 
the biopsy. There is no target set for providing urgent histopathology services, in cases such 
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as diagnosis of a possible cancer identified during the assessment of a potential donor. 
While such a service is likely to be invaluable in deciding the safety of the donor organ and 
reduce wastage of organs, setting up urgent histopathology services in hospitals across the 
UK is a significant challenge. This involves major re-structuring of pathology workforce, 
enabling on-call availability of the biomedical scientists to prepare the histopathology slides 
and the pathologists to report the samples.  
 
Autopsy of the donor following organ donation is also likely to increase the chances of 
identification of occult cancers. At present in the UK, donor autopsy is not routinely 
performed. The advantages of donor autopsy and the challenges in implementing it 
routinely to all organ donors are similar to the advantages and the challenges of cross-
sectional imaging, discussed in section 9.2.1. The availability of urgent histopathology 
services is also likely to expedite the reporting of autopsies resulting in early management 
of recipients of organs from donor with cancer.  
 
9.2.3 Tumour markers 
None of the tumour markers in clinical use at present have the levels of sensitivity or 
specificity to be suitable for screening for cancer in the general population (NCI, 2011). For 
the same reason, a routine use of tumour markers cannot be recommended for screening 
for cancer in organ donors. Tumour markers under development include proteomic-based 
or genomic-based markers which are expected to have higher sensitivity and specificity. 
Examples of such tumour markers under development include markers for prostate cancer 
(pro-prostate specific antigen (pro-PSA), prostate cancer antigen-3 (PCA3)), ovarian cancer 
(OVA1 and ROMA) and hepatocellular carcinoma (Des-gamma-carboxy prothrombin (DCP) 
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and alpha-fetoprotein-L3 (AFP-L3)) (NCI, 2015). At present, these biomarkers are approved 
by the United States Food and Drug Administration (USFDA) for clinical use in specific 
situations for diagnostic purposes, but not for screening of cancer.  Development of markers 
for screening of cancer in the future would be of interest to transplant specialists as these 
markers may be of use in identifying occult cancers in the organ donors and reduce the 
likelihood of inadvertent transmission of cancer to the transplant recipient. 
 
9.3 Improvements in the recipient management 
9.3.1 Lifestyle changes 
Post-transplant recipient management should have an emphasis on a healthy lifestyle. 
Providing guidance and advice on smoking cessation, alcohol moderation and weight 
management should start when the patient is listed for transplantation and continue 
throughout the post-transplant period. Transplant centres should develop close links with 
their local addiction services and nutrition/obesity specialist teams. Specialists such as 
dietitians, physiotherapists and nurses/doctors specialising in addiction medicine should be 
involved at an early stage, in the management of selected patients. Many transplant centres 
already have such facilities, however, with an increasing transplant activity in the UK it is 
likely that these services will be burdened with an increasing demand. It is imperative that 
the transplant centres recognise the need for adequate number of specialists and resources 
to be able to meet the needs of their patients. 
 
The UK national policies on harmful drinking (Alcoholpolicy, 2013) and smoking 
(Smokingpolicy, 2013) emphasised the ill-effects of excessive alcohol intake and smoking, 
and the interventions undertaken by the UK government at various levels to reduce the 
296 
 
 
burden of smoking and harmful drinking. The interventions against smoking include 
restrictions on sale and promotion of tobacco, implementation of tobacco taxes, anti-
smoking campaigns and regulation of e-cigarettes. The interventions against harmful 
drinking include Change4life campaign which focuses on provision of information, inclusion 
of an alcohol risk assessment as a routine within the NHS Health check, restriction on 
advertising alcohol to young people, cutting down the availability of cheap alcohol and a 
commitment to additional expenditure to be able to meet these services. The rates of 
smoking (ONS, 2013b) and harmful consumption of alcohol (ONS, 2013a) among adults in 
the UK are dropping and with these additional efforts it is likely that these trends will 
continue. Although it is difficult to predict the impact of these interventions on the 
outcomes after transplantation, the lower rates of tobacco and alcohol consumption will 
likely have a favourable impact on the risk of post-transplant cancer and cardiovascular 
disease, and consequently, on post-transplant recipient survival. 
 
9.3.2 Vaccination against oncogenic viruses 
The recipients of organ transplantation endure an increased risk of many types of cancers 
including some cancers in which the risk is increased by a viral infection. These include 
cancer of the cervix, vagina, vulva, anus, oral cavity (all predisposed by HPV), hepatocellular 
carcinoma (predisposed by HBV, HCV), NHL (predisposed by EBV) and Kaposi’s sarcoma 
(predisposed by HHV-8). Another intervention with a potential to reduce the risk of post-
transplant caner is vaccination of the recipients against oncogenic viruses. At present, 
among these viruses, effective vaccines are available against HPV and HBV.  
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In the UK, routine vaccination against HPV for girls aged between 11 years and 14 years was 
introduced in 2008 as a part of the national vaccination programme (NHSChoices, 2014). 
This is an important intervention because, vaccination as a part of the national vaccination 
programme is likely to reach large proportion of schoolgirls in the UK and provide protection 
against HPV. As a secondary effect of routine vaccination against HPV, in the coming years 
the proportion of transplant recipients who have been vaccinated against HPV is likely to 
increase. This is likely to have an impact on the incidence of post-transplant cancer, in 
particular, cancers predisposed by HPV.  
 
At present, routine vaccination against HBV is limited to individuals considered to be at 
high-risk of HBV, such as close contacts of a patient with HBV infection, people who are 
prone to occupational or lifestyle related exposure to HBV and patients listed for liver 
transplantation. Whilst routine use of HBV vaccination has the potential to reduce the risk 
of HBV infection and the consequent risk of hepatocellular carcinoma, the disadvantages of 
this strategy would include the side effects and the risk of vaccine failure along with the 
impact on healthcare expenditure and resources.  
 
At present, there are no vaccines available for clinical use against HHV-8, CMV, HCV or EBV. 
Advances in the development of these vaccines would be of interest to selected sub-groups 
of patients undergoing organ transplantation. 
 
9.3.3 Immunosuppressive agents with anti-neoplastic properties  
Post-transplant immunosuppression contributes significantly to the increased risk of cancer 
after transplantation. Some mTOR inhibitors such as sirolimus and everolimus have, in 
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addition to immunosuppressive effect, anti-neoplastic properties. Sirolimus is shown to be 
associated with a lower incidence of cancer, in particular NMSC, in several studies (Campbell 
et al., 2012, Hoogendijk-van den Akker et al., 2013, Euvrard et al., 2012, Gu et al., 2012). An 
important challenge in assessing the long-term impact of sirolimus on the risk of post-
transplant cancer is the lack of record of comprehensive immunosuppression data. Like the 
UK Transplant Registry, many large registries record immunosuppression data 
comprehensively during the initial post-transplant period. During long-term post-transplant 
follow-up, the degree of detail of immunosuppression data recorded by the registry is 
reduced significantly. Even the studies from large well-managed national transplant 
registries have limited the follow-up period to under 3 years whilst assessing the impact of 
sirolimus on the risk of post-transplant cancer (Kauffman et al., 2005). Sirolimus is often not 
a preferred first-line immunosuppressant in the early post-transplant period due to its side 
effects such as delayed wound healing and hepatic artery thrombosis among liver 
recipients, and is introduced later during long-term post-transplant follow-up. This 
highlights the importance of an accurate record of the long-term immunosuppression data 
by large transplant registries to enable assessment of the impact of sirolimus on post-
transplant cancer. Other mTOR inhibitors such as temsirolimus have exclusive anti-cancer 
activity but development of agents with anti-cancer as well as immunosuppressant activity 
would be of interest in the management of future transplant recipients. 
 
9.3.4 Cancer screening after transplantation 
The guidelines recommending cancer screening among transplant recipients include the 
European best practice guidelines (Europeanguidelines, 2002) and the American Society of 
Transplantation guidelines (Kasiske et al., 2000). These recommend screening for breast 
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cancer (annual or biennial mammography for women over 50 years of age), colorectal 
cancer (annual faecal occult blood test and/or 5-yearly flexible sigmoidoscopy for patients 
over 50 years), cervical cancer (annual cervical smear and pelvic examination once sexually 
active), prostate cancer (annual digital rectal examination and PSA measurement for men 
over 50 years) and skin cancer (monthly skin self-examination and 6 to 12 monthly 
examination by physician/dermatologist). These recommendations are adapted from the 
recommendations for screening for cancer in the non-transplant population. There are no 
published data demonstrating the survival benefit to the transplant recipients undergoing 
cancer screening or the cost-effectiveness of screening (Wong et al., 2008).  Considering the 
increased risk of several cancers among the transplant recipients and also the impact of the 
cancer on the survival of the immunosuppressed recipient, future research assessing the 
risks, benefits and cost-effectiveness of cancer screening will provide valuable evidence. 
 
9.3.5 Surveillance for cancer treated prior to transplantation   
The rates of recurrence after transplantation of cancers treated prior to transplantation are 
shown to be low in several national transplant registry data. However, the outcome of the 
recipients with cancer recurrence remains poor with limited survival. There are no data 
assessing the benefit of cancer surveillance in such recipients. Considering the small number 
of transplant recipients with a previous history of cancer, any research assessing the impact 
of cancer surveillance on the recurrence of cancer will need international collaboration. 
 
9.3.6 Role of CMV and EBV in post-transplant cancer 
There are several limitations in the data presented in this thesis, assessing the impact of 
CMV on the risk of post-transplant cancer, the most important ones being the incomplete 
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data and relatively small number of patients with individual types of cancer. The EBV data 
were not available resulting in significant limitation in the analyses and interpretation of the 
PTLD data. Several improvements in the recording of the data by the transplant registry 
would be necessary to undertake an assessment of the interplay of multiple risk factors 
involved in the development of post-transplant cancer. Future studies will need to be 
planned prospectively with comprehensive data from larger cohorts of transplant recipients. 
In such studies, individual types of cancer will likely be represented in bigger numbers and 
fewer patients will be excluded from the study for lack of record of CMV data, resulting in 
increased reliability of results and the conclusions. Comprehensive data will also enable an 
assessment of the incidence and survival rates in the PTLD cohort and in EBV positive and 
negative sub-groups. The additional data needed would include accurate record of the viral 
serological status at the time of transplantation and update at regular intervals in the post-
transplant period, comprehensive record of immunosuppression and anti-viral prophylaxis 
and treatment. 
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Cancer Transmission From Organ
DonorsVUnavoidable But Low Risk
Rajeev Desai,1,5 Dave Collett,1 Christopher J. Watson,2 Philip Johnson,3 Tim Evans,4 and James Neuberger1
Background. Donor origin cancer (DOC) in transplant recipients may be transmitted with the graft (donor-transmitted
cancer [DTC]) or develop subsequently from the graft (donor-derived cancer [DDC]).
Methods. Recipients with DOC between January 1, 2001, and December 31, 2010, were identified from the United
Kingdom Transplant Registry and database search at transplantation centers.
Results. Of 30,765 transplants from 14,986 donors, 18 recipients developed DOC from 16 donors (0.06%): 3 were
DDC (0.01%) and 15 were DTC (0.05%). Of the 15 DTCs, 6 were renal cell cancer; 5, lung cancer; 2, lymphoma; 1,
neuroendocrine cancer; and 1, colon cancer. Recipients with DTC underwent explant/excision (11), chemotherapy
(4), and radiotherapy (1). Of 15 recipients, 3 (20%) recipients with DTC died as a direct consequence of cancer. Early
DTC (diagnosed e6 weeks of transplantation) showed a better outcome (no DTC-related deaths in 11 cases) as
opposed to late DTC (DTC-related deaths in 3 of 4 cases). Five-year survival was 83% for kidney recipients with DTC
compared with 93% for recipients without DTC (P=0.077). None of the donors resulting in cancer transmission
was known to have cancer at donation.
Conclusions. DTC is rare but frequently results in graft loss and death. The risk of cancer transmission cannot be
eliminated because, in every case, the presence of cancer was not known at donation. This information will allow
informed consent for prospective recipients. Explantation/excision is likely to benefit recipients with localized cancer,
but in transplants other than kidney/pancreas, the benefits should be balanced against the risks of retransplantation.
Keywords: Organ transplantation, Transmitted cancer, Donor assessment, Cancer transmission risk.
(Transplantation 2012;94: 1200Y1207)
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Estimated risk of cancer transmission from organ donor
to graft recipient in a national transplantation registry
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Correspondence to: Dr R. Desai, NHS Blood and Transplant, Fox Den Road, Stoke Gifford, Bristol BS34 8RR, UK (e-mail: rajeev.desai@nhs.net)
Background: Transplanted organs carry the risk of inadvertent donor cancer transmission. Some cancers
in organ donors have been classified as being associated with a high or unacceptable risk, but the evidence
for such recommendations is scanty.
Methods: The risk of cancer transmission from donors characterized as high or unacceptable risk
was studied by analysing transplant and cancer registry data. Donors and recipients from England
(1990–2008) were identified from the UK Transplant Registry. Cancer details were obtained from
cancer registries and classified using guidelines from the Council of Europe and Organ Procurement
and Transplantation Network/United Network for Organ Sharing.
Results: Of 17639 donors, 202 (1·1 per cent) had a history of cancer, including 61 donors with cancers
classed as having an unacceptable/high risk of transmission. No cancer transmission was noted in 133
recipients of organs from these 61 donors. At 10 years after transplantation, the additional survival
benefit gained by transplanting organs from donors with unacceptable/high-risk cancer was 944 (95 per
cent confidence interval (c.i.) 851 to 1037) life-years, with a mean survival of 7·1 (95 per cent c.i. 6·4 to
7·8) years per recipient.
Conclusion: Strict implementation of present guidelines is likely to result in overestimation of cancer
transmission risk in some donors. Organs from some donors with cancers defined as unacceptable/high
risk can be used safely.
Paper accepted 16 January 2014
Published online 28 April 2014 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.9460






OriginalClinicalScienceçGeneralImpact of Cytomegalovirus on Long-term
Mortality and Cancer Risk After
Organ Transplantation
Rajeev Desai,1 DaveCollett,1 Christopher J. E. Watson,2 Philip J. Johnson,3,4 PaulMoss,5,6 and JamesNeuberger1
Background. There is conflicting evidence of the effect of cytomegalovirus (CMV) infection on survival and the risk of cancer
after transplantation.Methods. All recipients of kidney, liver, heart, and lung transplants in the United Kingdom between 1987
and 2007 with known CMV immunoglobulin G status were identified from the U.K. Transplant Registry. Based on the donor-
recipient CMV status, recipients were grouped into: donor (D) negative recipient (R) negative (D− R−), D−R+, D + R+ and D + R−.
Cancer data were obtained from the Office for National Statistics. The impact of CMV infection on survival and cancer incidence
was assessed. Results. The 10-year posttransplant survival in D−R− recipients (73.6% [95%CI, 72.3, 74.9]) was significantly
higher (P < 0.0001) than in other recipients (66.1% [65.3, 66.9]). Compared with the D− R− group, the risk-adjusted hazard of
death within 10 years of transplantation for D+ R− group was 14% higher for kidney recipients (P = 0.0495), 13% higher for liver
recipients (P = 0.16), 34% higher for heart recipients (P = 0.01), and 35% higher for lung recipients (P = 0.006). The proportion of
recipients with a cardiovascular cause of death was higher (P = 0.03) among the recipients exposed to CMV (18%) as compared
to the D− R− recipients (16%). The CMV status was not associated with an increased risk of cancer. Conclusions. The results
from this large study demonstrate that CMV is associated with a significantly increased long-term mortality in kidney and
cardiothoracic transplant recipients and an increased risk of cardiovascular death but not of posttransplant cancer.
(Transplantation 2015;99: 1989–1994)
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Abstract
Cancers in solid organ recipients may be classified as 
donor transmitted, donor derived, de novo  or recur-
rent. The risk of donor-transmitted cancer is very low 
and can be reduced by careful screening of the donor 
but cannot be abolished and, in the United Kingdom 
series is less than 0.03%. For donors with a known 
history of cancer, the risks will depend on the nature 
of the cancer, the interventions given and the interval 
between diagnosis and organ donation. The risks of 
cancer transmission must be balanced against the risks 
of death awaiting a new graft and strict adherence to 
current guidelines may result increased patient death. 
Organs from selected patients, even with high-grade 
central nervous system (CNS) malignancy and after a 
shunt, can, in some circumstances, be considered. Of 
potential donors with non-CNS cancers, whether organs 
may be safely used again depends on the nature of 
the cancer, the treatment and interval. Data are scarce 
about the most appropriate treatment when donor 
transmitted cancer is diagnosed: sometimes substitu-
tion of agents and reduction of the immunosuppressive 
load may be adequate and the impact of graft removal 
should be considered but not always indicated. Liver al-
lograft recipients are at increased risk of some de novo  
cancers, especially those grafted for alcohol-related 
liver disease and hepatitis C virus infection. The risk 
of lymphoproliferative disease and cancers of the skin, 
upper airway and bowel are increased but not breast. 
Recipients should be advised to avoid risk behavior and 
monitored appropriately.
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